Antisense modulation of fibroblast growth factor receptor 4 expression

ABSTRACT

Provided herein are methods, compounds, and compositions for reducing expression of fibroblast growth factor receptor 4 (FGFR4) mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease, or a symptom thereof.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.13/631,437, filed Sep. 28, 2012, which is a continuation of U.S. patentapplication Ser. No. 13/525,197, filed Jun. 15, 2012, which claimspriority under 35 U.S.C. §119(e) to U.S. Provisional Patent ApplicationNo. 61/497,921, filed Jun. 16, 2011, each of which is incorporatedherein by reference in its entirety.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format. The Sequence Listing is provided as a file entitledBIOL0157USC2SEQ_ST25.txt created Dec. 4, 2014, which is 160 Kb in size.The information in the electronic format of the sequence listing isincorporated herein by reference in its entirety.

FIELD

Provided herein are methods, compounds, and compositions for reducingexpression of fibroblast growth factor receptor 4 (FGFR4) mRNA andprotein in an animal. Such methods, compounds, and compositions areuseful, for example, to treat, prevent, delay or ameliorate diseasesassociated with metabolic disorders, particularly disorders associatedwith obesity.

BACKGROUND

Obesity is considered a long-term metabolic disease. There are severalserious medical sequelae related to obesity. There are over 1 billionoverweight individuals worldwide with 100 million clinically obese. Theincreasing health care costs of treating obesity related diseases in theUS alone are estimated at over $100 billion annually. Current methodsfor treating obesity include behavioral modification, diet, surgery(gastroplasty), administering pharmaceutical agents that block appetitestimulating signals or absorption of nutrients (fat), and administeringagents that increase thermogenesis or fat metabolism. Some of thesemethods have disadvantages in that they rely on patient resolve, areinvasive, or have unwanted side effects. An understanding of themechanisms by which obesity is regulated may provide importanttherapeutic information.

Obesity is frequently associated with insulin resistance and togetherconstitutes risk factors for later development of type 2 diabetes andcardiovascular diseases. Insulin resistance occurs well beforedevelopment of type 2 diabetes, and insulin is overproduced tocompensate for the insulin resistance and to maintain normal glucoselevels. Type 2 diabetes ensues, as the pancreas can no longer produceenough insulin to maintain normal glucose levels. Early stages of type 2diabetes are associated with elevated levels of insulin but as thedisease progresses the pancreas may fail to produce insulin, resultingin increased blood glucose levels. Diabetes is a significant risk factorfor both heart disease and stroke and is the leading cause of blindnessand end-stage renal failure.

Diabetes is a disorder characterized by hyperglycemia due to deficientinsulin action that may result from reduced insulin production orinsulin resistance or both. Diabetes mellitus is a polygenic disorderaffecting a significant portion of the people in the world. It isdivided into two types. In type I diabetes, or insulin-dependentdiabetes mellitus (IDDM), patients produce little or no insulin, thehormone that regulates glucose utilization. In type 2 diabetes, ornoninsulin-dependent diabetes mellitus (NIDDM), patients often haveplasma insulin levels that are the same compared to nondiabetic humans;however, these patients have developed a resistance to the insulinstimulating effect of glucose and lipid metabolism in the maininsulin-sensitive tissues, i.e., muscle, liver and adipose tissues, andthe plasma insulin levels are insufficient to overcome the pronouncedinsulin resistance. Additionally, glucotoxicity, which results fromlong-term hyperglycemia, induces tissue-dependent insulin resistance(Nawano et al., Am. J. Physiol. Endocrinol. Metab., 278, E535-543)exacerbating the disease. Type 2 diabetes accounts for over 90% of alldiabetes cases. It is a metabolic disorder characterized byhyperglycemia leading to secondary complications such as neuropathy,nephropathy, retinopathy, hypertriglyceridemia, obesity, and othercardiovascular diseases generally referred to as metabolic syndrome.

Metabolic syndrome is a combination of medical disorders that increaseone's risk for cardiovascular disease and diabetes. The symptoms,including high blood pressure, high triglycerides, decreased HDL andobesity, tend to appear together in some individuals. Metabolic syndromeis known under various other names, such as (metabolic) syndrome X,insulin resistance syndrome or Reaven's syndrome.

Diabetes and obesity (sometimes now collectively referred to as“diabesity”) are interrelated in that obesity is known to exacerbate thepathology of diabetes and greater than 60% of diabetics are obese. Mosthuman obesity is associated with insulin resistance and leptinresistance. In fact, it has been suggested that obesity may have an evengreater impact on insulin action than diabetes itself (Sindelka et al.,Physiol Res., 51, 85-91). Additionally, several compounds on the marketfor the treatment of diabetes are known to induce weight gain, a veryundesirable side effect to the treatment of this disease. Therefore, acompound that has the potential to treat both diabetes and obesity wouldprovide a significant improvement over current treatments.

Fibroblast growth factor receptor 4 (also known as FGF receptor-4, TKF;tyrosine kinase related to fibroblast growth factor receptor;hydroxyaryl-protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-4; FGFR4;CD334, FGFR4_HUMAN and JTK2) has high affinity for the acidic and/orbasic fibroblast growth factors. (Armstrong et al., Genes ChromosomesCancer, 4, 94-98).

Although FGFRs generally have been shown to have wide distributionthroughout the body, to date, FGFR4 has only been found in a fewtissues. Among a wide variety of cells and tissues tested, includinghuman lymphocytes and macrophages, FGFR4 was found to be expressed inthe lung and in some tumors of lung origin as well as in malignanciesnot derived from lung tissues. (Holtrich et al., Proc. Nat. Acad. Sci.,88, 10411-10415). FGFR4 has also been found to be expressed in the liverand in adipose tissues. (Patel et al., JCEM, 90(2), 1226-1232). FGFR4has also been found to be expressed in certain carcinoma cell lines.(Bange et al., Cancer Res., 62, 840-847).

Additionally, FGFR4 has been shown to play a role in systemic lipid andglucose homeostasis. FGFR4-deficient mice on a normal diet exhibitedfeatures of metabolic syndrome that include increase mass of insulinresistance, in addition to hypercholesterolemia. FGFR4 deficiency wasshown to alleviate high-fat diet-induced fatty liver in a certain obesemouse model, which is also a correlate of metabolic syndrome.Restoration of FGFR4, specifically in hepatocytes of FGFR4 deficientmice, decrease plasma lipid level and restored the high fat diet-inducedfatty liver but failed to restore glucose tolerance and sensitivity toinsulin. (Huang et al., Diabetes, 56, 2501-2510).

Antisense inhibition of FGFR4 provides a unique advantage overtraditional small molecule inhibitors in that antisense inhibitors donot rely on competitive binding of the compound to the protein andinhibit activity directly by reducing the expression of FGFR4. Arepresentative United States patent that teaches FGFR4 antisenseinhibitors includes US. Pat. Publication No. US2010/0292140, of which isherein incorporated by reference in its entirety. Antisense technologyis emerging as an effective means for reducing the expression of certaingene products and may therefore prove to be uniquely useful in a numberof therapeutic, diagnostic, and research applications for the modulationof FGFR4.

There is a currently a lack of acceptable options for treating metabolicdisorders. It is therefore an object herein to provide compounds andmethods for the treatment of such diseases and disorder. This inventionrelates to the discovery of novel, highly potent inhibitors of FGFR4gene expression.

All documents, or portions of documents, cited in this application,including, but not limited to, patents, patent applications, articles,books, and treatises, are hereby expressly incorporated-by-reference forthe portions of the document discussed herein, as well as in theirentirety.

SUMMARY

Provided herein are methods, compounds, and compositions for modulatingexpression of FGFR4 and treating, preventing, delaying or amelioratingdiseases associated with metabolic disorders, particularly disordersassociated with obesity and/or a symptom thereof.

DETAILED DESCRIPTION

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory onlyand are not restrictive described herein, as claimed. Herein, the use ofthe singular includes the plural unless specifically stated otherwise.As used herein, the use of “or” means “and/or” unless stated otherwise.Furthermore, the use of the term “including” as well as other forms,such as “includes” and “included”, is not limiting. Also, terms such as“element” or “component” encompass both elements and componentscomprising one unit and elements and components that comprise more thanone subunit, unless specifically stated otherwise.

The section headings used herein are for organizational purposes onlyand are not to be construed as limiting the subject matter described.All documents, or portions of documents, cited in this application,including, but not limited to, patents, patent applications, articles,books, and treatises, are hereby expressly incorporated-by-reference forthe portions of the document discussed herein, as well as in theirentirety.

DEFINITIONS

Unless specific definitions are provided, the nomenclature utilized inconnection with, and the procedures and techniques of, analyticalchemistry, synthetic organic chemistry, and medicinal and pharmaceuticalchemistry described herein are those well known and commonly used in theart. Standard techniques can be used for chemical synthesis, andchemical analysis. Where permitted, all documents, or portions ofdocuments, cited in this application, including, but not limited to, allpatents, applications, published applications and other journalpublications, GENBANK Accession Numbers and associated sequenceinformation obtainable through databases such as National Center forBiotechnology Information (NCBI) and other data referred to throughoutin the disclosure herein are incorporated by reference for the portionsof the document discussed herein, as well as in their entirety.

Unless otherwise indicated, the following terms have the followingmeanings:

“2′-O-methoxyethyl” (also 2′-MOE and 2′-O(CH₂)₂—OCH₃) refers to anO-methoxy-ethyl modification of the 2′ position of a furosyl ring. A2′-O-methoxyethyl modified sugar is a modified sugar.

“2′-O-methoxyethyl nucleotide” means a nucleotide comprising a2′-O-methoxyethyl modified sugar moiety.

“3′ target site” refers to the nucleotide of a target nucleic acid whichis complementary to the 3′-most nucleotide of a particular antisensecompound.

“5′ target site” refers to the nucleotide of a target nucleic acid whichis complementary to the 5′-most nucleotide of a particular antisensecompound.

“5-methylcytosine” means a cytosine modified with a methyl groupattached to the 5′ position. A 5-methylcytosine is a modifiednucleobase.

“About” means within ±10% of a value. For example, if it is stated, “amarker may be increased by about 50%”, it is implied that the marker maybe increased between 45%-55%.

“Active pharmaceutical agent” means the substance or substances in apharmaceutical composition that provide a therapeutic benefit whenadministered to an individual. For example, in certain embodiments anantisense oligonucleotide targeted to FGFR4 is an active pharmaceuticalagent.

“Active target region” or “target region” means a region to which one ormore active antisense compounds is targeted. “Active antisensecompounds” means antisense compounds that reduce target nucleic acidlevels or protein levels.

“Adipogenesis” means the development of fat cells from preadipocytes.“Lipogenesis” means the production or formation of fat, either fattydegeneration or fatty infiltration.

“Adipose tissue” or “body fat” or “fat depot” is loose connective tissuecomposed of adipocytes. Two types of adipose tissue exist: white adiposetissue (WAT) and brown adipose tissue (BAT).

“Adiposity” or “Obesity” refers to the state of being obese or anexcessively high amount of body fat or adipose tissue in relation tolean body mass. The amount of body fat includes concern for both thedistribution of fat throughout the body and the size and mass of theadipose tissue deposits. Body fat distribution can be estimated byskin-fold measures, waist-to-hip circumference ratios, or techniquessuch as ultrasound, computed tomography, or magnetic resonance imaging.According to the Center for Disease Control and Prevention, individualswith a body mass index (BMI) of 30 or more are considered obese. Theterm “Obesity” as used herein includes conditions where there is anincrease in body fat beyond the physical requirement as a result ofexcess accumulation of adipose tissue in the body. The term “obesity”includes, but is not limited to, the following conditions: adult-onsetobesity; alimentary obesity; endogenous or inflammatory obesity;endocrine obesity; familial obesity; hyperinsulinar obesity;hyperplastic-hypertrophic obesity; hypogonadal obesity; hypothyroidobesity; lifelong obesity; morbid obesity and exogenous obesity.

“Administered concomitantly” refers to the co-administration of twoagents in any manner in which the pharmacological effects of both aremanifest in the patient at the same time. Concomitant administrationdoes not require that both agents be administered in a singlepharmaceutical composition, in the same dosage form, or by the sameroute of administration. The effects of both agents need not manifestthemselves at the same time. The effects need only be overlapping for aperiod of time and need not be coextensive.

“Administering” means providing an agent to an animal, and includes, butis not limited to, administering by a medical professional andself-administering.

“Agent” means an active substance that can provide a therapeutic benefitwhen administered to an animal. “First Agent” means a therapeuticcompound provided herein. For example, a first agent can be an antisenseoligonucleotide targeting FGFR4. “Second agent” means a secondtherapeutic compound described herein (e.g. a second antisenseoligonucleotide targeting FGFR4) and/or a non-FGFR4 therapeuticcompound.

“Amelioration” refers to a lessening of at least one indicator, sign, orsymptom of an associated disease, disorder, or condition. The severityof indicators can be determined by subjective or objective measures,which are known to those skilled in the art.

“Animal” refers to a human or non-human animal, including, but notlimited to, mice, rats, rabbits, dogs, cats, pigs, and non-humanprimates, including, but not limited to, monkeys and chimpanzees.

“Antisense activity” means any detectable or measurable activityattributable to the hybridization of an antisense compound to its targetnucleic acid. In certain embodiments, antisense activity is a decreasein the amount or expression of a target nucleic acid or protein encodedby such target nucleic acid.

“Antisense compound” means an oligomeric compound that is capable ofundergoing hybridization to a target nucleic acid through hydrogenbonding.

“Antisense inhibition” means reduction of target nucleic acid levels ortarget protein levels in the presence of an antisense compoundcomplementary to a target nucleic acid compared to target nucleic acidlevels or target protein levels in the absence of the antisensecompound.

“Antisense oligonucleotide” means a single-stranded oligonucleotidehaving a nucleobase sequence that permits hybridization to acorresponding region or segment of a target nucleic acid.

“Bicyclic sugar” means a furosyl ring modified by the bridging of twonon-geminal ring atoms. A bicyclic sugar is a modified sugar.

“Bicyclic nucleic acid” or “BNA” refers to a nucleoside or nucleotidewherein the furanose portion of the nucleoside or nucleotide includes abridge connecting two carbon atoms on the furanose ring, thereby forminga bicyclic ring system.

“Biomarker” is meant to designate a gene or protein or protein fragmentwhich is indicative of the effect of an FGFR4 inhibitor. That means the“biomarker” is used as a detection agent.

“Cap structure” or “terminal cap moiety” means chemical modifications,which have been incorporated at either terminus of an antisensecompound.

“Chemically distinct region” refers to a region of an antisense compoundthat is in some way chemically different than another region of the sameantisense compound. For example, a region having 2′-O-methoxyethylnucleotides is chemically distinct from a region having nucleotideswithout 2′-O-methoxyethyl modifications.

“Chimeric antisense compound” means an antisense compound that has atleast two chemically distinct regions.

“Co-administration” means administration of two or more agents to anindividual. The two or more agents can be in a single pharmaceuticalcomposition, or can be in separate pharmaceutical compositions. Each ofthe two or more agents can be administered through the same or differentroutes of administration. Co-administration encompasses parallel orsequential administration.

“Cholesterol” is a sterol molecule found in the cell membranes of allanimal tissues. Cholesterol must be transported in an animal's bloodplasma by lipoproteins including very low density lipoprotein (VLDL),intermediate density lipoprotein (IDL), low density lipoprotein (LDL),and high density lipoprotein (HDL). “Plasma cholesterol” refers to thesum of all lipoproteins (VDL, IDL, LDL, HDL) esterified and/ornon-esterified cholesterol present in the plasma or serum.

“Complementarity” means the capacity for pairing between nucleobases ofa first nucleic acid and a second nucleic acid.

“cEt” or “constrained ethyl” means a bicyclic sugar moiety comprising abridge connecting the 4′-carbon and the 2′-carbon, wherein the bridgehas the formula: 4′-CH(CH₃)—O-2′.

“Constrained ethyl nucleoside” (also cEt nucleoside) means a nucleosidecomprising a bicyclic sugar moiety comprising a 4′-CH(CH₃)—O-2′ bridge.

“Contiguous nucleobases” means nucleobases immediately adjacent to eachother.

“Deoxyribonucleotide” means a nucleotide having a hydrogen at the 2′position of the sugar portion of the nucleotide. Deoxyribonucleotidesmay be modified with any of a variety of substituents.

“Diabetes mellitus” or “diabetes” is a syndrome characterized bydisordered metabolism and abnormally high blood sugar (hyperglycemia)resulting from insufficient levels of insulin or reduced insulinsensitivity. The characteristic symptoms are excessive urine production(polyuria) due to high blood glucose levels, excessive thirst andincreased fluid intake (polydipsia) attempting to compensate forincreased urination, blurred vision due to high blood glucose effects onthe eye's optics, unexplained weight loss, and lethargy.

“Diabetic dyslipidemia” or “type 2 diabetes with dyslipidemia” means acondition characterized by Type 2 diabetes, reduced HDL-C, elevatedtriglycerides, and elevated small, dense LDL particles.

“Diluent” means an ingredient in a composition that lackspharmacological activity, but is pharmaceutically necessary ordesirable. For example, the diluent in an injected composition can be aliquid, e.g. saline solution.

“Dyslipidemia” refers to a disorder of lipid and/or lipoproteinmetabolism, including lipid and/or lipoprotein overproduction ordeficiency. Dyslipidemias may be manifested by elevation of lipids suchas cholesterol and triglycerides as well as lipoproteins such aslow-density lipoprotein (LDL) cholesterol.

“Dosage unit” means a form in which a pharmaceutical agent is provided,e.g. pill, tablet, or other dosage unit known in the art. In certainembodiments, a dosage unit is a vial containing lyophilized antisenseoligonucleotide. In certain embodiments, a dosage unit is a vialcontaining reconstituted antisense oligonucleotide.

“Dose” means a specified quantity of a pharmaceutical agent provided ina single administration, or in a specified time period. In certainembodiments, a dose can be administered in one, two, or more boluses,tablets, or injections. For example, in certain embodiments wheresubcutaneous administration is desired, the desired dose requires avolume not easily accommodated by a single injection, therefore, two ormore injections can be used to achieve the desired dose. In certainembodiments, the pharmaceutical agent is administered by infusion overan extended period of time or continuously. Doses can be stated as theamount of pharmaceutical agent per hour, day, week, or month.

“Effective amount” or “therapeutically effective amount” means theamount of active pharmaceutical agent sufficient to effectuate a desiredphysiological outcome in an individual in need of the agent. Theeffective amount can vary among individuals depending on the health andphysical condition of the individual to be treated, the taxonomic groupof the individuals to be treated, the formulation of the composition,assessment of the individual's medical condition, and other relevantfactors.

“Fibroblast growth factor 4” or “FGFR4” means any nucleic acid orprotein of FGFR4.

“FGFR4 expression” means the level of mRNA transcribed from the geneencoding FGFR4 or the level of protein translated from the mRNA. FGFR4expression can be determined by art known methods such as a Northern orWestern blot.

“FGFR4 nucleic acid” means any nucleic acid encoding FGFR4. For example,in certain embodiments, a FGFR4 nucleic acid includes a DNA sequenceencoding FGFR4, a RNA sequence transcribed from DNA encoding FGFR4(including genomic DNA comprising introns and exons), and a mRNAsequence encoding FGFR4. “FGFR4 mRNA” means a mRNA encoding a FGFR4protein.

“Fully complementary” or “100% complementary” means each nucleobase of anucleobase sequence of a first nucleic acid has a complementarynucleobase in a second nucleobase sequence of a second nucleic acid. Incertain embodiments, a first nucleic acid is an antisense compound and atarget nucleic acid is a second nucleic acid.

“Gapmer” means a chimeric antisense compound in which an internal regionhaving a plurality of nucleosides that support RNase H cleavage ispositioned between external regions having one or more nucleosides,wherein the nucleosides comprising the internal region are chemicallydistinct from the nucleoside or nucleosides comprising the externalregions. The internal region can be referred to as a “gap segment” andthe external regions can be referred to as “wing segments.”

“Gap-widened” means a chimeric antisense compound having a gap segmentof 12 or more contiguous 2′-deoxyribonucleosides positioned between andimmediately adjacent to 5′ and 3′ wing segments having from one to sixnucleosides.

“Glucose” is a monosaccharide used by cells as a source of energy andinflammatory intermediate. “Plasma glucose” refers to glucose present inthe plasma.

“Hybridization” means the annealing of complementary nucleic acidmolecules. In certain embodiments, complementary nucleic acid moleculesinclude an antisense compound and a target nucleic acid.

“Hyperlipidemia” or “hyperlipemia” is a condition characterized byelevated serum lipids or circulating (plasma) lipids. This conditionmanifests an abnormally high concentration of fats. The lipid fractionsin the circulating blood are cholesterol, low density lipoproteins, verylow density lipoproteins and triglycerides.

“Hypertriglyceridemia” means a condition characterized by elevatedtriglyceride levels.

“Identifying” or “selecting an animal with metabolic” means identifyingor selecting a subject having been diagnosed with a metabolic disease,or a metabolic disorder; or, identifying or selecting a subject havingany symptom of a metabolic disease, including, but not limited to,metabolic syndrome, hyperglycemia, hypertriglyceridemia, hypertensionincreased insulin resistance, decreased insulin sensitivity, abovenormal body weight, and/or above normal body fat or any combinationthereof. Such identification may be accomplished by any method,including but not limited to, standard clinical tests or assessments,such as measuring serum or circulating (plasma) blood-glucose, measuringserum or circulating (plasma) triglycerides, measuring blood-pressure,measuring body fat, measuring body weight, and the like.

“Immediately adjacent” means there are no intervening elements betweenthe immediately adjacent elements.

“Individual” or “subject” or “animal” means a human or non-human animalselected for treatment or therapy.

“Inhibiting the expression or activity” refers to a reduction orblockade of the expression or activity of a RNA or protein and does notnecessarily indicate a total elimination of expression or activity.

“Insulin resistance” is defined as the condition in which normal amountsof insulin are inadequate to produce a normal insulin response from fat,muscle and liver cells. Insulin resistance in fat cells results inhydrolysis of stored triglycerides, which elevates free fatty acids inthe blood plasma. Insulin resistance in muscle reduces glucose uptakewhereas insulin resistance in liver reduces glucose storage, with botheffects serving to elevate blood glucose. High plasma levels of insulinand glucose due to insulin resistance often leads to metabolic syndromeand type 2 diabetes.

“Insulin sensitivity” is a measure of how effectively an individualprocesses glucose. An individual having high insulin sensitivityeffectively processes glucose whereas an individual with low insulinsensitivity does not effectively process glucose.

“Internucleoside linkage” refers to the chemical bond betweennucleosides.

“Intravenous administration” means administration into a vein.

“Linked nucleosides” means adjacent nucleosides which are bondedtogether.

“Lipid-lowering therapy” or “lipid lowering agent” means a therapeuticregimen provided to a subject to reduce one or more lipids in a subject.In certain embodiments, a lipid-lowering therapy is provided to reduceone or more of ApoB, total cholesterol, LDL-C, VLDL-C, IDL-C, non-HDL-C,triglycerides, small dense LDL particles, and Lp(a) in a subject.Examples of lipid-lowering therapy include statins, fibrates, and MTPinhibitors.

“Major risk factors” refers to factors that contribute to a high riskfor a particular disease or condition. In certain embodiments, majorrisk factors for coronary heart disease include, without limitation,cigarette smoking, hypertension, low HDL-C, family history of coronaryheart disease, age, and other factors disclosed herein.

“Metabolic disease” or “metabolic disorder” refers to a conditioncharacterized by an alteration or disturbance in metabolic function.“Metabolic” and “metabolism” are terms well known in the art andgenerally include the whole range of biochemical processes that occurwithin a living organism. Metabolic diseases or disorders include, butare not limited to, obesity, diabetes, hyperglycemia, prediabetes,non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, insulinresistance, diabetic dyslipidemia, or hypertriglyceridemia or acombination thereof.

“Metabolic syndrome” means a condition characterized by a clustering oflipid and non-lipid cardiovascular risk factors of metabolic origin. Incertain embodiments, metabolic syndrome is identified by the presence ofany 3 of the following factors: waist circumference of greater than 102cm in men or greater than 88 cm in women; serum triglyceride of at least150 mg/dL; HDL-C less than 40 mg/dL in men or less than 50 mg/dL inwomen; blood pressure of at least 130/85 mmHg; and fasting glucose of atleast 110 mg/dL. These determinants can be readily measured in clinicalpractice (JAMA, 2001, 285: 2486-2497).

“Mismatch” or “non-complementary nucleobase” refers to the case when anucleobase of a first nucleic acid is not capable of pairing with thecorresponding nucleobase of a second or target nucleic acid.

“Mixed dyslipidemia” means a condition characterized by elevatedcholesterol and elevated triglycerides.

“Modified internucleoside linkage” refers to a substitution or anychange from a naturally occurring internucleoside bond (i.e. aphosphodiester internucleoside bond).

“Modified nucleobase” refers to any nucleobase other than adenine,cytosine, guanine, thymidine, or uracil. An “unmodified nucleobase”means the purine bases adenine (A) and guanine (G), and the pyrimidinebases thymine (T), cytosine (C), and uracil (U).

“Modified nucleoside” means a nucleoside having, independently, amodified sugar moiety or modified nucleobase.

“Modified nucleotide” means a nucleotide having, independently, amodified sugar moiety, modified internucleoside linkage, or modifiednucleobase. A “modified nucleoside” means a nucleoside having,independently, a modified sugar moiety or modified nucleobase.

“Modified oligonucleotide” means an oligonucleotide comprising at leastone modified nucleotide.

“Modified sugar” refers to a substitution or change from a naturalsugar.

“Motif” means the pattern of chemically distinct regions in an antisensecompound.

“Naturally occurring internucleoside linkage” means a 3′ to 5′phosphodiester linkage.

“Natural sugar moiety” means a sugar found in DNA (2′-H) or RNA (2′-OH).

“Non-alcoholic fatty liver disease” or “NAFLD” means a conditioncharacterized by fatty inflammation of the liver that is not due toexcessive alcohol use (for example, alcohol consumption of over 20g/day). In certain embodiments, NAFLD is related to insulin resistanceand the metabolic syndrome. NAFLD encompasses a disease spectrum rangingfrom simple triglyceride accumulation in hepatocytes (hepatic steatosis)to hepatic steatosis with inflammation (steatohepatitis), fibrosis, andcirrhosis.

“Nonalcoholic steatohepatitis” (NASH) occurs from progression of NAFLDbeyond deposition of triglycerides. A “second hit” capable of inducingnecrosis, inflammation, and fibrosis is required for development ofNASH. Candidates for the second-hit can be grouped into broadcategories: factors causing an increase in oxidative stress and factorspromoting expression of proinflammatory cytokines

“Nucleic acid” refers to molecules composed of monomeric nucleotides. Anucleic acid includes ribonucleic acids (RNA), deoxyribonucleic acids(DNA), single-stranded nucleic acids, double-stranded nucleic acids,small interfering ribonucleic acids (siRNA), and microRNAs (miRNA). Anucleic acid can also comprise a combination of these elements in asingle molecule.

“Nucleobase” means a heterocyclic moiety capable of pairing with a baseof another nucleic acid.

“Nucleobase sequence” means the order of contiguous nucleobasesindependent of any sugar, linkage, or nucleobase modification.

“Nucleoside” means a nucleobase linked to a sugar.

“Nucleoside mimetic” includes those structures used to replace the sugaror the sugar and the base and not necessarily the linkage at one or morepositions of an oligomeric compound such as for example nucleosidemimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl,bicyclo or tricyclo sugar mimetics e.g. non furanose sugar units.

“Nucleotide” means a nucleoside having a phosphate group covalentlylinked to the sugar portion of the nucleoside.

“Nucleotide mimetic” includes those structures used to replace thenucleoside and the linkage at one or more positions of an oligomericcompound such as for example peptide nucleic acids or morpholinos(morpholinos linked by —N(H)—C(═O)—O— or other non-phosphodiesterlinkage).

“Oligomeric compound” or “oligomer” refers to a polymeric structurecomprising two or more sub-structures and capable of hybridizing to aregion of a nucleic acid molecule. In certain embodiments, oligomericcompounds are oligonucleosides. In certain embodiments, oligomericcompounds are oligonucleotides. In certain embodiments, oligomericcompounds are antisense compounds. In certain embodiments, oligomericcompounds are antisense oligonucleotides. In certain embodiments,oligomeric compounds are chimeric oligonucleotides.

“Oligonucleotide” means a polymer of linked nucleosides each of whichcan be modified or unmodified, independent one from another.

“Parenteral administration” means administration through injection orinfusion. Parenteral administration includes subcutaneousadministration, intravenous administration, intramuscularadministration, intraarterial administration, intraperitonealadministration, or intracranial administration, e.g. intrathecal orintracerebroventricular administration. Administration can becontinuous, or chronic, or short or intermittent.

“Peptide” means a molecule formed by linking at least two amino acids byamide bonds. Peptide refers to polypeptides and proteins.

“Pharmaceutical agent” means a substance that provides a therapeuticbenefit when administered to an individual. For example, in certainembodiments, an antisense oligonucleotide targeted to FGFR4 ispharmaceutical agent.

“Pharmaceutical composition” means a mixture of substances suitable foradministering to an individual. For example, a pharmaceuticalcomposition can comprise one or more active agents and a sterile aqueoussolution.

“Pharmaceutically acceptable carrier” means a medium or diluent thatdoes not interfere with the structure of the oligonucleotide. Certain,of such carries enable pharmaceutical compositions to be formulated as,for example, tablets, pills, dragees, capsules, liquids, gels, syrups,slurries, suspension and lozenges for the oral ingestion by a subject.For example, a pharmaceutically acceptable carrier can be a sterileaqueous solution.

“Pharmaceutically acceptable derivative” encompasses pharmaceuticallyacceptable salts, conjugates, prodrugs or isomers of the compoundsdescribed herein.

“Pharmaceutically acceptable salts” means physiologically andpharmaceutically acceptable salts of antisense compounds, i.e., saltsthat retain the desired biological activity of the parentoligonucleotide and do not impart undesired toxicological effectsthereto.

“Phosphorothioate linkage” means a linkage between nucleosides where thephosphodiester bond is modified by replacing one of the non-bridgingoxygen atoms with a sulfur atom. A phosphorothioate linkage is amodified internucleoside linkage.

“Portion” means a defined number of contiguous (i.e. linked) nucleobasesof a nucleic acid. In certain embodiments, a portion is a defined numberof contiguous nucleobases of a target nucleic acid. In certainembodiments, a portion is a defined number of contiguous nucleobases ofan antisense compound.

“Prevent” refers to delaying or forestalling the onset or development ofa disease, disorder, or condition for a period of time from minutes toindefinitely. Prevent also means reducing risk of developing a disease,disorder, or condition.

“Prodrug” means a therapeutic agent that is prepared in an inactive formthat is converted to an active form within the body or cells thereof bythe action of endogenous enzymes or other chemicals or conditions.

“Side effects” means physiological responses attributable to a treatmentother than the desired effects. In certain embodiments, side effectsinclude injection site reactions, liver function test abnormalities,renal function abnormalities, liver toxicity, renal toxicity, centralnervous system abnormalities, myopathies, and malaise. For example,increased aminotransferase levels in serum can indicate liver toxicityor liver function abnormality. For example, increased bilirubin canindicate liver toxicity or liver function abnormality.

“Single-stranded oligonucleotide” means an oligonucleotide which is nothybridized to a complementary strand.

“Specifically hybridizable” refers to an antisense compound having asufficient degree of complementarity between an antisenseoligonucleotide and a target nucleic acid to induce a desired effect,while exhibiting minimal or no effects on non-target nucleic acids underconditions in which specific binding is desired, i.e. underphysiological conditions in the case of in vivo assays and therapeutictreatments.

“Statin” means an agent that inhibits the activity of HMG-CoA reductase.

“Subcutaneous administration” means administration just below the skin.

“Targeting” or “targeted” means the process of design and selection ofan antisense compound that will specifically hybridize to a targetnucleic acid and induce a desired effect.

“Target nucleic acid,” “target RNA,” and “target RNA transcript” allrefer to a nucleic acid capable of being targeted by antisensecompounds.

“Target segment” means the sequence of nucleotides of a target nucleicacid to which an antisense compound is targeted. “5′ target site” refersto the 5′-most nucleotide of a target segment. “3′ target site” refersto the 3′-most nucleotide of a target segment.

“Therapeutically effective amount” means an amount of an agent thatprovides a therapeutic benefit to an individual.

“Therapeutic lifestyle change” means dietary and lifestyle changesintended to lower fat/adipose tissue mass and/or cholesterol. Suchchange can reduce the risk of developing heart disease, and may includesrecommendations for dietary intake of total daily calories, total fat,saturated fat, polyunsaturated fat, monounsaturated fat, carbohydrate,protein, cholesterol, insoluble fiber, as well as recommendations forphysical activity.

“Triglyceride” or “TG” means a lipid or neutral fat consisting ofglycerol combined with three fatty acid molecules.

“Type 2 diabetes,” (also known as “type 2 diabetes mellitus” or“diabetes mellitus, type 2”, and formerly called “diabetes mellitus type2”, “non-insulin-dependent diabetes (NIDDM)”, “obesity relateddiabetes”, or “adult-onset diabetes”) is a metabolic disorder that isprimarily characterized by insulin resistance, relative insulindeficiency, and hyperglycemia.

“Treat” refers to administering a pharmaceutical composition to ananimal to effect an alteration or improvement of a disease, disorder, orcondition.

“Unmodified nucleotide” means a nucleotide composed of naturallyoccurring nucleobases, sugar moieties, and internucleoside linkages. Incertain embodiments, an unmodified nucleotide is an RNA nucleotide (i.e.β-D-ribonucleosides) or a DNA nucleotide (i.e. β-D-deoxyribonucleoside).

Certain Embodiments

Certain embodiments provide methods, compounds, and compositions forinhibiting FGFR4 expression.

Certain embodiments provide antisense compounds targeted to a FGFR4nucleic acid. In certain embodiments, the FGFR4 nucleic acid is any ofthe sequences set forth in GENBANK Accession No. NM_(—)002011.3(incorporated herein as SEQ ID NO: 1), GENBANK Accession No:NT_(—)023133.11 truncated from nucleosides 21323018 to 21335213(incorporated herein as SEQ ID NO: 2); and GENBANK Accession No.AB209631.1 (incorporated herein as SEQ ID NO: 3); and GENBANK AccessionNo NM_(—)022963.2 (incorporated herein as SEQ ID NO: 4). In certainembodiments, FGFR4 has the rhesus monkey sequence as set forth inGENBANK Accession No. NW_(—)001121000.1 truncated from nucleosides3094000 to 3109000 (SEQ ID NO: 5). In certain embodiments, FGFR4 has themurine sequence as set forth in GENBANK Accession No. BC033313.1 (SEQ IDNO: 6).

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 12 to 30 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-6.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 12 to 30 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereinconsist of 12 to 30 linked nucleosides and have a nucleobase sequencecomprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleobases of any of SEQ ID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincan consist of 12 to 30 linked nucleosides and have a nucleobasesequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 contiguous nucleobases of any of SEQ ID NOs: 16, 17, 45, 46,70, 72, or 138.

In certain embodiments, the compound or composition provided herein isor comprises ISIS NOs: 463588, 463589, 463690, 463691, 463835, 463837,or 464225.

In certain embodiments, the compounds or compositions provided hereinconsist of 12 to 30 linked nucleosides and have a nucleobase sequencecomprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleobases of SEQ ID NO: 16.

In certain embodiments, the compounds or compositions provided hereinconsist of 12 to 30 linked nucleosides and have a nucleobase sequencecomprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleobases of SEQ ID NO: 45.

In certain embodiments, the compound or composition is or comprises ISISNO: 463588.

In certain embodiments, the compound or composition is or comprises ISISNO: 463690.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 15 to 30 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereinconsist of 15 to 30 linked nucleosides and have a nucleobase sequencecomprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleobases of any of SEQ ID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereinconsist of 15 to 30 linked nucleosides and have a nucleobase sequencecomprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleobases of any of SEQ ID NOs: 16, 17, 45, 46, 70, 72, or138.

In certain embodiments, the compound or composition provided herein isor comprises ISIS NOs: 463588, 463589, 463690, 463691, 463835, 463837,or 464225.

In certain embodiments, the compounds or compositions provided hereinconsist of 15 to 30 linked nucleosides and have a nucleobase sequencecomprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleobases of SEQ ID NO: 16.

In certain embodiments, the compounds or compositions provided hereinconsist of 15 to 30 linked nucleosides and have a nucleobase sequencecomprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleobases of SEQ ID NO: 45.

In certain embodiments, the compound or composition provided herein isor comprise ISIS NO: 463588.

In certain embodiments, the compound or composition provided herein isor comprise ISIS NO: 463690.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 18 to 21 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 18 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of anyof SEQ ID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 18 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of anyof SEQ ID NOs: 16, 17, 45, 46, 70, 72, or 138

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 18 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 18 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 35 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 35 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 35 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 16, 17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincan consist of 20 to 35 linked nucleosides and have a nucleobasesequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 contiguous nucleobases of SEQ ID NO: 16.

In certain embodiments, the compounds or compositions provided hereincan consist of 20 to 35 linked nucleosides and have a nucleobasesequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 contiguous nucleobases of SEQ ID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 30 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 30 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 30 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 16, 17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 30 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 30 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 25 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 25 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 25 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16, 17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 25 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 25 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 45.

In certain embodiments, the compounds or compositions described hereincomprise a modified oligonucleotide consisting of 20 to 24 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 24 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 24 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16, 17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 24 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 24 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 23 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 23 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 23 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16, 17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 23 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 23 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 22 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 22 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 22 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16, 17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 221 inkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 22 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 21 nucleosideshaving a nucleobase sequence complementary to an equal length portion ofany of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 21 linkednucleosides and having a nucleobase sequence complementary to an equallength portion of any of SEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NOs: 7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16, 17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 to 21 linkednucleosides and have a nucleobase sequence comprising at least 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 nucleosides havinga nucleobase sequence complementary to an equal length portion of any ofSEQ ID NOs: 1-4.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosidesand have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQ ID NOs:7-322.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosidesand have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQ ID NO: 16,17, 45, 46, 70, 72, or 138.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosidesand have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQ ID NO: 16.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosidesand have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of SEQ ID NO: 45.

In certain embodiments, the compounds or compositions provided hereincomprise a salt of the modified oligonucleotide.

In certain embodiments, the compounds or compositions provided hereinfurther comprise a pharmaceutically acceptable carrier or diluent.

In certain embodiments, the nucleobase sequence of the modifiedoligonucleotide is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,99% or 100% complementary to any one of SEQ ID NOs: 1-4 as measured overthe entirety of the modified oligonucleotide.

In certain embodiments, the nucleobase sequence of the modifiedoligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,98%, 99% or 100% identity to any one of SEQ ID NOs: 7-322 as measuredover the entirety of the modified oligonucleotide.

In certain embodiments, the nucleobase sequence of the modifiedoligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,98%, 99% or 100% identity to any one of SEQ ID NOs: 16, 17, 45, 46, 70,72, or 138 as measured over the entirety of the modifiedoligonucleotide.

In certain embodiments, the nucleobase sequence of the modifiedoligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,98%, 99% or 100% identity to SEQ ID NO: 16 as measured over the entiretyof the modified oligonucleotide.

In certain embodiments, the nucleobase sequence of the modifiedoligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,98%, 99% or 100% identity to SEQ ID NO: 45 as measured over the entiretyof the modified oligonucleotide.

In certain embodiments, antisense compounds or modified oligonucleotidestargets a region of a FGFR4 nucleic acid. In certain embodiments, suchcompounds or oligonucleotides targeted to a region of a FGFR4 nucleicacid have a contiguous nucleobase portion that is complementary to anequal length nucleobase portion of the region. For example, the portioncan be at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20contiguous nucleobases portion complementary to an equal length portionof a region recited herein. In certain embodiments, such compounds oroligonucleotide target the following nucleotide regions of SEQ ID NO: 1:160-179, 191-210, 191-211, 191-212, 191-213, 192-211, 192-212, 192-213,193-212, 193-213, 194-213, 196-215, 196-216, 197-216, 200-219, 202-221,202-222, 203-222, 290-310, 290-309, 290-311, 290-312, 290-312, 291-310,291-311, 291-312, 292-311, 292-312, 293-312, 309-328, 332-351, 338-357,338-358, 339-358, 347-366, 349-368, 357-376, 368-387, 368-388, 368-389,368-390, 368-391, 369-380, 369-389, 369-390, 369-391, 370-389, 370-390,370-391, 371-390, 371-391, 372-391, 388-407, 388-408, 389-408, 392-411,404-423, 431-450, 431-451, 432-451, 443-462, 443-463, 444-463, 601-620,624-643, 734-753, 757-806, 787-807, 788-807, 790-809, 790-810, 791-810,970-989, 1024-1043, 1024-1044, 1024-1045, 1024-1046, 1024-1047,1024-1048, 1024-1105, 1025-1044, 1025-1045, 1025-1046, 1025-1047,1025-1048, 1026-1045, 1026-1046, 1026-1047, 1026-1048, 1027-1046,1027-1047, 1027-1048, 1028-1047, 1028-1048, 1029-1048, 1031-1050,1031-1051, 1032-1051, 1084-1103, 1084-1105, 1086-1105, 1097-1116,1097-1117, 1097-1122, 1100-1119, 1100-1120, 1100-1121, 1100-1122,1101-1120, 1101-1121, 1101-1122, 1102-1121, 1102-1122, 1103-1122,1105-1124, 1105-1125, 1106-1125, 1110-1029, 1110-1130, 1111-1130,1115-1134, 1185-1204, 1255-1274, 1290-1309, 1290-1310, 1291-1310,1301-1320, 1417-1436, 1468-1487, 1468-1488, 1469-1488, 1559-1578,1562-1581, 1564-1583, 1619-1638, 2325-2344, 2325-2345, 2326-2345,2438-2457, 2812-2831, 2816-2835, 2816-2836, 2816-2837, 2816-2838,2817-2836, 2817-2837, 2817-2838, 2818-2837, 2818-2838, 2819-2838,2822-2481, 2822-2842, 2822-2843, 2822-2844, 2823-2842, 2823-2843,2823-2844, 2824-2843, 2824-2844, 2825-2844, 2951-2970, 2951-2971,2951-2972, 2951-2973, 2951-2974, 2951-2975, 2951-3000, 2952-2971,2952-2972, 2952-2973, 2952-2974, 2952-2975, 2953-2972, 2953-2973,2953-2974, 2953-2975, 2954-2973, 2954-2974, 2954-2975, 2955-2974,2955-2975, 2956-2975.

In certain embodiments, antisense compounds or modified oligonucleotidestargets a region of a FGFR4 nucleic acid. In certain embodiments, suchcompounds or oligonucleotides targeted to a region of a FGFR4 nucleicacid have a contiguous nucleobase portion that is complementary to anequal length nucleobase portion of the region. For example, the portioncan be at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20contiguous nucleobases portion complementary to an equal length portionof a region recited herein. In certain embodiments, such compounds oroligonucleotide target the following nucleotide regions of SEQ ID NO: 2:3165-3184, 3196-3215, 3197-3216, 3196-3217, 3196-3218, 3197-3216,3197-3217, 3197-3218, 3198-3217, 3198-3218, 3199-3218, 3201-3220,3201-3221, 3202-3221, 3205-3224, 3207-3226, 3207-3227, 3208-3227,3991-4011, 3991-4010, 3991-4012, 3991-4013, 3992-4011, 3992-4012,3992-4013, 3993-4012, 3993-4013, 3994-4013, 4010-4029, 4033-4052,4039-4058, 4039-4059, 4040-4059, 4048-4067, 4050-4069, 4058-4077,4069-4088, 4069-4089, 4069-4091, 4069-4091, 4069-4092, 4070-4091,4070-4090, 4070-4091, 4070-4092, 4071-4090, 4071-4091, 4071-4092,4072-4091, 4072-4092, 4073-4092, 4089-4108, 4089-4109, 4090-4109,4093-4112, 4105-4124, 4132-4151, 4132-4152, 4133-4152, 4144-4163,4144-4164, 4145-4164, 4506-4522, 4528-4547, 4638-4657, 5268-5290,5271-5291, 5272-5291, 5274-5293, 5274-5294, 5275-5294, 5966-5985,6020-6039, 6020-6040, 6020-6041, 6020-6042, 6020-6043, 6020-6044,6020-6235, 6021-6040, 6021-6041, 6021-6042, 6021-6043, 6021-6044,6022-6041, 6022-6042, 6022-6043, 6022-6044, 6023-6042, 6023-6043,6023-6044, 6024-6043, 6024-6044, 6025-6044, 6027-6046, 6027-6047,6028-6047, 6214-6235, 6214-6233, 6214-6235, 6216-6235, 6227-6246,6227-6247, 6227-6252, 6230-6249, 6230-6250, 6230-6251, 6230-6252,6231-6250, 6231-6251, 6231-6252, 6232-6251, 6232-6252, 6233-6252,6235-6254, 6235-6255, 6236-6255, 6241-6260, 6245-6264, 6315-6334,6784-6803, 6974-6993, 7025-7044, 7025-7045, 7026-7045, 7059-7081,7221-7240, 7223-7242, 7278-7297, 10866-10885, 10866-10866, 10867-10886,11108-11127, 11482-11501, 11486-11505, 11486-11506, 11486-11507,11486-11508, 11487-11506, 11487-11507, 11487-11508, 11488-11507,11488-11508, 11489-11508, 11492-11511, 11492-11512, 11492-11513,11492-1151, 11493-11512, 11493-11513, 11493-11514, 11494-11513,11494-11514, 11495-11514, 11621-11640, 11621-11641, 11621-11642,11621-11643, 11621-11644, 11621-11645, 11621-11670, 11622-11641,11622-11642, 11622-11643, 11622-11644, 11622-11645, 11623-11642,11623-11643, 11623-11644, 11623-11645, 11624-11643, 11624-11644,11624-11645, 11625-11644, 11625-11645, 11626-11645.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides wherein the linkednucleosides comprise at least an 8 contiguous nucleobase portion that iscomplementary to an equal length nucleobase portion within the regionselected from nucleotides 191-210 or 369-388 of SEQ ID NO: 1. In certainembodiments, the modified oligonucleotide has at least a 9, at least a10, at least an 11, at least a 12, at least a 13, at least a 14, atleast a 15, at least a 16, at least a 17, at least an 18, at least 19 orat least a 20 contiguous nucleobase portion of which is complementary toan equal length portion within the region selected from nucleotides191-210 or 369-388 of SEQ ID NO: 1. In certain embodiments, the modifiedoligonucleotide is 90%, 95%, 99%, or 100% complementary to a nucleicacid encoding human FGFR4, eg. SEQ ID No: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides wherein the linkednucleosides comprise at least an 8 contiguous nucleobase portion that iscomplementary to an equal length nucleobase portion within the regionselected from nucleotides 3196-3215 or 4070-4089 of SEQ ID NO: 2. Incertain embodiments, the modified oligonucleotide has at least a 9, atleast a 10, at least an 11, at least a 12, at least a 13, at least a 14,at least a 15, at least a 16, at least a 17, at least an 18, at least 19or at least a 20 contiguous nucleobase portion of which is complementaryto an equal length portion within the region selected from nucleotides3196-3215 or 4070-4089 of SEQ ID NO: 2. In certain embodiments, themodified oligonucleotide is 90%, 95%, 99%, or 100% complementary to anucleic acid encoding human FGFR4, eg. SEQ ID No: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 60% complementarywithin the region selected from nucleotides 191-210, 193-212, 369-388,370-389, 788-807, 790-809 and 2954-2973 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 60% complementarywithin the region selected from nucleotides 3196-3215, 3198-3217,4070-4089, 4071-4090, 5272-5291, 5274-5293, and 11624-11643 of SEQ IDNO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 70% complementarywithin the region selected from nucleotides 191-210, 193-212, 369-388,370-389, 188-807, 790-809 and 2954-2973 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 70% complementarywithin the region selected from nucleotides 3196-3215, 3198-3217,4070-4089, 4071-4090, 5272-5291, 5274-5293, and 11624-11643 of SEQ IDNO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 80% complementarywithin the region selected from nucleotides 191-210, 193-212, 369-388,370-389, 188-807, 790-809 and 2954-2973 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 80% complementarywithin the region selected from nucleotides 3196-3215, 3198-3217,4070-4089, 4071-4090, 5272-5291, 5274-5293, and 11624-11643 of SEQ IDNO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 90% complementarywithin the region selected from nucleotides 191-210, 193-212, 369-388,370-389, 188-807, 790-809 and 2954-2973 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 90% complementarywithin the region selected from nucleotides 3196-3215, 3198-3217,4070-4089, 4071-4090, 5272-5291, 5274-5293, and 11624-11643 of SEQ IDNO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 95% complementarywithin the region selected from nucleotides 191-210, 193-212, 369-388,370-389, 188-807, 790-809 and 2954-2973 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 95% complementarywithin the region selected from nucleotides 3196-3215, 3198-3217,4070-4089, 4071-4090, 5272-5291, 5274-5293, and 11624-11643 of SEQ IDNO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 99% complementarywithin the region selected from nucleotides 191-210, 193-212, 369-388,370-389, 188-807, 790-809 and 2954-2973 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 99% complementarywithin the region selected from nucleotides 3196-3215, 3198-3217,4070-4089, 4071-4090, 5272-5291, 5274-5293, and 11624-11643 of SEQ IDNO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 100% complementarywithin the region selected from nucleotides 191-210, 193-212, 369-388,370-389, 188-807, 790-809 and 2954-2973 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 100% complementarywithin the region selected from nucleotides 3196-3215, 3198-3217,4070-4089, 4071-4090, 5272-5291, 5274-5293, and 11624-11643 of SEQ IDNO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 60% complementarywithin nucleotides 191-210 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 60% complementarywithin the region selected from nucleotides 3196-3215 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 70% complementarywithin nucleotides 191-210 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 70% complementarywithin the region selected from nucleotides 3196-3215 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 80% complementarywithin nucleotides 191-210 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 80% complementarywithin the region selected from nucleotides 3196-3215 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 90% complementarywithin nucleotides 191-210 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 90% complementarywithin the region selected from nucleotides 3196-3215 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 95% complementarywithin nucleotides 191-210 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 95% complementarywithin the region selected from nucleotides 3196-3215 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 99% complementarywithin nucleotides 191-210 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 99% complementarywithin the region selected from nucleotides 3196-3215 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 100% complementarywithin nucleotides 191-210 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 100% complementarywithin the region selected from nucleotides 3196-3215 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 60% complementarywithin nucleotides 369-388 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 60% complementarywithin nucleotides 4070-4089 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 70% complementarywithin nucleotides 369-388 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 70% complementarywithin nucleotides 4070-4089 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 80% complementarywithin nucleotides 369-388 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 80% complementarywithin nucleotides 4070-4089 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 90% complementarywithin nucleotides 369-388 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 90% complementarywithin nucleotides 4070-4089 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 95% complementarywithin nucleotides 369-388 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 95% complementarywithin nucleotides 4070-4089 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 99% complementarywithin nucleotides 369-388 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 99% complementarywithin nucleotides 4070-4089 of SEQ ID NO: 2.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 100% complementarywithin nucleotides 369-388 of SEQ ID NO: 1.

Certain embodiments provide compounds comprising a modifiedoligonucleotide consisting of 20 linked nucleosides 99% complementarywithin nucleotides 4070-4089 of SEQ ID NO: 2.

In certain embodiments, such compounds or oligonucleotides targeted to aregion of a FGFR4 nucleic acid have a contiguous nucleobase portion thatis complementary to an equal length nucleobase portion of the region191-210 or 369-388 of SEQ ID NO: 1.

In certain embodiments, such compounds or oligonucleotides targeted to aregion of a FGFR4 nucleic acid have a contiguous nucleobase portion thatis complementary to an equal length nucleobase portion of the region3196-3215 or 4070-4089 of SEQ ID NO: 2.

In certain embodiments, the following nucleotide regions of SEQ ID NO:1, when targeted by antisense compounds or oligonucleotides, displays atleast 65% inhibition: 160-179, 191-210, 191-211, 191-212, 191-213,192-211, 192-212, 192-213, 193-212, 193-213, 194-213, 196-215, 196-216,197-216, 200-219, 202-221, 202-222, 203-222, 290-210, 290-309, 290-311,290-312, 290-312, 291-310, 291-311, 291-312, 292-311, 292-312, 293-312,309-328, 332-351, 338-357, 338-358, 339-358, 347-366, 349-368, 357-376,368-387, 368-388, 368-389, 368-390, 368-391, 369-380, 369-389, 369-390,369-391, 370-389, 370-390, 370-391, 371-390, 371-391, 372-391, 388-407,388-408, 389-408, 392-411, 404-423, 431-450, 431-451, 432-451, 443-462,443-463, 444-463, 601-620, 624-643, 734-753, 767-806, 787-807, 788-807,790-809, 790-810, 791-810, 970-989, 1024-1043, 1024-1044, 1024-1045,1024-1046, 1024-1047, 1024-1048, 1024-1105, 1025-1044, 1025-1045,1025-1046, 1025-1047, 1025-1048, 1026-1045, 1026-1046, 1026-1047,1026-1048, 1027-1046, 1027-1047, 1027-1048, 1028-1047, 1028-1048,1029-1048, 1031-1050, 1031-1051, 1032-1051, 1074-1051, 1084-1103,1084-1105, 1086-1105, 1097-1116, 1097-1117, 1097-1122, 1100-1119,1100-1119, 1100-1120, 1100-1121, 1100-1122, 1101-1120, 1101-1121,1101-1122, 1102-1121, 1102-1122, 1103-1122, 1105-1124, 1105-1125,1106-1125, 1110-1029, 1110-1130, 1111-1130, 1115-1134, 1185-1204,1255-1274, 1290-1309, 1290-1310, 1291-1310, 1301-1320, 1417-1436,1468-1487, 1468-1488, 1469-1488, 1559-1578, 1562-1581, 1564-1583,1619-1638, 2325-2344, 2325-2345, 2326-2345, 2438-2457, 2812-2831,2816-2835, 2816-2836, 2816-2837, 2816-2838, 2817-2836, 2817-2837,2817-2838, 2818-2837, 2818-2838, 2819-2838, 2822-2481, 2822-2842,2822-2843, 2822-2844, 2822-2844, 2823-2842, 2823-2843, 2823-2844,2824-2843, 2824-2844, 2825-2844, 2951-2970, 2951-2971, 2951-2972,2951-2973, 2951-2974, 2951-2975, 2951-2975, 2951-3000, 2952-2971,2952-2972, 2952-2973, 2952-2974, 2952-2975, 2953-2972, 2953-2973,2953-2974, 2953-2975, 2954-2973, 2954-2974, 2954-2975, 2955-2974,2955-2975, and 2956-2975.

In certain embodiments, the following nucleotide regions of SEQ ID NO:2, when targeted by antisense compounds or oligonucleotides, displays atleast 65% inhibition: 3165-3184, 3196-3215, 3196-3216, 3196-3217,3196-3218, 3197-3216, 3197-3217, 3197-3218, 3198-3217, 3198-3218,3199-3218, 3201-3220, 3201-3221, 3202-3221, 3205-3224, 3207-3226,3207-3227, 3208-3227, 3991-4011, 3991-4010, 3991-4012, 3991-4013,3991-4014, 3992-4011, 3992-4012, 3992-4013, 3993-4012, 3993-4013,3994-4013, 4010-4029, 4033-4052, 4039-4058, 4039-4059, 4040-4059,4048-4067, 4050-4069, 4058-4077, 4069-4088, 4069-4089, 4069-4090,4069-4091, 4069-4092, 4070-380, 4070-4090, 4070-4091, 4070-4092,4071-4090, 4071-4091, 4071-4092, 4072-4091, 4072-4092, 4073-4092,4089-4108, 4089-4109, 4090-4109, 4093-4112, 4105-4124, 4132-4151,4132-4152, 4133-4152, 4144-4163, 4144-4164, 4145-4164, 4506-4522,4528-4547, 4638-4657, 5268-5290, 5271-5291, 5272-5291, 5274-5293,5274-5294, 5275-5294, 5966-5985, 6020-6039, 6020-6040, 6020-6041,6020-6042, 6020-6043, 6020-6044, 6020-6045, 6021-6040, 6021-6041,6021-6042, 6021-6043, 6021-6044, 6022-6041, 6022-6042, 6022-6043,6022-6044, 6023-6042, 6023-6043, 6023-6047, 6024-6043, 6024-6044,6025-6044, 6027-6046, 6027-6047, 6028-6047, 6214-6235, 6214-6233,6214-6235, 6216-6235, 6227-6246, 6227-6247, 6227-6252, 6230-6249,6230-6249, 6230-6250, 6230-6251, 6230-6252, 6231-6250, 6231-6251,6231-6252, 6232-6251, 6232-6252, 6233-6252, 6235-6254, 6235-6255,6236-6255, 6230-6260, 6241-6260, 6245-6264, 6315-6334, 6784-6803,6974-6993, 7025-7044, 7025-7045, 7026-7045, 7221-7240, 7223-7242,7278-7297, 10866-10885, 10866-10886, 10867-10886, 11008-11127,11482-11501, 11486-11505, 11486-11506, 11486-11507, 11486-11508,11487-11506, 11487-11507, 11487-11508, 11488-11507, 11488-11508,11489-11508, 11492-11511, 11492-11512, 11492-11513, 11492-11514,11493-11512, 11493-11513, 11493-11514, 11494-11513, 11494-11514,11495-11514, 11621-11640, 11621-11641, 11621-11642, 11621-11643,11621-11644, 11621-11645, 11621-11670, 11622-11641, 11622-11642,11622-11643, 11622-11644, 11622-11645, 11623-11642, 11623-11643,11623-11644, 11623-1645, 11624-11643, 11624-11644, 11624-11645,11625-11644, 11625-11645, and 11626-11645.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NO: 1, when targeted by antisensecompounds or oligonucleotides, displays at least 65% inhibition: 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 61, 62, 64, 65,66, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101,102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,and 116.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NO: 1, when targeted by antisensecompounds or oligonucleotides, displays at least 70% inhibition: 7, 14,15, 16, 17, 18, 19, 20, 22, 23, 24, 27, 28, 29, 30, 32, 33, 34, 35, 38,39, 43, 44, 45, 46, 47, 48, 49, 50, 51, 54, 59, 61, 64, 69, 70, 72, 73,75, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 89, 90, 91, 92, 94, 97, 98,103, 105, 106, 111, 112, 113, and 116.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NO: 1, when targeted by antisensecompounds or oligonucleotides, displays at least 75% inhibition: 7, 14,16, 17, 22, 24, 28, 29, 30, 32, 33, 34, 39, 43, 44, 45, 46, 47, 49, 50,59, 61, 69, 70, 72, 73, 75, 77, 78, 79, 80, 83, 85, 89, 90, 91, 92, 105,106, 111, and 112.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NO: 1, when targeted by antisensecompounds or oligonucleotides, displays at least 80% inhibition: 7, 14,16, 17, 28, 29, 33, 39, 45, 47, 49, 50, 72, 80, 90, 91, and 106.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NO: 1, when targeted by antisensecompounds or oligonucleotides, displays at least 85% inhibition 7, 14,16, 29, 45, 50, 80, 90, and 91.

In certain embodiments, the following nucleotide regions of SEQ ID NOs:1 or 2, when targeted by antisense compounds or oligonucleotides,displays at least 65% inhibition: 908-927, 992-1011, 1138-1157,1138-1161, 1142-1161, 1345-1364, 1386-1405, 1386-1413, 1394-1413,1461-1480, 1461-1482, 1461-1484, 1461-1486, 1461-1490, 1463-1482,1463-1484, 1463-1486, 1463-1490, 1465-1484, 1465-1486, 1465-1490,1467-1486, 1467-1490, 1471-1490, 1542-1561, 1941-1960, 1941-1962,1941-1964, 1943-1962, 1943-1964, 1945-1964, 2053-2072, 2104-2123,2104-2125, 2104-2127, 2104-2129, 2104-2131, 2104-2133, 2104-2135,2104-2137, 2106-2125, 2106-2127, 2106-2129, 2106-2131, 2106-2133,2106-2135, 2106-2137, 2108-2127, 2108-2129, 2108-2131, 2108-2133,2108-2135, 2108-2137, 2110-2129, 2110-2131, 2110-2133, 2110-2135,2110-2137, 2112-2131, 2112-2133, 2112-2135, 2112-2137, 2114-2133,2114-2135, 2114-2137, 2116-2135, 2116-2137, 2118-2137, 2271-2290,2838-2857, 3122-3141, 3122-3144, 3125-3144, 3165-3184, 3325-3344,3325-3346, 3325-3348, 3325-3350, 3325-3352, 3325-3354, 3325-3356,3325-3358, 3325-3360, 3325-3362, 3325-3362, 3327-3346, 3327-3346,3327-3348, 3327-3350, 3327-3352, 3327-3354, 3327-3356, 3327-3358,3327-3360, 3327-3362, 3329-3348, 3329-3348, 3329-3350, 3329-3352,3329-3354, 3329-3356, 3329-3358, 3329-3360, 3329-3362, 3331-3350,3331-3352, 3331-3354, 3331-3356, 3331-3358, 3331-3360, 3331-3362,3333-3352, 3333-3354, 3333-3356, 3333-3358, 3333-3360, 3333-3362,3335-3354, 3335-3356, 3335-3358, 3335-3360, 3335-3362, 3337-3356,3337-3358, 3337-3360, 3337-3362, 3339-3358, 3339-3360, 3339-3362,3341-3360, 3341-3362, 3343-3362, 3386-3405, 3386-3413, 3386-3417,3386-3419, 3386-3423, 3386-3427, 3386-3434, 3386-3434, 3394-3413,3394-3417, 3394-3423, 3394-3427, 3394-3434, 3398-3417, 3398-3419,3398-3423, 3398-3427, 3398-3434, 3400-3419, 3400-3423, 3400-3427,3400-3434, 3404-3423, 3404-3427, 3404-3434, 3408-3427, 3408-3434,3415-3434, 3445-3464, 3445-3466, 3445-3468, 3445-3470, 3447-3466,3447-3468, 3447-3470, 3449-3468, 3449-3470, 3451-3470, 3499-3518,3571-3590, 3571-3592, 3571-3594, 3571-3596, 3571-3598, 3573-3592,3573-3594, 3573-3596, 3573-3598, 3575-3594, 3575-3596, 3575-3598,3577-3596, 3577-3598, 3579-3598, 3772-3791, 3772-3793, 3772-3795,3772-3797, 3772-3801, 3772-3807, 3772-3817, 3774-3793, 3774-3795,3774-3797, 3776-3795, 3776-3797, 3778-3797, 3782-3801, 3782-3817,3788-3807, 3788-3817, 3798-3817, 3993-4012, 4799-4818, 7684-7703,7690-7709, 7692-7711.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2, when targeted by antisensecompounds or oligonucleotides, displays at least 65% inhibition: 29,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, and 235.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2, when targeted by antisensecompounds or oligonucleotides, displays at least 70% inhibition: 29,117, 119, 120, 122, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135,136, 137, 138, 139, 140, 141, 142, 145, 146, 147, 150, 151, 152, 153,154, 155, 156, 157, 158, 160, 161, 162, 163, 164, 165, 166, 167, 169,170, 171, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 193, 195,198, 199, 200, 201, 202, 203, 206, 207, 208, 209, 210, 211, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 225, 226, 227, 228, 229,231, 233, 234, and 235.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2, when targeted by antisensecompounds or oligonucleotides, displays at least 75% inhibition: 29,117, 120, 128, 129, 131, 132, 133, 135, 136, 137, 138, 139, 140, 141,146, 152, 153, 154, 155, 156, 160, 161, 162, 163, 164, 165, 166, 167,169, 174, 180, 186, 187, 188, 198, 199, 201, 202, 207, 208, 209, 213,214, 215, 216, 217, 219, 220, 221, 223, 225, 227, 228, 229, 231, 233,and 235.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2, when targeted by antisensecompounds or oligonucleotides, displays at least 80% inhibition: 29,117, 131, 132, 133, 135, 136, 137, 138, 140, 141, 152, 153, 154, 155,156, 160, 162, 163, 164, 174, 186, 187, 188, 199, 201, 202, 207, 208,213, 214, 215, 216, 217, 219, 220, 221, 223, 227, 229, 231, and 233.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2, when targeted by antisensecompounds or oligonucleotides, displays at least 85% inhibition: 29,117, 132, 135, 136, 140, 141, 154, 156, 163, 164, 187, 188, 199, 201,215, 216, 217, 219, 220, 221, 223, 227, 229, 231, and 233.

In certain embodiments, the following nucleotide regions of SEQ ID NOs:1 or 2 or 3, when targeted by antisense compounds or oligonucleotides,displays at least 65% inhibition: 101-120, 101-122, 101-124, 101-125,101-126, 101-127, 102-126, 103-122, 103-124, 103-125, 103-126, 103-127,105-124, 105-125, 105-127, 106-125, 106-126, 106-127, 107-126, 107-127,108-127, 1122-1141, 1165-1184, 1193-1218, 1198-1217, 1199-1218,1323-1342, 1323-1344, 1323-1346, 1323-1347, 1323-1352, 1325-1344,1325-1346, 1325-1347, 1327-1346, 1327-1347, 1328-1347, 1333-1352,1333-1354, 1333-1354, 1333-1356, 1333-1358, 1333-1360, 1335-1354,1335-1356, 1335-1358, 1335-1360, 1337-1356, 1337-1358, 1337-1360,1339-1358, 1339-1360, 1341-1360, 1392-1411, 1392-1417, 1393-1412,1394-1413, 1394-1415, 1394-1417, 1396-1415, 1396-1417, 1398-1417,1413-1432, 1413-1433, 1413-1434, 1414-1433, 1414-1434, 1415-1434,1445-1464, 1445-1466, 1445-1468, 1445-1470, 1445-1471, 1447-1466,1447-1468, 1447-1470, 1447-1471, 1449-1468, 1449-1470, 1449-1471,1451-1470, 1451-1471, 1452-1471, 1462-1481, 1462-1481, 1462-1482,1462-1483, 1462-1484, 1462-1485, 1462-1487, 1463-1482, 1463-1482,1463-1483, 1463-1484, 1463-1485, 1463-1487, 1464-1483, 1464-1484,1464-1485, 1464-1487, 1465-1484, 1465-1485, 1465-1487, 1466-1485,1466-1487, 1468-1487, 1501-1521, 1501-1522, 1503-1522, 1569-1588,1569-1589, 1569-1590, 1569-1591, 1569-1592, 1569-1593, 1569-1594,1569-1596, 1569-1598, 1570-1589, 1570-1590, 1570-1591, 1570-1592,1570-1593, 1570-1594, 1570-1596, 1570-1598, 1571-1590, 1571-1591,1571-1591, 1571-1592, 1571-1592, 1571-1593, 1571-1593, 1571-1594,1571-1594, 1571-1596, 1571-1596, 1571-1598, 1571-1598, 1572-1591,1572-1592, 1572-1593, 1572-1594, 1572-1596, 1572-1598, 1573-1592,1573-1593, 1573-1594, 1573-1596, 1573-1598, 1574-1593, 1574-1594,1574-1596, 1574-1598, 1575-1594, 1575-1596, 1575-1598, 1577-1596,1577-1598, 1579-1598, 1778-1797, 1778-1799, 1778-1805, 1778-1809,1778-1811, 1778-1821, 1780-1799, 1786-1805, 1790-1809, 1790-1811,1790-1821, 1792-1811, 1792-1821, 1802-1821, 1944-1963, 1996-2015,2053-2072, 2074-2093, 2418-2437, 4988-5007, 5120-5139, 5121-5140,5121-5146, 5122-5141, 5122-5142, 5122-5143, 5122-5144, 5122-5146,5123-5142, 5123-5143, 5123-5144, 5123-5146, 5124-5143, 5124-5144,5124-5144, 5124-5146, 5125-5146, 5127-5146, 5150-5169, 5150-5170,5150-5171, 5151-5170, 5151-5171, 5152-5171, 7801-7820, 7801-7822,7803-7822.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2 or 3, when targeted byantisense compounds or oligonucleotides, displays at least 65%inhibition: 29, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249,250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263,264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277,278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291,292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305,306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319,320, 321, and 322.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2 or 3, when targeted byantisense compounds or oligonucleotides, displays at least 70%inhibition: 29, 239, 240, 241, 242, 243, 244, 245, 247, 249, 250, 251,252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265,266, 268, 269, 270, 271, 272, 274, 275, 276, 277, 278, 279, 280, 282,283, 284, 285, 286, 287, 288, 289, 290, 291, 294, 295, 296, 297, 298,299, 300, 301, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314,315, 317, 319, 320, and 322.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2 or 3, when targeted byantisense compounds or oligonucleotides, displays at least 75%inhibition: 29, 239, 240, 241, 242, 243, 244, 245, 247, 250, 251, 252,253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 264, 266, 269, 271,272, 274, 275, 276, 277, 278, 279, 283, 284, 286, 287, 288, 291, 298,299, 300, 305, 306, 307, 308, 309, 310, 312, 313, 315, 317, 319, and320.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2 or 3, when targeted byantisense compounds or oligonucleotides, displays at least 80%inhibition: 29, 241, 242, 243, 244, 245, 247, 250, 253, 254, 255, 256,259, 260, 261, 262, 264, 266, 271, 272, 274, 276, 278, 283, 284, 286,287, 299, 300, 305, 306, 307, 308, 310, 312, 313, 317, and 320.

In certain embodiments, the nucleobase sequences recited in thefollowing SEQ ID NOs of SEQ ID NOs: 1 or 2 or 3, when targeted byantisense compounds or oligonucleotides, displays at least 85%inhibition: 29, 241, 242, 243, 244, 247, 254, 256, 259, 260, 264, 272,278, 299, 300, 305, 306, 307, 308, 310, 317, and 320.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NO: 1, a nucleic acid encoding human FGFR4, anddemonstrate at least 65% inhibition of a FGFR4 mRNA: ISIS NOs: 299005,299010, 299018, 299022, 299024, 299025, 299028, 299029, 299030, 463588,463589, 463590, 463592, 463593, 463594, 463596, 463598, 463599, 463601,463625, 463627, 463628, 463629, 463630, 463636, 463645, 463648, 463654,463655, 463656, 463657, 463670, 463672, 463673, 463677, 463678, 463679,463689, 463690, 463691, 463692, 463693, 463708, 463709, 463712, 463717,463718, 463724, 463733, 463734, 463735, 463751, 463763, 463770, 463774,463791, 463805, 463832, 463834, 463835, 463836, 463837, 463838, 463860,463861, 463871, 463874, 463875, 463876, 463877, 463878, 463880, 463882,463883, 463884, 463893, 463894, 463906, 463907, 463908, 463909, 463910,463912, 463913, 463918, 463919, 463922, 463937, 463938, 463947, 463967,463994, 464002, 464004, 464013, 464014, 464015, 464030, 464033, 464037,464038, 464041, 464043, 464046, 464048, and 464049.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NO: 1, a nucleic acid encoding human FGFR4 anddemonstrate at least 70% inhibition of a FGFR4 mRNA: ISIS NOs: 299005,299029, 299030, 463588, 463589, 463590, 463592, 463593, 463596, 463598,463599, 463627, 463628, 463629, 463630, 463645, 463648, 463654, 463655,463670, 463672, 463679, 463689, 463690, 463691, 463692, 463693, 463708,463709, 463712, 463724, 463751, 463763, 463774, 463834, 463835, 463837,463838, 463861, 463874, 463875, 463876, 463877, 463878, 463880, 463882,463884, 463893, 463894, 463907, 463908, 463909, 463910, 463913, 463922,463937, 464002, 464013, 464014, 464038, 464041, 464043, and 464049.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NO: 1, a nucleic acid encoding human FGFR4 anddemonstrate at least 75% inhibition of a FGFR4 mRNA: ISIS NOs: 299005,299029, 463588, 463589, 463596, 463599, 463628, 463629, 463630, 463645,463648, 463654, 463672, 463679, 463689, 463690, 463691, 463692, 463708,463709, 463751, 463763, 463834, 463835, 463837, 463838, 463861, 463874,463875, 463876, 463877, 463882, 463884, 463907, 463908, 463909, 463910,464013, 464014, 464038, and 464041.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NO: 1, a nucleic acid encoding human FGFR4 anddemonstrate at least 80% inhibition of a FGFR4 mRNA: ISIS NOs: 299005,299029, 463588, 463589, 463628, 463629, 463648, 463672, 463690, 463692,463708, 463709, 463837, 463877, 463908, 463909, and 464014.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NO: 1, a nucleic acid encoding human FGFR4 anddemonstrate at least 85% inhibition of a FGFR4 mRNA: ISIS NOs: 299005,299029, 463588, 463629, 463690, 463709, 463877, 463908, and 463909.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2, a nucleic acid encoding human FGFR4, anddemonstrate at least 65% inhibition of a FGFR4 mRNA: ISIS NOs: 463629,299004, 464138, 464139, 464167, 464168, 464170, 464173, 299055, 464181,464203, 464207, 464208, 464209, 464210, 464213, 464214, 464215, 464216,464222, 464223, 464224, 464225, 464226, 464227, 464228, 464238, 464239,464254, 464258, 464266, 464268, 464269, 464270, 464278, 464280, 464284,464285, 464286, 464287, 464288, 464290, 464291, 464292, 464298, 464299,464300, 464308, 464309, 464310, 464311, 464333, 464342, 464425, 464428,464429, 464430, 464433, 464449, 464453, 464568, 464569, 464575, 464576,464579, 464581, 464582, 464584, 464585, 464586, 464587, 464588, 464589,464590, 464591, 464593, 464617, 464622, 464623, 464657, 464658, 464677,464682, 464683, 464684, 464685, 464686, 464687, 464688, 464689, 464692,464696, 464698, 464699, 464701, 464703, 464705, 464706, 464707, 464708,464709, 464710, 464711, 464716, 464717, 464718, 464719, 464720, 464726,464727, 464728, 464729, 464730, 464732, 464734, 464735, 464736, 464740,464800, and 464801.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2, a nucleic acid encoding human FGFR4 anddemonstrate at least 70% inhibition of a FGFR4 mRNA: ISIS NOs: 463629,299004, 464138, 464139, 464168, 464203, 464207, 464208, 464209, 464210,464213, 464214, 464215, 464216, 464222, 464223, 464224, 464225, 464226,464227, 464228, 464238, 464258, 464266, 464268, 464278, 464280, 464284,464285, 464286, 464287, 464288, 464290, 464291, 464298, 464299, 464300,464308, 464309, 464310, 464311, 464333, 464425, 464428, 464429, 464449,464579, 464584, 464585, 464586, 464587, 464588, 464589, 464590, 464591,464622, 464657, 464682, 464683, 464684, 464685, 464686, 464687, 464692,464696, 464698, 464699, 464701, 464703, 464706, 464707, 464708, 464709,464710, 464711, 464716, 464717, 464718, 464719, 464720, 464727, 464728,464729, 464730, 464732, 464735, 464740, 464800, and 464801.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2, a nucleic acid encoding human FGFR4 anddemonstrate at least 75% inhibition of a FGFR4 mRNA: ISIS NOs: 463629,299004, 464139, 464208, 464209, 464213, 464214, 464215, 464222, 464223,464224, 464225, 464226, 464227, 464228, 464266, 464284, 464285, 464286,464287, 464288, 464298, 464299, 464300, 464308, 464309, 464310, 464311,464333, 464425, 464449, 464579, 464587, 464588, 464589, 464682, 464683,464685, 464686, 464696, 464698, 464699, 464706, 464707, 464708, 464709,464710, 464716, 464717, 464718, 464720, 464727, 464729, 464730, 464732,464735, 464740, and 464801.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2, a nucleic acid encoding human FGFR4 anddemonstrate at least 80% inhibition of a FGFR4 mRNA: ISIS NOs: 463629,299004, 464213, 464214, 464215, 464222, 464223, 464224, 464225, 464227,464228, 464284, 464285, 464286, 464287, 464288, 464298, 464300, 464308,464309, 464449, 464587, 464588, 464589, 464683, 464685, 464686, 464696,464698, 464706, 464707, 464708, 464709, 464710, 464716, 464717, 464718,464720, 464729, 464732, 464735, and 464740.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2, a nucleic acid encoding human FGFR4 anddemonstrate at least 85% inhibition of a FGFR4 mRNA: ISIS NOs: 463629,299004, 464214, 464222, 464223, 464227, 464228, 464286, 464288, 464308,464309, 464588, 464589, 464683, 464685, 464708, 464709, 464710, 464716,464717, 464718, 464720, 464729, 464732, 464735, and 464740.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs:1 or 2 or 3, a nucleic acid encoding human FGFR4,and demonstrate at least 65% inhibition of a FGFR4 mRNA: ISIS NOs:463629, 479530, 479532, 479533, 479534, 479535, 479536, 479537, 479538,479539, 479540, 479541, 479542, 479543, 479544, 479545, 479546, 479547,479548, 479549, 479550, 479551, 479552, 479553, 479554, 479555, 479556,479557, 479558, 479560, 479561, 479562, 479564, 479565, 479566, 479567,479568, 479569, 479570, 479572, 479573, 479574, 479576, 479577, 479582,479583, 479584, 479585, 479594, 479596, 479597, 479608, 479613, 479614,479622, 479625, 479626, 479641, 479682, 479689, 479690, 479691, 479692,479693, 479694, 479696, 479697, 479698, 479699, 479703, 479704, 479705,479706, 479716, 479721, 479722, 479725, 479731, 479732, 479736, 479737,479738, 479739, 479740, and 479741.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2 or 3, a nucleic acid encoding human FGFR4and demonstrate at least 70% inhibition of a FGFR4 mRNA: ISIS NOs:463629, 479530, 479532, 479533, 479534, 479535, 479536, 479537, 479539,479541, 479542, 479543, 479544, 479545, 479546, 479547, 479548, 479549,479550, 479551, 479552, 479553, 479554, 479555, 479556, 479557, 479558,479561, 479562, 479564, 479565, 479566, 479568, 479569, 479570, 479572,479573, 479574, 479576, 479582, 479583, 479584, 479585, 479594, 479596,479597, 479608, 479613, 479614, 479626, 479641, 479682, 479689, 479690,479691, 479692, 479693, 479697, 479698, 479699, 479703, 479704, 479705,479706, 479716, 479721, 479722, 479725, 479731, 479736, 479738, 479739,and 479741.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2 or 3, a nucleic acid encoding human FGFR4and demonstrate at least 75% inhibition of a FGFR4 mRNA: ISIS NOs:463629, 479530, 479532, 479533, 479534, 479535, 479536, 479537, 479539,479542, 479543, 479544, 479545, 479546, 479547, 479548, 479549, 479550,479551, 479552, 479553, 479554, 479556, 479558, 479562, 479565, 479566,479568, 479569, 479570, 479572, 479573, 479574, 479583, 479584, 479594,479596, 479597, 479614, 479690, 479691, 479692, 479698, 479699, 479703,479704, 479705, 479706, 479721, 479722, 479731, 479736, 479738, and479739.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2 or 3, a nucleic acid encoding human FGFR4and demonstrate at least 80% inhibition of a FGFR4 mRNA: ISIS NOs:463629, 479533, 479534, 479535, 479536, 479537, 479539, 479542, 479545,479546, 479547, 479548, 479551, 479552, 479553, 479554, 479556, 479558,479565, 479566, 479568, 479570, 479573, 479583, 479584, 479594, 479596,479691, 479692, 479698, 479699, 479703, 479704, 479706, 479721, 479722,479736, and 479739.

In certain embodiments, the following antisense compounds target aregion of SEQ ID NOs: 1 or 2 or 3, a nucleic acid encoding human FGFR4and demonstrate at least 85% inhibition of a FGFR4 mRNA: ISIS NOs:463629, 479533, 479534, 479535, 479536, 479539, 479546, 479548, 479551,479552, 479556, 479566, 479573, 479691, 479692, 479698, 479699, 479703,479704, 479706, 479736, and 479739.

In certain embodiments, the compounds provided herein have a greatertherapeutic potential than ISIS NO: 299005. In certain embodiments, thecompounds provided herein have better in vivo inhibition over ISIS NO:299005. In certain embodiments, the compounds provided herein have abetter tolerability profile than ISIS NO: 299005.

In certain embodiments, the compound provided herein consists of asingle-stranded modified oligonucleotide.

In certain embodiments, the modified oligonucleotide consists of 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30, 31, 32, 33, 34 or 35 linked nucleosides. In certainembodiments, the modified oligonucleotide consists of 20 linkednucleosides. In certain embodiments, the modified oligonucleotideconsists of 19 linked nucleosides. In certain embodiments, the modifiedoligonucleotide consists of 18 linked nucleosides. In certainembodiments, the modified oligonucleotide consists of 17 linkednucleosides. In certain embodiments, the modified oligonucleotideconsists of 16 linked nucleosides.

In certain embodiments, at least one internucleoside linkage of themodified oligonucleotide is a modified internucleoside linkage. Incertain embodiments, each internucleoside linkage is a phosphorothioateinternucleoside linkage.

In certain embodiments, at least one nucleoside of said modifiedoligonucleotide comprises a modified nucleobase. In certain embodiments,the modified nucleobase is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide comprises: a) a gapsegment consisting of linked deoxynucleosides; b) a 5′ wing segmentconsisting of linked nucleosides; and c) a 3′ wing segment consisting oflinked nucleosides. The gap segment is positioned between the 5′ wingsegment and the 3′ wing segment and each nucleoside of each wing segmentcomprises a modified sugar.

In certain embodiments, the modified oligonucleotide consists of 20linked nucleosides, the gap segment consisting of ten linkeddeoxynucleosides, the 5′ wing segment consisting of five linkednucleosides, the 3′ wing segment consisting of five linked nucleosides,each nucleoside of each wing segment comprises a 2′-O-methoxyethylmodified sugar, each internucleoside linkage is a phosphorothioatelinkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 17linked nucleosides, the gap segment consisting of ten linkeddeoxynucleosides, the 5′ wing segment consisting of three linkednucleosides, the 3′ wing segment consisting of four linked nucleosides,each nucleoside of each wing segment comprises a 2′-O-methoxyethylmodified sugar, each internucleoside linkage is a phosphorothioatelinkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 8 contiguousnucleobases complementary to an equal length portion of any of SEQ IDNOs: 1-4, wherein the modified oligonucleotide comprises: a) a gapsegment consisting of ten linked deoxynucleosides; b) a 5′ wing segmentconsisting of five linked nucleosides; and c) a 3′ wing segmentconsisting of five linked nucleosides. The gap segment is positionedbetween the 5′ wing segment and the 3′ wing segment, each nucleoside ofeach wing segment comprises a 2′-O-methoxyethyl modified sugar, eachinternucleoside linkage is a phosphorothioate linkage and each cytosineresidue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 8 contiguousnucleobases complementary to an equal length portion of any of SEQ IDNO: 1, wherein the modified oligonucleotide comprises: a) a gap segmentconsisting of ten linked deoxynucleosides; b) a 5′ wing segmentconsisting of five linked nucleosides; and c) a 3′ wing segmentconsisting of five linked nucleosides. The gap segment is positionedbetween the 5′ wing segment and the 3′ wing segment, each nucleoside ofeach wing segment comprises a 2′-O-methoxyethyl modified sugar, eachinternucleoside linkage is a phosphorothioate linkage and each cytosineresidue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 19 contiguousnucleobases of SEQ ID NOs: 7-322 wherein the modified oligonucleotidecomprises: a) a gap segment consisting of ten linked deoxynucleosides;b) a 5′ wing segment consisting of five linked nucleosides; and c) a 3′wing segment consisting of five linked nucleosides. The gap segment ispositioned between the 5′ wing segment and the 3′ wing segment, eachnucleoside of each wing segment comprises a 2′-O-methoxyethyl modifiedsugar, each internucleoside linkage is a phosphorothioate linkage andeach cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 19 contiguousnucleobases of SEQ ID NOs: 16, 17, 45, 46, 70, 72, or 138, wherein themodified oligonucleotide comprises: a) a gap segment consisting of tenlinked deoxynucleosides; b) a 5′ wing segment consisting of five linkednucleosides; and c) a 3′ wing segment consisting of five linkednucleosides. The gap segment is positioned between the 5′ wing segmentand the 3′ wing segment, each nucleoside of each wing segment comprisesa 2′-O-methoxyethyl modified sugar, each internucleoside linkage is aphosphorothioate linkage and each cytosine residue is a5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 19 contiguousnucleobases of SEQ ID NO: 16, wherein the modified oligonucleotidecomprises: a) a gap segment consisting of ten linked deoxynucleosides;b) a 5′ wing segment consisting of five linked nucleosides; and c) a 3′wing segment consisting of five linked nucleosides. The gap segment ispositioned between the 5′ wing segment and the 3′ wing segment, eachnucleoside of each wing segment comprises a 2′-O-methoxyethyl modifiedsugar, each internucleoside linkage is a phosphorothioate linkage andeach cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 19 contiguousnucleobases of SEQ ID NO: 45, wherein the modified oligonucleotidecomprises: a) a gap segment consisting of ten linked deoxynucleosides;b) a 5′ wing segment consisting of five linked nucleosides; and c) a 3′wing segment consisting of five linked nucleosides. The gap segment ispositioned between the 5′ wing segment and the 3′ wing segment, eachnucleoside of each wing segment comprises a 2′-O-methoxyethyl modifiedsugar, each internucleoside linkage is a phosphorothioate linkage andeach cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 20 contiguousnucleobases of SEQ ID NOs: 7-322, wherein the modified oligonucleotidecomprises: a) a gap segment consisting of ten linked deoxynucleosides;b) a 5′ wing segment consisting of five linked nucleosides; and c) a 3′wing segment consisting of five linked nucleosides. The gap segment ispositioned between the 5′ wing segment and the 3′ wing segment, eachnucleoside of each wing segment comprises a 2′-O-methoxyethyl modifiedsugar, each internucleoside linkage is a phosphorothioate linkage andeach cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 20 contiguousnucleobases of SEQ ID NOs: 16, 17, 45, 46, 70, 72, or 138, wherein themodified oligonucleotide comprises: a) a gap segment consisting of tenlinked deoxynucleosides; b) a 5′ wing segment consisting of five linkednucleosides; and c) a 3′ wing segment consisting of five linkednucleosides. The gap segment is positioned between the 5′ wing segmentand the 3′ wing segment, each nucleoside of each wing segment comprisesa 2′-O-methoxyethyl modified sugar, each internucleoside linkage is aphosphorothioate linkage and each cytosine residue is a5-methylcytosine. In certain embodiments, the compound or compositioncomprises the compound of any of ISIS NOs: 463588, 463589, 463690,463691, 463835, 463837, or 464225.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 20 contiguousnucleobases of SEQ ID NO: 16, wherein the modified oligonucleotidecomprises: a) a gap segment consisting of ten linked deoxynucleosides;b) a 5′ wing segment consisting of five linked nucleosides; and c) a 3′wing segment consisting of five linked nucleosides. The gap segment ispositioned between the 5′ wing segment and the 3′ wing segment, eachnucleoside of each wing segment comprises a 2′-O-methoxyethyl modifiedsugar, each internucleoside linkage is a phosphorothioate linkage andeach cytosine residue is a 5-methylcytosine. In certain embodiments, thecompound or composition comprises the compound of ISIS NO: 463588.

In certain embodiments, the compounds or compositions provided hereincomprise a modified oligonucleotide consisting of 20 linked nucleosideshaving a nucleobase sequence comprising at least 20 contiguousnucleobases of SEQ ID NO: 45, wherein the modified oligonucleotidecomprises: a) a gap segment consisting of ten linked deoxynucleosides;b) a 5′ wing segment consisting of five linked nucleosides; and c) a 3′wing segment consisting of five linked nucleosides. The gap segment ispositioned between the 5′ wing segment and the 3′ wing segment, eachnucleoside of each wing segment comprises a 2′-O-methoxyethyl modifiedsugar, each internucleoside linkage is a phosphorothioate linkage andeach cytosine residue is a 5-methylcytosine. In certain embodiments, thecompound or composition comprises the compound of ISIS NO: 463690.

Certain embodiments provide methods, compounds, and compositions forinhibiting FGFR4 expression.

Certain embodiments provide a method of reducing FGFR4 expression in ananimal comprising administering to the animal a compound as describedherein. In certain embodiments, the compound comprises a modifiedoligonucleotide 12 to 30 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 15 to 30 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 18 to 21 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 to 35 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 to 25 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 to 24 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 to 23 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 to 22 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 to 21 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4.

Certain embodiments provide a method of preventing, ameliorating ortreating a metabolic disease in an animal comprising administering tothe animal a compound as described herein. In certain embodiments, thecompound comprises a modified oligonucleotide 12 to 30 linkednucleosides in length targeted to FGFR4. In certain embodiments, thecompound comprises a modified oligonucleotide 20 linked nucleosides inlength targeted to FGFR4. Examples of metabolic diseases or disordersinclude, but are not limited to obesity, diabetes, hyperglycemia,prediabetes, non-alcoholic fatty liver disease (NAFLD), metabolicsyndrome, insulin resistance, diabetic dyslipidemia, orhypertriglyceridemia or a combination thereof.

Certain embodiments provide a compound as described herein for use inpreventing, ameliorating or treating a metabolic disease in an animal.In certain embodiments, the compound comprises a modifiedoligonucleotide 12 to 30 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4.Examples of metabolic diseases or disorders include, but are not limitedto obesity, diabetes, hyperglycemia, prediabetes, non-alcoholic fattyliver disease (NAFLD), metabolic syndrome, insulin resistance, diabeticdyslipidemia, or hypertriglyceridemia or a combination thereof.

Certain embodiments provide use of a compound as described herein in themanufacture of a medicament for preventing, ameliorating or treating ametabolic disease in an animal. In certain embodiments, the compoundcomprises a modified oligonucleotide 12 to 30 linked nucleosides inlength targeted to FGFR4. In certain embodiments, the compound comprisesa modified oligonucleotide 20 linked nucleosides in length targeted toFGFR4. Examples of metabolic diseases or disorders include, but are notlimited to obesity, diabetes, hyperglycemia, prediabetes, non-alcoholicfatty liver disease (NAFLD), metabolic syndrome, insulin resistance,diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof.

Certain embodiments provide a method of preventing, ameliorating ortreating obesity in an animal comprising administering to the animal acompound as described herein. In certain embodiments, the compoundcomprises a modified oligonucleotide 12 to 30 linked nucleosides inlength targeted to FGFR4. In certain embodiments, the compound comprisesa modified oligonucleotide 20 linked nucleosides in length targeted toFGFR4. In certain embodiments, the compound or composition comprises thecompound of ISIS NOs: 463588, 463589, 463690, 463691, 463835, 463837, or464225. In certain embodiments, the compound or composition comprisesthe compound of ISIS NO: 463588. In certain embodiments, the compound orcomposition comprises the compound of ISIS NO: 463690.

Certain embodiments provide a compound as described herein for use inpreventing, ameliorating or treating obesity in an animal. In certainembodiments, the compound comprises a modified oligonucleotide 12 to 30linked nucleosides in length targeted to FGFR4. In certain embodiments,the compound comprises a modified oligonucleotide 20 linked nucleosidesin length targeted to FGFR4. In certain embodiments, the compound orcomposition comprises the compound of ISIS NOs: 463588, 463589, 463690,463691, 463835, 463837, or 464225. In certain embodiments, the compoundor composition comprises the compound of ISIS NO: 463588. In certainembodiments, the compound or composition comprises the compound of ISISNO: 463690.

Certain embodiments provide use of a compound as described herein in themanufacture of a medicament for preventing, ameliorating or treatingobesity in an animal. In certain embodiments, the compound comprises amodified oligonucleotide 12 to 30 linked nucleosides in length targetedto FGFR4. In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4. Incertain embodiments, the compound or composition comprises the compoundof ISIS NOs: 463588, 463589, 463690, 463691, 463835, 463837, or 464225.In certain embodiments, the compound or composition comprises thecompound of ISIS NO: 463588. In certain embodiments, the compound orcomposition comprises the compound of ISIS NO: 463690.

Certain embodiments provide a method of reducing body weight in ananimal comprising administering to the animal a compound as describedherein. In certain embodiments, the compound comprises a modifiedoligonucleotide 12 to 30 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4. Incertain embodiments, reduction of body weight in an animal prevents,ameliorates or treats a metabolic disease. In certain embodiments,reduction of body weight in an animal prevents, ameliorates or treatsdiabetes. In certain embodiments, reduction of body weight in an animalprevents, ameliorates or treats obesity. In certain embodiments,reduction of body weight in an animal prevents, ameliorates or treatsmetabolic syndrome. In certain embodiments, reduction of body weight inan animal prevents, ameliorates or treats insulin resistance. In certainembodiments, reduction of body weight in an animal prevents, amelioratesor treats hyperglycemia. In certain embodiments, reduction of bodyweight in an animal prevents, ameliorates or treats NAFLD. In certainembodiments, reduction of body weight in an animal prevents, amelioratesor treats diabetic dyslipidemia. In certain embodiments, the body weightis reduced by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide a compound as described herein for use inreducing body weight in an animal. In certain embodiments, the compoundcomprises a modified oligonucleotide 12 to 30 linked nucleosides inlength targeted to FGFR4. In certain embodiments, the compound comprisesa modified oligonucleotide 20 linked nucleosides in length targeted toFGFR4. In certain embodiments, reduction of body weight in an animalprevents, ameliorates or treats a metabolic disease. In certainembodiments, reduction of body weight in an animal prevents, amelioratesor treats diabetes. In certain embodiments, reduction of body weight inan animal prevents, ameliorates or treats obesity. In certainembodiments, reduction of body weight in an animal prevents, amelioratesor treats metabolic syndrome. In certain embodiments, reduction of bodyweight in an animal prevents, ameliorates or treats insulin resistance.In certain embodiments, reduction of body weight in an animal prevents,ameliorates or treats hyperglycemia. In certain embodiments, reductionof body weight in an animal prevents, ameliorates or treats NAFLD. Incertain embodiments, reduction of body weight in an animal prevents,ameliorates or treats diabetic dyslipidemia. In certain embodiments, thebody weight is reduced by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide use of a compound as described herein in themanufacture of a medicament for reducing body weight in an animal. Incertain embodiments, the compound comprises a modified oligonucleotide12 to 30 linked nucleosides in length targeted to FGFR4. In certainembodiments, the compound comprises a modified oligonucleotide 20 linkednucleosides in length targeted to FGFR4. In certain embodiments,reduction of body weight in an animal prevents, ameliorates or treats ametabolic disease. In certain embodiments, reduction of body weight inan animal prevents, ameliorates or treats diabetes. In certainembodiments, reduction of body weight in an animal prevents, amelioratesor treats obesity. In certain embodiments, reduction of body weight inan animal prevents, ameliorates or treats metabolic syndrome. In certainembodiments, reduction of body weight in an animal prevents, amelioratesor treats insulin resistance. In certain embodiments, reduction of bodyweight in an animal prevents, ameliorates or treats hyperglycemia. Incertain embodiments, reduction of body weight in an animal prevents,ameliorates or treats NAFLD. In certain embodiments, reduction of bodyweight in an animal prevents, ameliorates or treats diabeticdyslipidemia. In certain embodiments, the body weight is reduced by atleast 5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95% or 100%.

Certain embodiments provide a method of reducing adipose tissue in ananimal comprising administering to the animal a compound as describedherein. In certain embodiments, the compound comprises a modifiedoligonucleotide 12 to 30 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4. Incertain embodiments, reduction in adiposity in an animal prevents,ameliorates or treats a metabolic disease. In certain embodiments,reduction in adiposity in an animal prevents, ameliorates or treatsdiabetes. In certain embodiments, reduction in adiposity in an animalprevents, ameliorates or treats obesity. In certain embodiments,reduction in adiposity in an animal prevents, ameliorates or treatsmetabolic syndrome. In certain embodiments, reduction in adiposity in ananimal prevents, ameliorates or treats insulin resistance. In certainembodiments, reduction in adiposity in an animal prevents, amelioratesor treats hyperglycemia. In certain embodiments, reduction in adiposityin an animal prevents, ameliorates or treats NAFLD. In certainembodiments, reduction in adiposity in an animal prevents, amelioratesor treats diabetic dyslipidemia. In certain embodiments, adiposity isreduced by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide a compound as described herein for use inreducing adipose tissue in an animal. In certain embodiments, thecompound comprises a modified oligonucleotide 12 to 30 linkednucleosides in length targeted to FGFR4. In certain embodiments, thecompound comprises a modified oligonucleotide 20 linked nucleosides inlength targeted to FGFR4. In certain embodiments, reduction in adiposityin an animal prevents, ameliorates or treats a metabolic disease. Incertain embodiments, reduction in adiposity in an animal prevents,ameliorates or treats diabetes. In certain embodiments, reduction inadiposity in an animal prevents, ameliorates or treats obesity. Incertain embodiments, reduction in adiposity in an animal prevents,ameliorates or treats metabolic syndrome. In certain embodiments,reduction in adiposity in an animal prevents, ameliorates or treatsinsulin resistance. In certain embodiments, reduction in adiposity in ananimal prevents, ameliorates or treats hyperglycemia. In certainembodiments, reduction in adiposity in an animal prevents, amelioratesor treats NAFLD. In certain embodiments, reduction in adiposity in ananimal prevents, ameliorates or treats diabetic dyslipidemia. In certainembodiments, adiposity is reduced by at least 5%, 10%, 20%, 30%, 35%,40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide use of a compound as described herein in themanufacture of a medicament for reducing adipose tissue in an animal. Incertain embodiments, the compound comprises a modified oligonucleotide12 to 30 linked nucleosides in length targeted to FGFR4. In certainembodiments, the compound comprises a modified oligonucleotide 20 linkednucleosides in length targeted to FGFR4. In certain embodiments,reduction in adiposity in an animal prevents, ameliorates or treats ametabolic disease. In certain embodiments, reduction in adiposity in ananimal prevents, ameliorates or treats diabetes. In certain embodiments,reduction in adiposity in an animal prevents, ameliorates or treatsobesity. In certain embodiments, reduction in adiposity in an animalprevents, ameliorates or treats metabolic syndrome. In certainembodiments, reduction in adiposity in an animal prevents, amelioratesor treats insulin resistance. In certain embodiments, reduction inadiposity in an animal prevents, ameliorates or treats hyperglycemia. Incertain embodiments, reduction in adiposity in an animal prevents,ameliorates or treats NAFLD. In certain embodiments, reduction inadiposity in an animal prevents, ameliorates or treats diabeticdyslipidemia. In certain embodiments, adiposity is reduced by at least5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,85%, 90%, 95% or 100%.

Certain embodiments provide a method of increasing fatty acid oxidationin an animal comprising administering to the animal a compound asdescribed herein. In certain embodiments, the compound comprises amodified oligonucleotide 12 to 30 linked nucleosides in length targetedto FGFR4. In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4. Incertain embodiments, increasing fatty acid oxidation in an animalprevents, ameliorates or treats a metabolic disease. In certainembodiments, increasing fatty acid oxidation in an animal prevents,ameliorates or treats diabetes. In certain embodiments, increasing fattyacid oxidation an animal prevents, ameliorates or treats obesity. Incertain embodiments, increasing fatty acid oxidation in an animalprevents, ameliorates or treats metabolic syndrome. In certainembodiments, increasing fatty acid oxidation in an animal prevents,ameliorates or treats insulin resistance. In certain embodiments,increasing fatty acid oxidation in an animal prevents, ameliorates ortreats hyperglycemia. In certain embodiments, increasing fatty acidoxidation in an animal prevents, ameliorates or treats NAFLD. In certainembodiments, increasing fatty acid oxidation prevents, ameliorates ortreats diabetic dyslipidemia. In certain embodiments, the fatty acidoxidation is increased by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide a compound as described herein for use inincreasing fatty acid oxidation in an animal. In certain embodiments,the compound comprises a modified oligonucleotide 12 to 30 linkednucleosides in length targeted to FGFR4. In certain embodiments, thecompound comprises a modified oligonucleotide 20 linked nucleosides inlength targeted to FGFR4. In certain embodiments, increasing fatty acidoxidation in an animal prevents, ameliorates or treats a metabolicdisease. In certain embodiments, increasing fatty acid oxidation in ananimal prevents, ameliorates or treats diabetes. In certain embodiments,increasing fatty acid oxidation an animal prevents, ameliorates ortreats obesity. In certain embodiments, increasing fatty acid oxidationin an animal prevents, ameliorates or treats metabolic syndrome. Incertain embodiments, increasing fatty acid oxidation in an animalprevents, ameliorates or treats insulin resistance. In certainembodiments, increasing fatty acid oxidation in an animal prevents,ameliorates or treats hyperglycemia. In certain embodiments, increasingfatty acid oxidation in an animal prevents, ameliorates or treats NAFLD.In certain embodiments, increasing fatty acid oxidation prevents,ameliorates or treats diabetic dyslipidemia. In certain embodiments, thefatty acid oxidation is increased by at least 5%, 10%, 20%, 30%, 35%,40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide use of a compound as described herein in themanufacture of a medicament for increasing fatty acid oxidation in ananimal. In certain embodiments, the compound comprises a modifiedoligonucleotide 12 to 30 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4. Incertain embodiments, increasing fatty acid oxidation in an animalprevents, ameliorates or treats a metabolic disease. In certainembodiments, increasing fatty acid oxidation in an animal prevents,ameliorates or treats diabetes. In certain embodiments, increasing fattyacid oxidation an animal prevents, ameliorates or treats obesity. Incertain embodiments, increasing fatty acid oxidation in an animalprevents, ameliorates or treats metabolic syndrome. In certainembodiments, increasing fatty acid oxidation in an animal prevents,ameliorates or treats insulin resistance. In certain embodiments,increasing fatty acid oxidation in an animal prevents, ameliorates ortreats hyperglycemia. In certain embodiments, increasing fatty acidoxidation in an animal prevents, ameliorates or treats NAFLD. In certainembodiments, increasing fatty acid oxidation prevents, ameliorates ortreats diabetic dyslipidemia. In certain embodiments, the fatty acidoxidation is increased by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide a method of reducing glucose levels in ananimal comprising administering to the animal a compound as describedherein. In certain embodiments, the compound comprises a modifiedoligonucleotide 12 to 30 linked nucleosides in length targeted to FGFR4.In certain embodiments, the compound comprises a modifiedoligonucleotide 20 linked nucleosides in length targeted to FGFR4. Incertain embodiments, reduction of glucose levels in an animal prevents,ameliorates or treats a metabolic disease. In certain embodiments,reduction of glucose levels in an animal prevents, ameliorates or treatsdiabetes. In certain embodiments, reduction of glucose levels in ananimal prevents, ameliorates or treats obesity. In certain embodiments,reduction of glucose levels in an animal prevents, ameliorates or treatsmetabolic syndrome. In certain embodiments, reduction of glucose levelsin an animal prevents, ameliorates or treats insulin resistance. Incertain embodiments, reduction of glucose levels in an animal prevents,ameliorates or treats hyperglycemia. In certain embodiments, reductionof glucose levels in an animal prevents, ameliorates or treats NAFLD. Incertain embodiments, reduction of glucose levels in an animal prevents,ameliorates or treats diabetic dyslipidemia. In certain embodiments, theglucose level is reduced by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide a compound as described herein for use inreducing glucose levels in an animal. In certain embodiments, thecompound comprises a modified oligonucleotide 12 to 30 linkednucleosides in length targeted to FGFR4. In certain embodiments, thecompound comprises a modified oligonucleotide 20 linked nucleosides inlength targeted to FGFR4. In certain embodiments, reduction of glucoselevels in an animal prevents, ameliorates or treats a metabolic disease.In certain embodiments, reduction of glucose levels in an animalprevents, ameliorates or treats diabetes. In certain embodiments,reduction of glucose levels in an animal prevents, ameliorates or treatsobesity. In certain embodiments, reduction of glucose levels in ananimal prevents, ameliorates or treats metabolic syndrome. In certainembodiments, reduction of glucose levels in an animal prevents,ameliorates or treats insulin resistance. In certain embodiments,reduction of glucose levels in an animal prevents, ameliorates or treatshyperglycemia. In certain embodiments, reduction of glucose levels in ananimal prevents, ameliorates or treats NAFLD. In certain embodiments,reduction of glucose levels in an animal prevents, ameliorates or treatsdiabetic dyslipidemia. In certain embodiments, the glucose level isreduced by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

Certain embodiments provide use of a compound as described herein in themanufacture of a medicament for reducing glucose levels in an animal. Incertain embodiments, the compound comprises a modified oligonucleotide12 to 30 linked nucleosides in length targeted to FGFR4. In certainembodiments, the compound comprises a modified oligonucleotide 20 linkednucleosides in length targeted to FGFR4. In certain embodiments,reduction of glucose levels in an animal prevents, ameliorates or treatsa metabolic disease. In certain embodiments, reduction of glucose levelsin an animal prevents, ameliorates or treats diabetes. In certainembodiments, reduction of glucose levels in an animal prevents,ameliorates or treats obesity. In certain embodiments, reduction ofglucose levels in an animal prevents, ameliorates or treats metabolicsyndrome. In certain embodiments, reduction of glucose levels in ananimal prevents, ameliorates or treats insulin resistance. In certainembodiments, reduction of glucose levels in an animal prevents,ameliorates or treats hyperglycemia. In certain embodiments, reductionof glucose levels in an animal prevents, ameliorates or treats NAFLD. Incertain embodiments, reduction of glucose levels in an animal prevents,ameliorates or treats diabetic dyslipidemia. In certain embodiments, theglucose level is reduced by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

In certain embodiments, FGFR4 has the sequence as set forth in any ofthe GENBANK Accession Numbers: GENBANK Accession No. NM_(—)002011.3(incorporated herein as SEQ ID NO: 1), GENBANK Accession No:NT_(—)023133.11 truncated from nucleosides 21323018 to 21335213(incorporated herein as SEQ ID NO: 2); GENBANK Accession No. AB209631.1(incorporated herein as SEQ ID NO: 3); and GENBANK Accession NoNM_(—)022963.2 (incorporated herein as SEQ ID NO: 4).). In certainembodiments, FGFR4 has the human sequence as set forth in SEQ ID NOs:1-4. In certain embodiments, FGFR4 has the rhesus monkey sequence as setforth in GENBANK Accession No. NW_(—)001121000.1 truncated fromnucleosides 3094000 to 3109000 (SEQ ID NO: 5). In certain embodiments,FGFR4 has the murine sequence as set forth in GENBANK Accession No.BC033313.1 (SEQ ID NO: 6).

In certain embodiments, the compounds or compositions provided hereincomprise a salt thereof, and a pharmaceutically acceptable carrier ordiluent. In certain embodiments, the composition comprises a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NOs: 16, 17, 45, 46, 70, 72, or138 or a salt thereof and a pharmaceutically acceptable carrier ordiluent. In certain embodiments, the composition comprises a modifiedoligonucleotide consisting of 20 to 25 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NOs: 16, 17, 45, 46, 70, 72, or138 or a salt thereof and a pharmaceutically acceptable carrier ordiluent. In certain embodiments, the composition comprises a modifiedoligonucleotide consisting of 20 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NO: 16, 17, 45, 46, 70, 72, or 138or a salt thereof and a pharmaceutically acceptable carrier or diluent.

In certain embodiments, the compounds or compositions provided hereincomprise a salt thereof, and a pharmaceutically acceptable carrier ordiluent. In certain embodiments, the composition comprises a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NO: 16 or a salt thereof and apharmaceutically acceptable carrier or diluent. In certain embodiments,the composition comprises a modified oligonucleotide consisting of 20 to25 linked nucleosides and having a nucleobase sequence comprising atleast 20 contiguous nucleobases of a nucleobase sequence recited in SEQID NO: 16 or a salt thereof and a pharmaceutically acceptable carrier ordiluent. In certain embodiments, the composition comprises a modifiedoligonucleotide consisting of 20 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NO: 16 or a salt thereof and apharmaceutically acceptable carrier or diluent.

In certain embodiments, the compounds or compositions provided hereincomprise a salt thereof, and a pharmaceutically acceptable carrier ordiluent. In certain embodiments, the composition comprises a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NO: 45 or a salt thereof and apharmaceutically acceptable carrier or diluent. In certain embodiments,the composition comprises a modified oligonucleotide consisting of 20 to25 linked nucleosides and having a nucleobase sequence comprising atleast 20 contiguous nucleobases of a nucleobase sequence recited in SEQID NO: 45 or a salt thereof and a pharmaceutically acceptable carrier ordiluent. In certain embodiments, the composition comprises a modifiedoligonucleotide consisting of 20 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NO: 45 or a salt thereof and apharmaceutically acceptable carrier or diluent.

Certain embodiments provide a method for treating an animal with a FGFR4related disease or condition comprising: a) identifying said animal withthe FGFR4 related disease or condition, and b) administering to saidanimal a therapeutically effective amount of a compound comprising amodified oligonucleotide consisting of 12 to 30 linked nucleosides andhaving a nucleobase sequence at least 90% complementary to any of SEQ IDNOs: 1-4 as measured over the entirety of said modified oligonucleotide.In certain embodiments, the therapeutically effective amount of thecompound administered to the animal treats or reduces the FGFR4 relateddisease or condition, or a symptom thereof, in the animal. In certainembodiments, the FGFR4 related disease or condition is obesity. Incertain embodiments, the FGFR4 related disease or condition is diabetes.

Certain embodiments provide a compound comprising a modifiedoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence at least 90% complementary to any of SEQ ID NOs: 1-4as measured over the entirety of said modified oligonucleotide fortreating a FGFR4 related disease or condition. In certain embodiments,the FGFR4 related disease or condition is obesity. In certainembodiments, the FGFR4 related disease or condition is diabetes.

Certain embodiments provide use of a compound comprising a modifiedoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence at least 90% complementary to any of SEQ ID NOs: 1-4as measured over the entirety of said modified oligonucleotide in thepreparation of a medicament for treating a FGFR4 related disease orcondition. In certain embodiments, the FGFR4 related disease orcondition is obesity. In certain embodiments, the FGFR4 related diseaseor condition is diabetes.

Certain embodiments provide a method for treating an animal with a FGFR4related disease or condition comprising: a) identifying said animal withthe FGFR4 related disease or condition, and b) administering to saidanimal a therapeutically effective amount of a compound comprising amodified oligonucleotide consisting of 20 linked nucleosides and havinga nucleobase sequence at least 100% complementary to any of SEQ ID NOs:1-4 as measured over the entirety of said modified oligonucleotide. Incertain embodiments, the therapeutically effective amount of thecompound administered to the animal treats or reduces the FGFR4 relateddisease or condition, or a symptom thereof, in the animal. In certainembodiments, the FGFR4 related disease or condition is obesity. Incertain embodiments, the FGFR4 related disease or condition is diabetes.

Certain embodiments provide a compound comprising a modifiedoligonucleotide consisting of 20 linked nucleosides and having anucleobase sequence at least 100% complementary to any of SEQ ID NOs:1-4 as measured over the entirety of said modified oligonucleotide fortreating a FGFR4 related disease or condition. In certain embodiments,the FGFR4 related disease or condition is obesity. In certainembodiments, the FGFR4 related disease or condition is diabetes.

Certain embodiments provide use of a compound comprising a modifiedoligonucleotide consisting of 20 linked nucleosides and having anucleobase sequence at least 100% complementary to any of SEQ ID NOs:1-4 as measured over the entirety of said modified oligonucleotide inthe preparation of a medicament for treating a FGFR4 related disease orcondition. In certain embodiments, the FGFR4 related disease orcondition is obesity. In certain embodiments, the FGFR4 related diseaseor condition is diabetes.

Certain embodiments provide methods of treating, preventing, orameliorating a metabolic disease. In certain embodiments the metabolicdisease is obesity, diabetes, hyperglycemia, prediabetes, non-alcoholicfatty liver disease (NAFLD), metabolic syndrome, insulin resistance,diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof.

Certain embodiments provide compounds described herein for treating,preventing, or ameliorating a metabolic disease. In certain embodimentsthe metabolic disease is obesity, diabetes, hyperglycemia, prediabetes,non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, insulinresistance, diabetic dyslipidemia, or hypertriglyceridemia or acombination thereof.

Certain embodiments provide use of compounds described herein in thepreparation of a medicament for treating, preventing, or ameliorating ametabolic disease. In certain embodiments the metabolic disease isobesity, diabetes, hyperglycemia, prediabetes, non-alcoholic fatty liverdisease (NAFLD), metabolic syndrome, insulin resistance, diabeticdyslipidemia, or hypertriglyceridemia or a combination thereof.

Certain embodiments provide methods comprising administering to ananimal a compound as described herein to an animal. In certainembodiments, the method comprises administering to an animal a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence recited in SEQ ID NOs: 16, 17, 45, 46, 70, 72, or138.

Certain embodiments provide a modified oligonucleotide consisting of 20to 35 linked nucleosides and having a nucleobase sequence comprising atleast 20 contiguous nucleobases of a nucleobase sequence recited in SEQID NOs: 16, 17, 45, 46, 70, 72, or 138 for treating a metabolic disease,diabetes, and/or obesity.

Certain embodiments provide use of a modified oligonucleotide consistingof 20 to 35 linked nucleosides and having a nucleobase sequencecomprising at least 20 contiguous nucleobases of a nucleobase sequencerecited in SEQ ID NOs: 16, 17, 45, 46, 70, 72, or 138 in the preparationof a medicament for treating metabolic disease, diabetes, and/orobesity.

Certain embodiments provide methods comprising administering to ananimal a compound as described herein to an animal. In certainembodiments, the method comprises administering to an animal a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence selected from among the nucleobase sequences recitedin SEQ ID NO: 16.

Certain embodiments provide a modified oligonucleotide consisting of 20to 35 linked nucleosides and having a nucleobase sequence comprising atleast 20 contiguous nucleobases of a nucleobase sequence recited in SEQID NO: 16 for treating metabolic disease, diabetes, and/or obesity.

Certain embodiments provide use of a modified oligonucleotide consistingof 20 to 35 linked nucleosides and having a nucleobase sequencecomprising at least 20 contiguous nucleobases of a nucleobase sequencerecited in SEQ ID NO: 16 in the preparation of a medicament for treatingmetabolic disease, diabetes, and/or obesity.

Certain embodiments provide methods comprising administering to ananimal a compound as described herein to an animal. In certainembodiments, the method comprises administering to an animal a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence selected from among the nucleobase sequences recitedin SEQ ID NO: 45.

Certain embodiments provide a modified oligonucleotide consisting of 20to 35 linked nucleosides and having a nucleobase sequence comprising atleast 20 contiguous nucleobases of a nucleobase sequence recited in SEQID NO: 45 for treating metabolic disease, diabetes, and/or obesity.

Certain embodiments provide use of a modified oligonucleotide consistingof 20 to 35 linked nucleosides and having a nucleobase sequencecomprising at least 20 contiguous nucleobases of a nucleobase sequencerecited in SEQ ID NO: 45 in the preparation of a medicament for treatingmetabolic disease, diabetes, and/or obesity.

Certain embodiments provide methods comprising administering to ananimal a compound as described herein to an animal. In certainembodiments, the method comprises administering to an animal a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence selected from among the nucleobase sequences recitedin ISIS NO: 463588.

Certain embodiments provide a modified oligonucleotide consisting of 20to 35 linked nucleosides and having a nucleobase sequence comprising atleast 20 contiguous nucleobases of a nucleobase sequence of ISIS NO:463588 for treating metabolic disease, diabetes, and/or obesity.

Certain embodiments provide use of a modified oligonucleotide consistingof 20 to 35 linked nucleosides and having a nucleobase sequencecomprising at least 20 contiguous nucleobases of a nucleobase sequenceof ISIS NO: 463588 in the preparation of a medicament for treatingmetabolic disease, diabetes, and/or obesity.

Certain embodiments provide methods comprising administering to ananimal a compound as described herein to an animal. In certainembodiments, the method comprises administering to an animal a modifiedoligonucleotide consisting of 20 to 35 linked nucleosides and having anucleobase sequence comprising at least 20 contiguous nucleobases of anucleobase sequence selected from among the nucleobase sequences recitedin ISIS NO: 463690.

Certain embodiments provide a modified oligonucleotide consisting of 20to 35 linked nucleosides and having a nucleobase sequence comprising atleast 20 contiguous nucleobases of a nucleobase sequence of ISIS NO:463690 for treating metabolic disease, diabetes, and/or obesity.

Certain embodiments provide use of a modified oligonucleotide consistingof 20 to 35 linked nucleosides and having a nucleobase sequencecomprising at least 20 contiguous nucleobases of a nucleobase sequenceof ISIS NO: 463690 in the preparation of a medicament for treatingmetabolic disease, diabetes, and/or obesity.

In certain embodiments, the animal is a human.

In certain embodiments, the administering prevents, treats, ameliorates,or slows progression of a metabolic disease as described herein.

In certain embodiments, the administering prevents, treats, ameliorates,or slows progression of obesity as described herein.

In certain embodiments, the administering prevents, treats, ameliorates,or slows progression of diabetes as described herein.

In certain embodiments, the compound is co-administered with a secondagent.

In certain embodiments, the compound and the second agent areadministered concomitantly.

In certain embodiments, the administering is parenteral administration.

Certain embodiments further provide a method to reduce FGFR4 mRNA orprotein expression in an animal comprising administering to the animal acompound or composition as described herein to reduce FGFR4 mRNA orprotein expression in the animal. In certain embodiments, the animal isa human. In certain embodiments, reducing FGFR4 mRNA or proteinexpression prevents, treats, ameliorates, or slows progression ofmetabolic disease. In certain embodiments, the metabolic disease orcondition is diabetes. In certain embodiments, the metabolic disease orcondition is obesity.

Certain embodiments provide a method for treating a human with ametabolic disease comprising identifying the human with the disease andadministering to the human a therapeutically effective amount of acompound or composition as described herein. In certain embodiments, thetreatment reduces a symptom selected from the group consisting ofmetabolic syndrome, hyperglycemia, hypertriglyceridemia, hypertension,increased glucose levels, increased insulin resistance, decreasedinsulin sensitivity, above normal body weight, and/or above normal bodyfat or any combination thereof.

Certain embodiments provide a method for treating a human with obesitycomprising identifying the human with the disease and administering tothe human a therapeutically effective amount of a compound orcomposition as described herein. In certain embodiments, the treatmentreduces a symptom selected from the group consisting of metabolicsyndrome, hyperglycemia, hypertriglyceridemia, hypertension, increasedglucose levels, increased insulin resistance, decreased insulinsensitivity, above normal body weight, and/or above normal body fat orany combination thereof

Certain embodiments provide a method for treating a human with diabetescomprising identifying the human with the disease and administering tothe human a therapeutically effective amount of a compound orcomposition as described herein. In certain embodiments, the treatmentreduces a symptom selected from the group consisting of metabolicsyndrome, hyperglycemia, hypertriglyceridemia, hypertension, increasedglucose levels, increased insulin resistance, decreased insulinsensitivity, above normal body weight, and/or above normal body fat orany combination thereof

Further provided is a method for reducing or preventing metabolicdisease comprising administering to a human a therapeutically effectiveamount compound or composition as described herein, thereby reducing orpreventing metabolic disease.

Further provided is a method for reducing or preventing obesitycomprising administering to a human a therapeutically effective amountcompound or composition as described herein, thereby reducing orpreventing diabetes.

Further provided is a method for reducing or preventing diabetescomprising administering to a human a therapeutically effective amountcompound or composition as described herein, thereby reducing orpreventing diabetes.

Further provided is a method for ameliorating a symptom of metabolicdisease, comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 20 to 35 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic disease in the human.

Further provided is a method for ameliorating a symptom of obesity,comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 20 to 35 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic disease in the human.

Further provided is a method for ameliorating a symptom of diabetes,comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 20 to 35 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic disease in the human.

Further provided is a method for ameliorating a symptom of metabolicsyndrome, comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 12 to 30 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic syndrome in the human.

Further provided is a method for ameliorating a symptom of metabolicdisease, comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 12 to 30 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic disease in the human.

Further provided is a method for ameliorating a symptom of obesity,comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 12 to 30 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof obesity in the human.

Further provided is a method for ameliorating a symptom of diabetes,comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 12 to 30 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof diabetes in the human.

Further provided is a method for ameliorating a symptom of metabolicsyndrome, comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 12 to 30 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic syndrome in the human.

Further provided is a method for ameliorating a symptom of metabolicdisease, comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 20 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic disease in the human.

Further provided is a method for ameliorating a symptom of obesity,comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 20 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof obesity in the human.

Further provided is a method for ameliorating a symptom of diabetes,comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 20 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof diabetes in the human.

Further provided is a method for ameliorating a symptom of metabolicsyndrome, comprising administering to a human in need thereof a compoundcomprising a modified oligonucleotide consisting of 20 linkednucleosides, wherein said modified oligonucleotide specificallyhybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby ameliorating a symptomof metabolic syndrome in the human.

Further provided is a method for reducing the rate of progression of asymptom associated with metabolic disease, comprising administering to ahuman in need thereof a compound comprising a modified oligonucleotideconsisting of 20 to 35 linked nucleosides, wherein said modifiedoligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5,thereby reducing the rate of progression a symptom of metabolic diseasein the human.

Further provided is a method for reducing the rate of progression of asymptom associated with obesity, comprising administering to a human inneed thereof a compound comprising a modified oligonucleotide consistingof 20 to 35 linked nucleosides, wherein said modified oligonucleotidespecifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby reducingthe rate of progression a symptom of obesity in the human.

Further provided is a method for reducing the rate of progression of asymptom associated with diabetes, comprising administering to a human inneed thereof a compound comprising a modified oligonucleotide consistingof 20 to 35 linked nucleosides, wherein said modified oligonucleotidespecifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby reducingthe rate of progression a symptom of diabetes in the human.

Further provided is a method for reducing the rate of progression of asymptom associated with metabolic syndrome, comprising administering toa human in need thereof a compound comprising a modified oligonucleotideconsisting of 20 to 35 linked nucleosides, wherein said modifiedoligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5,thereby reducing the rate of progression a symptom of metabolic syndromein the human.

Further provided is a method for reducing the rate of progression of asymptom associated with metabolic disease, comprising administering to ahuman in need thereof a compound comprising a modified oligonucleotideconsisting of 12 to 30 linked nucleosides, wherein said modifiedoligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5,thereby reducing the rate of progression a symptom of metabolic diseasein the human.

Further provided is a method for reducing the rate of progression of asymptom associated with obesity, comprising administering to a human inneed thereof a compound comprising a modified oligonucleotide consistingof 12 to 30 linked nucleosides, wherein said modified oligonucleotidespecifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby reducingthe rate of progression a symptom of obesity in the human.

Further provided is a method for reducing the rate of progression of asymptom associated with diabetes, comprising administering to a human inneed thereof a compound comprising a modified oligonucleotide consistingof 12 to 30 linked nucleosides, wherein said modified oligonucleotidespecifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby reducingthe rate of progression a symptom of diabetes in the human.

Further provided is a method for reducing the rate of progression of asymptom associated with metabolic syndrome, comprising administering toa human in need thereof a compound comprising a modified oligonucleotideconsisting of 12 to 30 linked nucleosides, wherein said modifiedoligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5,thereby reducing the rate of progression a symptom of metabolic syndromein the human.

Further provided is a method for reducing the rate of progression of asymptom associated with metabolic disease, comprising administering to ahuman in need thereof a compound comprising a modified oligonucleotideconsisting of 20 linked nucleosides, wherein said modifiedoligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5,thereby reducing the rate of progression a symptom of metabolic diseasein the human.

Further provided is a method for reducing the rate of progression of asymptom associated with obesity, comprising administering to a human inneed thereof a compound comprising a modified oligonucleotide consistingof 20 linked nucleosides, wherein said modified oligonucleotidespecifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby reducingthe rate of progression a symptom of obesity in the human.

Further provided is a method for reducing the rate of progression of asymptom associated with diabetes, comprising administering to a human inneed thereof a compound comprising a modified oligonucleotide consistingof 20 linked nucleosides, wherein said modified oligonucleotidespecifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5, thereby reducingthe rate of progression a symptom of diabetes in the human.

Further provided is a method for reducing the rate of progression of asymptom associated with metabolic syndrome, comprising administering toa human in need thereof a compound comprising a modified oligonucleotideconsisting of 20 linked nucleosides, wherein said modifiedoligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, 3, 4 or 5,thereby reducing the rate of progression a symptom of metabolic syndromein the human.

Also provided are methods and compounds for the preparation of amedicament for the treatment, prevention, or amelioration of metabolicdisease.

Also provided are methods and compounds for the preparation of amedicament for the treatment, prevention, or amelioration of obesity.

Also provided are methods and compounds for the preparation of amedicament for the treatment, prevention, or amelioration of diabetes.

Also provided are methods and compounds for the preparation of amedicament for the treatment, prevention, or amelioration of metabolicsyndrome.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, ameliorating, orpreventing metabolic disease.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, ameliorating, orpreventing obesity.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, ameliorating, orpreventing diabetes.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, ameliorating, orpreventing metabolic syndrome.

Certain embodiments provide a compound as described herein for use intreating, preventing, or ameliorating metabolic disease as describedherein by combination therapy with an additional agent or therapy asdescribed herein. Agents or therapies can be co-administered oradministered concomitantly.

Certain embodiments provide a compound as described herein for use intreating, preventing, or ameliorating diabetes as described herein bycombination therapy with an additional agent or therapy as describedherein. Agents or therapies can be co-administered or administeredconcomitantly.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating metabolic disease as described herein by combinationtherapy with an additional agent or therapy as described herein. Agentsor therapies can be co-administered or administered concomitantly.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating obesity as described herein by combination therapy with anadditional agent or therapy as described herein. Agents or therapies canbe co-administered or administered concomitantly.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating diabetes as described herein by combination therapy with anadditional agent or therapy as described herein. Agents or therapies canbe co-administered or administered concomitantly.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating diabetes as described herein by combination therapy with anadditional agent or therapy as described herein. Agents or therapies canbe co-administered or administered concomitantly.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating metabolic disease as described herein in a patient who issubsequently administered an additional agent or therapy as describedherein.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating obesity as described herein in a patient who issubsequently administered an additional agent or therapy as describedherein.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating diabetes as described herein in a patient who issubsequently administered an additional agent or therapy as describedherein.

Certain embodiments provide the use of a compound as described herein inthe manufacture of a medicament for treating, preventing, orameliorating metabolic syndrome as described herein in a patient who issubsequently administered an additional agent or therapy as describedherein.

Certain embodiments provide a kit for treating, preventing, orameliorating metabolic disease as described herein wherein the kitcomprises:

(i) a compound as described herein; and alternatively(ii) an additional agent or therapy as described herein.

Certain embodiments provide a kit for treating, preventing, orameliorating obesity as described herein wherein the kit comprises:

(i) a compound as described herein; and alternatively(ii) an additional agent or therapy as described herein.

Certain embodiments provide a kit for treating, preventing, orameliorating diabetes as described herein wherein the kit comprises:

(i) a compound as described herein; and alternatively(ii) an additional agent or therapy as described herein.

Certain embodiments provide a kit for treating, preventing, orameliorating metabolic syndrome as described herein wherein the kitcomprises:

(i) a compound as described herein; and alternatively(ii) an additional agent or therapy as described herein.

A kit as described herein may further include instructions for using thekit to treat, prevent, or ameliorate metabolic disease as describedherein by combination therapy as described herein. In certainembodiments, the metabolic disease is obesity. In certain embodiments,the metabolic disease is diabetes.

In certain embodiments, a biomarker of the anti-obesity effect of anFGFR4 inhibitor is an increase in FGF15 and/or FGF19 protein levels. Incertain embodiments, a biomarker of FGFR4 antisenseoligonucleotide-caused anti-obesity effect is an increase in FGF15and/or FGF19 gene expression levels. In certain embodiments, a biomarkerof FGFR4 antisense oligonucleotide-caused anti-obesity effect is anincrease in FGF15 and/or FGF19 protein levels. In certain embodiments, abiomarker of FGFR4 antisense oligonucleotide-caused anti-obesity effectis an increase in FGF15 and/or FGF19 gene expression levels. In certainembodiments, the FGF15 and/or FGF19 nucleic acid is any of the sequencesset forth in GENBANK Accession No. NM_(—)008003.2 (incorporated hereinas SEQ ID NO: 345), GENBANK Accession No: XM_(—)001100825.1(incorporated herein as SEQ ID NO: 346); and GENBANK Accession No.NM_(—)005117.1 (incorporated herein as SEQ ID NO: 347).

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal by measuring an increase in ileumFGF15 and/or ileum FGF19 gene expression and plasma FGF15 and/or plasmaFGF19 protein levels.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor by measuring an increase in ileum FGF15and/or ileum FGF19 gene expression and plasma FGF15 and/or plasma FGF19protein levels.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF15 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF15 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF15 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF19 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF19 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF19 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF15protein levels in an individual prior to administration of a FGFR4inhibitor (b) administering an FGFR4 inhibitor (c) measuring FGF15protein levels after administration of a FGFR4 inhibitor (d) detectingan increase of FGF15 protein levels. In certain embodiments, the FGFR4inhibitor is a modified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF19protein levels in an individual prior to administration of a FGFR4inhibitor (b) administering an FGFR4 inhibitor (c) measuring FGF19protein levels after administration of a FGFR4 inhibitor (d) detectingan increase of FGF19 protein levels. In certain embodiments, the FGFR4inhibitor is a modified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF15 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF15 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF15 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF19 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF19 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF19 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF15 proteinlevels in an individual prior to administration of a FGFR4 inhibitor (b)administering an FGFR4 inhibitor (c) measuring FGF15 protein levelsafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF15 protein levels. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF19 proteinlevels in an individual prior to administration of a FGFR4 inhibitor (b)administering an FGFR4 inhibitor (c) measuring FGF19 protein levelsafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF19 protein levels. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide a method for treating a metabolic disease,including obesity, diabetes, hyperglycemia, prediabetes, non-alcoholicfatty liver disease (NAFLD), metabolic syndrome, insulin resistance,diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof,comprising administering a first dose of a compound or composition asdescribed herein to a subject having a baseline level of FGF15 or FGF19mRNA or protein in the blood or a tissue and administering one or moreadditional doses of the compound or composition to the subject until thelevel of FGF15 or FGF19 in the blood or a tissue is not increased fromthe baseline level by a certain extent for a certain amount of time.

In some aspects, one or more additional doses of the compound orcomposition described herein is administered to the subject until thelevel of FGF15 or FGF19 mRNA or protein in the blood or a tissue is notincreased from the baseline level for at least about one week, twoweeks, three weeks, four weeks, five weeks, six weeks, seven weeks,eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks, thirteenweeks, fourteen weeks, fifteen weeks, sixteen weeks, seventeen weeks,eighteen weeks, nineteen weeks, twenty weeks, twenty-one weeks,twenty-two weeks, twenty-three weeks, twenty-four, twenty-five,twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one,thirty-two, thirty-three, thirty-four, thirty-five, thirty-six,thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two,forty-three, forty-four, forty-five, forty-six, forty-seven,forty-eight, forty-nine, or fifty weeks.

In certain aspects, one or more additional doses of the compound orcomposition described herein is administered to the subject until thelevel of FGF15 or FGF19 mRNA or protein in the blood or a tissue is notincreased from the baseline level by at least about 1%, 2%, 3%, 4%, 5%,6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%,21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%,35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%,63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%,116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%,128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%,140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%,152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%,164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%,176%, 177%, 178%, 179%, 180%, 181%, 182%, 183%, 184%, 185%, 186%, 187%,188%, 189%, 190%, 191%, 192%, 193%, 194%, 195%, 196%, 197%, 198%, 199%,200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, or any value inbetween any of the aforementioned percentages.

Administration of one or more additional doses of the compound orcomposition described herein can continue until such increases in thelevel of FGF15 or FGF19 mRNA or protein in the blood or a tissuerelative to the baseline level does not occur for at least about oneweek, two weeks, three weeks, four weeks, five weeks, six weeks, sevenweeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks,thirteen weeks, fourteen weeks, fifteen weeks, sixteen weeks, seventeenweeks, eighteen weeks, nineteen weeks, twenty weeks, twenty-one weeks,twenty-two weeks, twenty-three weeks, twenty-four, twenty-five,twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one,thirty-two, thirty-three, thirty-four, thirty-five, thirty-six,thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two,forty-three, forty-four, forty-five, forty-six, forty-seven,forty-eight, forty-nine, or fifty weeks. In several aspects, each doseof compound or composition described herein can be about 50-2000 mg,about 50-400 mg, about 50-200 mg, about 50-100 mg, about 100-200 mg, orany amount in between any of the aforementioned ranges.

In certain aspects, one or more additional doses of the compound orcomposition described herein is administered to the subject until thelevel of FGF15 or FGF19 protein in the blood or a tissue is notincreased from the baseline level by at least about 1 pg/mL, 5 pg/mL, 10pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 35 pg/mL, 40 pg/mL, 45pg/mL, 50 pg/mL, 55 pg/mL, 60 pg/mL, 65 pg/mL, 70 pg/mL, 75 pg/mL, 80pg/mL, 85 pg/mL, 90 pg/mL, 95 pg/mL, 100 pg/mL, 105 pg/mL, 110 pg/mL,115 pg/mL, 120 pg/mL, 125 pg/mL, 130 pg/mL, 135 pg/mL, 140 pg/mL, 145pg/mL, 150 pg/mL, 155 pg/mL, 160 pg/mL, 165 pg/mL, 170 pg/mL, 175 pg/mL,180 pg/mL, 185 pg/mL, 190 pg/mL, 195 pg/mL, 200 pg/mL, 205 pg/mL, 210pg/mL, 215 pg/mL, 220 pg/mL, 225 pg/mL, 230 pg/mL, 235 pg/mL, 240 pg/mL,245 pg/mL, 250 pg/mL, 255 pg/mL, 260 pg/mL, 265 pg/mL, 270 pg/mL, 275pg/mL, 280 pg/mL, 290 pg/mL, 295 pg/mL, 300 pg/mL, 350 pg/mL, 400 pg/mL,450 pg/mL, 500 pg/mL, 550 pg/mL, 600 pg/mL, 650 pg/mL, 700 pg/mL, 750pg/mL, 800 pg/mL, 850 pg/mL, 900 pg/mL, 950 pg/mL, 1,000 pg/mL, 2,000pg/mL, or any value in between any of the aforementioned concentrations.Administration of one or more additional doses of the compound orcomposition described herein can continue until such increases in thelevel of FGF15 or FGF19 protein in the blood or a tissue relative to thebaseline level does not occur for at least about one week, two weeks,three weeks, four weeks, five weeks, six weeks, seven weeks, eightweeks, nine weeks, ten weeks, eleven weeks, twelve weeks, thirteenweeks, fourteen weeks, fifteen weeks, sixteen weeks, seventeen weeks,eighteen weeks, nineteen weeks, twenty weeks, twenty-one weeks,twenty-two weeks, twenty-three weeks, twenty-four, twenty-five,twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one,thirty-two, thirty-three, thirty-four, thirty-five, thirty-six,thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two,forty-three, forty-four, forty-five, forty-six, forty-seven,forty-eight, forty-nine, or fifty weeks. In several aspects, each doseof compound or composition described herein can be about 50-2000 mg,about 50-400 mg, about 50-200 mg, about 50-100 mg, about 100-200 mg, orany amount in between any of the aforementioned ranges.

It will be understood that one or more doses of the compound orcomposition described herein can be administered during theaforementioned time periods. For example, a subject may have beenadministered one or more doses of the compound or composition describedherein during the at least about one week, two weeks, three weeks, fourweeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, tenweeks, eleven weeks, twelve weeks, thirteen weeks, fourteen weeks,fifteen weeks, sixteen weeks, seventeen weeks, eighteen weeks, nineteenweeks, twenty weeks, twenty-one weeks, twenty-two weeks, twenty-threeweeks, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight,twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four,thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty,forty-one, forty-two, forty-three, forty-four, forty-five, forty-six,forty-seven, forty-eight, forty-nine, or fifty weeks. In certainembodiments, additional doses of the compound or composition describedherein are administered to the subject until the level of FGF15 or FGF19mRNA or protein in the blood or a tissue is not increased from thebaseline level by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%,24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%,38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%,52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%,80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103% 104%, 105%, 106%,107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%,119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%,131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%,143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%,155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%,167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%, 176%, 177%, 178%,179%, 180%, 181%, 182%, 183%, 184%, 185%, 186%, 187%, 188%, 189%, 190%,191%, 192%, 193%, 194%, 195%, 196%, 197%, 198%, 199%, 200%, 300%, 400%,500%, 600%, 700%, 800%, 900%, 1,000%, or any value in between any of theaforementioned percentages in the aforementioned time periods. Inseveral aspects, each dose of compound or composition described hereincan be about 50-2000 mg, about 50-400 mg, about 50-200 mg, about 50-100mg, about 100-200 mg, or any amount in between any of the aforementionedranges.

Various embodiments are directed to a method of treating a metabolicdisease, including obesity, diabetes, hyperglycemia, prediabetes,non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, insulinresistance, diabetic dyslipidemia, or hypertriglyceridemia or acombination thereof, comprising (a) obtaining the baseline level ofFGF15 or FGF19 mRNA or protein in the blood or a tissue of a subject,(b) administering to the subject a dose of a compound or compositiondescribed herein, (c) obtaining the level of FGF15 or FGF19 mRNA orprotein in the blood or a tissue after the administration of thecompound or composition described herein; and (d) repeating steps (b)and (c) until the level of FGF15 or FGF19 mRNA or protein in the bloodor a tissue does not increase by a certain extent for a certain amountof time relative to baseline.

In several aspects, steps (b) and (c) are repeated until the level ofFGF15 or FGF19 mRNA or protein in the blood or a tissue does notincrease relative to baseline for at least about one week, two weeks,three weeks, four weeks, five weeks, six weeks, seven weeks, eightweeks, nine weeks, ten weeks, eleven weeks, twelve weeks, thirteenweeks, fourteen weeks, fifteen weeks, sixteen weeks, seventeen weeks,eighteen weeks, nineteen weeks, twenty weeks, twenty-one weeks,twenty-two weeks, twenty-three weeks, twenty-four, twenty-five,twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one,thirty-two, thirty-three, thirty-four, thirty-five, thirty-six,thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two,forty-three, forty-four, forty-five, forty-six, forty-seven,forty-eight, forty-nine, or fifty weeks. In several aspects, each doseof compound or composition described herein can be about 50-2000 mg,about 50-400 mg, about 50-200 mg, about 50-100 mg, about 100-200 mg, orany amount in between any of the aforementioned ranges.

In certain aspects, one or more additional doses of the compound orcomposition described herein is administered to the subject until thelevel of FGF15 or FGF19 protein in the blood or a tissue is notincreased from the baseline level by at least about 1 pg/mL, 5 pg/mL, 10pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 35 pg/mL, 40 pg/mL, 45pg/mL, 50 pg/mL, 55 pg/mL, 60 pg/mL, 65 pg/mL, 70 pg/mL, 75 pg/mL, 80pg/mL, 85 pg/mL, 90 pg/mL, 95 pg/mL, 100 pg/mL, 105 pg/mL, 110 pg/mL,115 pg/mL, 120 pg/mL, 125 pg/mL, 130 pg/mL, 135 pg/mL, 140 pg/mL, 145pg/mL, 150 pg/mL, 155 pg/mL, 160 pg/mL, 165 pg/mL, 170 pg/mL, 175 pg/mL,180 pg/mL, 185 pg/mL, 190 pg/mL, 195 pg/mL, 200 pg/mL, 205 pg/mL, 210pg/mL, 215 pg/mL, 220 pg/mL, 225 pg/mL, 230 pg/mL, 235 pg/mL, 240 pg/mL,245 pg/mL, 250 pg/mL, 255 pg/mL, 260 pg/mL, 265 pg/mL, 270 pg/mL, 275pg/mL, 280 pg/mL, 290 pg/mL, 295 pg/mL, 300 pg/mL, 350 pg/mL, 400 pg/mL,450 pg/mL, 500 pg/mL, 550 pg/mL, 600 pg/mL, 650 pg/mL, 700 pg/mL, 750pg/mL, 800 pg/mL, 850 pg/mL, 900 pg/mL, 950 pg/mL, 1,000 pg/mL, 2,000pg/mL, or any value in between any of the aforementioned concentrations.Administration of one or more additional doses of the compound orcomposition described herein can continue until such increases in thelevel of FGF15 or FGF19 protein in the blood or a tissue relative to thebaseline level does not occur for at least about one week, two weeks,three weeks, four weeks, five weeks, six weeks, seven weeks, eightweeks, nine weeks, ten weeks, eleven weeks, twelve weeks, thirteenweeks, fourteen weeks, fifteen weeks, sixteen weeks, seventeen weeks,eighteen weeks, nineteen weeks, twenty weeks, twenty-one weeks,twenty-two weeks, twenty-three weeks, twenty-four, twenty-five,twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one,thirty-two, thirty-three, thirty-four, thirty-five, thirty-six,thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two,forty-three, forty-four, forty-five, forty-six, forty-seven,forty-eight, forty-nine, or fifty weeks. In several aspects, each doseof compound or composition described herein can be about 50-2000 mg,about 50-400 mg, about 50-200 mg, about 50-100 mg, about 100-200 mg, orany amount in between any of the aforementioned ranges.

In certain embodiments, a method of treating a metabolic disease and/orobesity comprises (a) obtaining the baseline level of FGF15 or FGF19mRNA or protein in the blood or a tissue of a subject, (b) administeringto the subject a dose of a compound or composition described herein, (c)obtaining the level of FGF15 or FGF19 mRNA or protein in the blood or atissue after the administration of the compound or composition describedherein; and (d) repeating steps (b) and (c) until the level of FGF15 orFGF19 mRNA or protein in the blood or a tissue does not increase byabout 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%,16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%,30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%,44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%,58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%,72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,100%, 101%, 102%, 103% 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%,112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%,124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%,136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%,148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%,160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%,172%, 173%, 174%, 175%, 176%, 177%, 178%, 179%, 180%, 181%, 182%, 183%,184%, 185%, 186%, 187%, 188%, 189%, 190%, 191%, 192%, 193%, 194%, 195%,196%, 197%, 198%, 199%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%,1,000%, or any value in between any of the aforementioned percentagesrelative to baseline for at least about one week, two weeks, threeweeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nineweeks, ten weeks, eleven weeks, twelve weeks, thirteen weeks, fourteenweeks, fifteen weeks, sixteen weeks, seventeen weeks, eighteen weeks,nineteen weeks, twenty weeks, twenty-one weeks, twenty-two weeks,twenty-three weeks, twenty-four, twenty-five, twenty-six, twenty-seven,twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three,thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight,thirty-nine, forty, forty-one, forty-two, forty-three, forty-four,forty-five, forty-six, forty-seven, forty-eight, forty-nine, or fiftyweeks. In several aspects, each dose of compound or compositiondescribed herein can be about 50-2000 mg, about 50-400 mg, about 50-200mg, about 50-100 mg, about 100-200 mg, or any amount in between any ofthe aforementioned ranges.

Certain embodiments provide a method for treating a metabolic disease,including obesity, diabetes, hyperglycemia, prediabetes, non-alcoholicfatty liver disease (NAFLD), metabolic syndrome, insulin resistance,diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof,comprising administering a first dose of a compound or composition asdescribed herein to a subject having a baseline level of FGF15 or FGF19mRNA or protein in the blood or a tissue and administering one or moreadditional higher doses of the compound or composition to the subjectuntil the level of FGF15 or FGF19 in the blood or a tissue is increasedfrom the baseline level by a certain extent for a certain amount oftime. In several aspects, such method further comprises administeringadditional doses of the compound or composition to the subject tomaintain FGF15 or FGF19 mRNA or protein in the blood or a tissue at acertain level above the baseline level. It will be understood that theone or more additional higher doses can be relative to the first dose orthe most recently administered additional higher dose.

In some aspects, one or more additional higher doses of the compound orcomposition described herein is administered to the subject until thelevel of FGF15 or FGF19 mRNA or protein in the blood or a tissue isincreased from the baseline level for at least about one week, twoweeks, three weeks, four weeks, five weeks, six weeks, seven weeks,eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks, thirteenweeks, fourteen weeks, fifteen weeks, sixteen weeks, seventeen weeks,eighteen weeks, nineteen weeks, twenty weeks, twenty-one weeks,twenty-two weeks, twenty-three weeks, twenty-four, twenty-five,twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one,thirty-two, thirty-three, thirty-four, thirty-five, thirty-six,thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two,forty-three, forty-four, forty-five, forty-six, forty-seven,forty-eight, forty-nine, or fifty weeks.

In several aspects, one or more additional higher doses of the compoundor composition described herein is an amount at least about 1.1, 1.2,1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3., 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0,4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4,5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8,6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2,8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6,9.7, 9.8, 9.9, or 10.0 fold greater than the first dose or most recentlyadministered additional higher dose. In certain aspects, each dose ofcompound or composition described herein can be about 50-2000 mg, about50-400 mg, about 50-200 mg, about 50-100 mg, about 100-200 mg, or anyamount in between any of the aforementioned ranges.

In certain aspects, one or more additional higher doses of the compoundor composition described herein is administered to the subject until thelevel of FGF15 or FGF19 mRNA or protein in the blood or a tissue isincreased from the baseline level by at least about 1%, 2%, 3%, 4%, 5%,6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%,21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%,35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%,63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%,116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%,128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%,140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%,152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%,164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%,176%, 177%, 178%, 179%, 180%, 181%, 182%, 183%, 184%, 185%, 186%, 187%,188%, 189%, 190%, 191%, 192%, 193%, 194%, 195%, 196%, 197%, 198%, 199%,200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, or any value inbetween any of the aforementioned percentages.

Administration of one or more additional higher doses of the compound orcomposition described herein can continue until such increases in thelevel of FGF15 or FGF19 mRNA or protein in the blood or a tissuerelative to the baseline level occurs for at least about one week, twoweeks, three weeks, four weeks, five weeks, six weeks, seven weeks,eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks, thirteenweeks, fourteen weeks, fifteen weeks, sixteen weeks, seventeen weeks,eighteen weeks, nineteen weeks, twenty weeks, twenty-one weeks,twenty-two weeks, twenty-three weeks, twenty-four, twenty-five,twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one,thirty-two, thirty-three, thirty-four, thirty-five, thirty-six,thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two,forty-three, forty-four, forty-five, forty-six, forty-seven,forty-eight, forty-nine, or fifty weeks. In certain aspects, additionaldoses of the compound or composition can be administered to the subjectto maintain FGF15 or FGF19 mRNA or protein in the blood or a tissue at acertain level above the baseline level. In several aspects, each dose ofcompound or composition described herein can be about 50-2000 mg, about50-400 mg, about 50-200 mg, about 50-100 mg, about 100-200 mg, or anyamount in between any of the aforementioned ranges.

In certain aspects, one or more additional higher doses of the compoundor composition described herein is administered to the subject until thelevel of FGF15 or FGF19 protein in the blood or a tissue is increasedfrom the baseline level by at least about 1 pg/mL, 5 pg/mL, 10 pg/mL, 15pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 35 pg/mL, 40 pg/mL, 45 pg/mL, 50pg/mL, 55 pg/mL, 60 pg/mL, 65 pg/mL, 70 pg/mL, 75 pg/mL, 80 pg/mL, 85pg/mL, 90 pg/mL, 95 pg/mL, 100 pg/mL, 105 pg/mL, 110 pg/mL, 115 pg/mL,120 pg/mL, 125 pg/mL, 130 pg/mL, 135 pg/mL, 140 pg/mL, 145 pg/mL, 150pg/mL, 155 pg/mL, 160 pg/mL, 165 pg/mL, 170 pg/mL, 175 pg/mL, 180 pg/mL,185 pg/mL, 190 pg/mL, 195 pg/mL, 200 pg/mL, 205 pg/mL, 210 pg/mL, 215pg/mL, 220 pg/mL, 225 pg/mL, 230 pg/mL, 235 pg/mL, 240 pg/mL, 245 pg/mL,250 pg/mL, 255 pg/mL, 260 pg/mL, 265 pg/mL, 270 pg/mL, 275 pg/mL, 280pg/mL, 290 pg/mL, 295 pg/mL, 300 pg/mL, 350 pg/mL, 400 pg/mL, 450 pg/mL,500 pg/mL, 550 pg/mL, 600 pg/mL, 650 pg/mL, 700 pg/mL, 750 pg/mL, 800pg/mL, 850 pg/mL, 900 pg/mL, 950 pg/mL, 1,000 pg/mL, 2,000 pg/mL, or anyvalue in between any of the aforementioned concentrations.Administration of one or more additional higher doses of the compound orcomposition described herein can continue until such increases in thelevel of FGF15 or FGF19 protein in the blood or a tissue relative to thebaseline level occurs for at least about one week, two weeks, threeweeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nineweeks, ten weeks, eleven weeks, twelve weeks, thirteen weeks, fourteenweeks, fifteen weeks, sixteen weeks, seventeen weeks, eighteen weeks,nineteen weeks, twenty weeks, twenty-one weeks, twenty-two weeks,twenty-three weeks, twenty-four, twenty-five, twenty-six, twenty-seven,twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three,thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight,thirty-nine, forty, forty-one, forty-two, forty-three, forty-four,forty-five, forty-six, forty-seven, forty-eight, forty-nine, or fiftyweeks. In certain aspects, additional doses of the compound orcomposition can be administered to the subject to maintain FGF15 orFGF19 protein in the blood or a tissue at any of the aforementionedconcentrations above the baseline level. In several aspects, each doseof compound or composition described herein can be about 50-2000 mg,about 50-400 mg, about 50-200 mg, about 50-100 mg, about 100-200 mg, orany amount in between any of the aforementioned ranges.

It will be understood that one or more higher doses of the compound orcomposition described herein can be administered during theaforementioned time periods. For example, a subject may have beenadministered one or more doses of the compound or composition describedherein during the at least about one week, two weeks, three weeks, fourweeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, tenweeks, eleven weeks, twelve weeks, thirteen weeks, fourteen weeks,fifteen weeks, sixteen weeks, seventeen weeks, eighteen weeks, nineteenweeks, twenty weeks, twenty-one weeks, twenty-two weeks, twenty-threeweeks, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight,twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four,thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty,forty-one, forty-two, forty-three, forty-four, forty-five, forty-six,forty-seven, forty-eight, forty-nine, or fifty weeks. In certainembodiments, additional higher doses of the compound or compositiondescribed herein are administered to the subject until the level ofFGF15 or FGF19 mRNA or protein in the blood or a tissue is increasedfrom the baseline level by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%,8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%,23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%,37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%,65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%,79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103% 104%, 105%,106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%,118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%,130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%,142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%,154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%,166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%, 176%, 177%,178%, 179%, 180%, 181%, 182%, 183%, 184%, 185%, 186%, 187%, 188%, 189%,190%, 191%, 192%, 193%, 194%, 195%, 196%, 197%, 198%, 199%, 200%, 300%,400%, 500%, 600%, 700%, 800%, 900%, 1,000%, or any value in between anyof the aforementioned percentages in the aforementioned time periods. Incertain aspects, additional doses of the compound or composition can beadministered to the subject to maintain FGF15 or FGF19 mRNA or proteinin the blood or a tissue at any of the aforementioned increased levelsabove the baseline level. In several aspects, each dose of compound orcomposition described herein can be about 50-2000 mg, about 50-400 mg,about 50-200 mg, about 50-100 mg, about 100-200 mg, or any amount inbetween any of the aforementioned ranges.

In certain embodiments, a method of treating a metabolic disease,including obesity, diabetes, hyperglycemia, prediabetes, non-alcoholicfatty liver disease (NAFLD), metabolic syndrome, insulin resistance,diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof,comprises (a) obtaining the baseline level of FGF15 or FGF19 mRNA orprotein in the blood or a tissue of a subject, (b) administering to thesubject a dose of a compound or composition described herein, (c)obtaining the level of FGF15 or FGF19 mRNA or protein in the blood or atissue after the administration of the compound or composition describedherein; and (d) repeating steps (b) and (c) until the level of FGF15 orFGF19 mRNA or protein in the blood or a tissue is increased by at leastabout 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%,16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%,30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%,44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%,58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%,72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,100%, 101%, 102%, 103% 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%,112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%,124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%,136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%,148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%,160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%,172%, 173%, 174%, 175%, 176%, 177%, 178%, 179%, 180%, 181%, 182%, 183%,184%, 185%, 186%, 187%, 188%, 189%, 190%, 191%, 192%, 193%, 194%, 195%,196%, 197%, 198%, 199%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%,1,000%, or any value in between any of the aforementioned percentagesrelative to the baseline level. In certain aspects, the doseadministered in step (d) can be a higher dose than previouslyadministered until the level of FGF15 or FGF19 mRNA or protein in theblood or a tissue is increased by any of the aforementioned percentages.In certain aspects, such method further comprises administeringadditional doses of the compound or composition to the subject tomaintain FGF15 or FGF19 mRNA or protein in the blood or a tissue at anyof the aforementioned increased levels above the baseline level. Inseveral aspects, each dose of compound or composition described hereincan be about 50-2000 mg, about 50-400 mg, about 50-200 mg, about 50-100mg, about 100-200 mg, or any amount in between any of the aforementionedranges.

In certain embodiments, a method of treating a metabolic disease,including obesity, diabetes, hyperglycemia, prediabetes, non-alcoholicfatty liver disease (NAFLD), metabolic syndrome, insulin resistance,diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof,comprises (a) obtaining the baseline level of FGF15 or FGF19 protein inthe blood or a tissue of a subject, (b) administering to the subject adose of a compound or composition described herein, (c) obtaining thelevel of FGF15 or FGF19 protein in the blood or a tissue after theadministration of the compound or composition described herein; and (d)repeating steps (b) and (c) until the level of FGF15 or FGF19 protein inthe blood or a tissue is increased by at least about 1 pg/mL, 5 pg/mL,10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 35 pg/mL, 40 pg/mL, 45pg/mL, 50 pg/mL, 55 pg/mL, 60 pg/mL, 65 pg/mL, 70 pg/mL, 75 pg/mL, 80pg/mL, 85 pg/mL, 90 pg/mL, 95 pg/mL, 100 pg/mL, 105 pg/mL, 110 pg/mL,115 pg/mL, 120 pg/mL, 125 pg/mL, 130 pg/mL, 135 pg/mL, 140 pg/mL, 145pg/mL, 150 pg/mL, 155 pg/mL, 160 pg/mL, 165 pg/mL, 170 pg/mL, 175 pg/mL,180 pg/mL, 185 pg/mL, 190 pg/mL, 195 pg/mL, 200 pg/mL, 205 pg/mL, 210pg/mL, 215 pg/mL, 220 pg/mL, 225 pg/mL, 230 pg/mL, 235 pg/mL, 240 pg/mL,245 pg/mL, 250 pg/mL, 255 pg/mL, 260 pg/mL, 265 pg/mL, 270 pg/mL, 275pg/mL, 280 pg/mL, 290 pg/mL, 295 pg/mL, 300 pg/mL, 350 pg/mL, 400 pg/mL,450 pg/mL, 500 pg/mL, 550 pg/mL, 600 pg/mL, 650 pg/mL, 700 pg/mL, 750pg/mL, 800 pg/mL, 850 pg/mL, 900 pg/mL, 950 pg/mL, 1,000 pg/mL, 2,000pg/mL, or any value in between any of the aforementioned concentrations.In certain aspects, the dose administered in step (d) can be a higherdose than previously administered until the level of FGF15 or FGF19 mRNAor protein in the blood or a tissue is increased by any of theaforementioned percentages. In certain aspects, such method furthercomprises administering additional doses of the compound or compositionto the subject to maintain FGF15 or FGF19 protein in the blood or atissue at any of the aforementioned increased concentrations above thebaseline level. In several aspects, each dose of compound or compositiondescribed herein can be about 50-2000 mg, about 50-400 mg, about 50-200mg, about 50-100 mg, about 100-200 mg, or any amount in between any ofthe aforementioned ranges.

The level of FGF15 or FGF19 mRNA or protein in a blood or a tissue, suchas liver tissue, may be obtained by several known assays. For instance,FGF15 or FGF19 mRNA levels can be obtained by quantitative RT-PCR. FGF15or FGF19 protein levels can be obtained, for example, by using any of anumber of well recognized immunological binding assays such as, but notlimited to, an enzyme linked immunosorbent assay (ELISA), which is alsoknown as a “sandwich assay”, an enzyme immunoassay, a radioimmunoassay(RIA), a fluoroimmunoassay (FIA), a chemiluminescent immunoassay (CLIA)a counting immunoassay (CIA), a filter media enzyme immunoassay (MEIA),or a fluorescence-linked immunosorbent assay (FLISA). Several commercialantibodies against FGF15 or FGF19 mRNA or protein are suitable forobtaining the level of FGF15 or FGF19 mRNA or protein in a blood or atissue. Such commercially available antibodies can be obtained fromAbcam or Santa Cruz Biotechnology, for example. FGF15 or FGF19 proteinlevels can be also be obtained by high performance liquid chromatography(HPLC), mass spectrometry, or surface plasmon resonance.

Antisense Compounds

Oligomeric compounds include, but are not limited to, oligonucleotides,oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics,antisense compounds, antisense oligonucleotides, and siRNAs. Anoligomeric compound may be “antisense” to a target nucleic acid, meaningthat is capable of undergoing hybridization to a target nucleic acidthrough hydrogen bonding.

In certain embodiments, an antisense compound has a nucleobase sequencethat, when written in the 5′ to 3′ direction, comprises the reversecomplement of the target segment of a target nucleic acid to which it istargeted. In certain such embodiments, an antisense oligonucleotide hasa nucleobase sequence that, when written in the 5′ to 3′ direction,comprises the reverse complement of the target segment of a targetnucleic acid to which it is targeted.

In certain embodiments, an antisense compound targeted to a FGFR4nucleic acid is 12 to 30 nucleotides in length. In other words,antisense compounds are from 12 to 30 linked nucleobases. In otherembodiments, the antisense compound comprises a modified oligonucleotideconsisting of 8 to 80, 10 to 50, 15 to 30, 18 to 21, 20 to 80, 20 to 35,20 to 30, 20 to 29, 20 to 28, 20 to 27, 20 to 26, 20 to 25, 20 to 24, 20to 23, 20 to 22, 20 to 21 or 20 linked nucleobases. In certain suchembodiments, the antisense compound comprises a modified oligonucleotideconsisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,77, 78, 79, or 80 linked nucleobases in length, or a range defined byany two of the above values.

In certain embodiments, the antisense compound comprises a shortened ortruncated modified oligonucleotide. The shortened or truncated modifiedoligonucleotide can have a single nucleoside deleted from the 5′ end (5′truncation), or alternatively from the 3′ end (3′ truncation). Ashortened or truncated oligonucleotide may have two nucleosides deletedfrom the 5′ end, or alternatively may have two subunits deleted from the3′ end. Alternatively, the deleted nucleosides may be dispersedthroughout the modified oligonucleotide, for example, in an antisensecompound having one nucleoside deleted from the 5′ end and onenucleoside deleted from the 3′ end.

When a single additional nucleoside is present in a lengthenedoligonucleotide, the additional nucleoside may be located at the 5′ or3′ end of the oligonucleotide. When two or more additional nucleosidesare present, the added nucleosides may be adjacent to each other, forexample, in an oligonucleotide having two nucleosides added to the 5′end (5′ addition), or alternatively to the 3′ end (3′ addition), of theoligonucleotide. Alternatively, the added nucleoside may be dispersedthroughout the antisense compound, for example, in an oligonucleotidehaving one nucleoside added to the 5′ end and one subunit added to the3′ end.

It is possible to increase or decrease the length of an antisensecompound, such as an antisense oligonucleotide, and/or introducemismatch bases without eliminating activity. For example, in Woolf etal. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series ofantisense oligonucleotides 13-25 nucleobases in length were tested fortheir ability to induce cleavage of a target RNA in an oocyte injectionmodel. Antisense oligonucleotides 25 nucleobases in length with 8 or 11mismatch bases near the ends of the antisense oligonucleotides were ableto direct specific cleavage of the target mRNA, albeit to a lesserextent than the antisense oligonucleotides that contained no mismatches.Similarly, target specific cleavage was achieved using 13 nucleobaseantisense oligonucleotides, including those with 1 or 3 mismatches.

Gautschi et al (J. Natl. Cancer Inst. 93:463-471, March 2001)demonstrated the ability of an oligonucleotide having 100%complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xLmRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and invivo. Furthermore, this oligonucleotide demonstrated potent anti-tumoractivity in vivo.

Maher and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988) tested a seriesof tandem 14 nucleobase antisense oligonucleotides, and a 28 and 42nucleobase antisense oligonucleotides comprised of the sequence of twoor three of the tandem antisense oligonucleotides, respectively, fortheir ability to arrest translation of human DHFR in a rabbitreticulocyte assay. Each of the three 14 nucleobase antisenseoligonucleotides alone was able to inhibit translation, albeit at a moremodest level than the 28 or 42 nucleobase antisense oligonucleotides.

Antisense Compound Motifs

In certain embodiments, antisense compounds targeted to a FGFR4 nucleicacid have chemically modified subunits arranged in patterns, or motifs,to confer to the antisense compounds properties such as enhancedinhibitory activity, increased binding affinity for a target nucleicacid, or resistance to degradation by in vivo nucleases.

Chimeric antisense compounds typically contain at least one regionmodified so as to confer increased resistance to nuclease degradation,increased cellular uptake, increased binding affinity for the targetnucleic acid, and/or increased inhibitory activity. A second region of achimeric antisense compound may optionally serve as a substrate for thecellular endonuclease RNase H, which cleaves the RNA strand of anRNA:DNA duplex.

Antisense compounds having a gapmer motif are considered chimericantisense compounds. In a gapmer an internal region having a pluralityof nucleotides that supports RNaseH cleavage is positioned betweenexternal regions having a plurality of nucleotides that are chemicallydistinct from the nucleosides of the internal region. In the case of anantisense oligonucleotide having a gapmer motif, the gap segmentgenerally serves as the substrate for endonuclease cleavage, while thewing segments comprise modified nucleosides. In certain embodiments, theregions of a gapmer are differentiated by the types of sugar moietiescomprising each distinct region. The types of sugar moieties that areused to differentiate the regions of a gapmer may in some embodimentsinclude β-D-ribonucleosides, β-D-deoxyribonucleosides, 2′-modifiednucleosides (such 2′-modified nucleosides may include 2′-MOE and2′-O—CH₃, among others), and bicyclic sugar modified nucleosides (suchbicyclic sugar modified nucleosides may include those having aconstrained ethyl). In certain embodiments, wings may include severalmodified sugar moieties, including, for example 2′-MOE and constrainedethyl. In certain embodiments, wings may include several modified andunmodified sugar moieties. In certain embodiments, wings may includevarious combinations of 2′-MOE nucleosides, constrained ethylnucleosides, and 2′-deoxynucleosides.

Each distinct region may comprise uniform sugar moieties, variant, oralternating sugar moieties. The wing-gap-wing motif is frequentlydescribed as “X-Y-Z”, where “X” represents the length of the 5′-wing,“Y” represents the length of the gap, and “Z” represents the length ofthe 3′-wing. “X” and “Z” may comprise uniform, variant, or alternatingsugar moieties. In certain embodiments, “X” and “Y” may include one ormore 2′-deoxynucleosides.“Y” may comprise 2′-deoxynucleosides. As usedherein, a gapmer described as “X-Y-Z” has a configuration such that thegap is positioned immediately adjacent to each of the 5′-wing and the 3′wing. Thus, no intervening nucleotides exist between the 5′-wing andgap, or the gap and the 3′-wing. Any of the antisense compoundsdescribed herein can have a gapmer motif. In certain embodiments, “X”and “Z” are the same, in other embodiments they are different. Incertain embodiments, “Y” is between 8 and 15 nucleosides. X, Y, or Z canbe any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 25, 30 or more nucleosides.

In certain embodiments, antisense compounds targeted to a FGFR4 nucleicacid possess a 5-10-5 gapmer motif.

In certain embodiments, antisense compounds targeted to a FGFR4 nucleicacid possess a 3-10-4 gapmer motif.

Target Nucleic Acids, Target Regions and Nucleotide Sequences

In certain embodiments, the FGFR4 nucleic acid is any of the sequencesset forth in GENBANK Accession No. NM_(—)002011.3 (incorporated hereinas SEQ ID NO: 1), GENBANK Accession No: NT_(—)023133.11 truncated fromnucleosides 21323018 to 21335213 (incorporated herein as SEQ ID NO: 2);GENBANK Accession No. AB209631.1 (incorporated herein as SEQ ID NO: 3)and GENBANK Accession No NM_(—)022963.2 (incorporated herein as SEQ IDNO: 4). In certain embodiments, FGFR4 has the rhesus monkey sequence asset forth in GENBANK Accession No. NW_(—)001121000.1 truncated fromnucleosides 3094000 to 3109000 (SEQ ID NO: 5 In certain embodiments,FGFR4 has the murine sequence as set forth in GENBANK Accession No.BC033313.1 (SEQ ID NO: 6).

It is understood that the sequence set forth in each SEQ ID NO in theExamples contained herein is independent of any modification to a sugarmoiety, an internucleoside linkage, or a nucleobase. As such, antisensecompounds defined by a SEQ ID NO may comprise, independently, one ormore modifications to a sugar moiety, an internucleoside linkage, or anucleobase. Antisense compounds described by Isis Number (Isis No)indicate a combination of nucleobase sequence and motif.

In certain embodiments, a target region is a structurally defined regionof the target nucleic acid. For example, a target region may encompass a3′ UTR, a 5′ UTR, an exon, an intron, an exon/intron junction, a codingregion, a translation initiation region, translation termination region,or other defined nucleic acid region. The structurally defined regionsfor FGFR4 can be obtained by accession number from sequence databasessuch as NCBI and such information is incorporated herein by reference.In certain embodiments, a target region may encompass the sequence froma 5′ target site of one target segment within the target region to a 3′target site of another target segment within the same target region.

Targeting includes determination of at least one target segment to whichan antisense compound hybridizes, such that a desired effect occurs. Incertain embodiments, the desired effect is a reduction in mRNA targetnucleic acid levels. In certain embodiments, the desired effect isreduction of levels of protein encoded by the target nucleic acid or aphenotypic change associated with the target nucleic acid.

A target region may contain one or more target segments. Multiple targetsegments within a target region may be overlapping. Alternatively, theymay be non-overlapping. In certain embodiments, target segments within atarget region are separated by no more than about 300 nucleotides. Incertain embodiments, target segments within a target region areseparated by a number of nucleotides that is, is about, is no more than,is no more than about, 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30,20, or 10 nucleotides on the target nucleic acid, or is a range definedby any two of the preceeding values. In certain embodiments, targetsegments within a target region are separated by no more than, or nomore than about, 5 nucleotides on the target nucleic acid. In certainembodiments, target segments are contiguous. Contemplated are targetregions defined by a range having a starting nucleic acid that is any ofthe 5′ target sites or 3′ target sites listed herein.

Suitable target segments may be found within a 5′ UTR, a coding region,a 3′ UTR, an intron, an exon, or an exon/intron junction. Targetsegments containing a start codon or a stop codon are also suitabletarget segments. A suitable target segment may specifically exclude acertain structurally defined region such as the start codon or stopcodon.

The determination of suitable target segments may include a comparisonof the sequence of a target nucleic acid to other sequences throughoutthe genome. For example, the BLAST algorithm may be used to identifyregions of similarity amongst different nucleic acids. This comparisoncan prevent the selection of antisense compound sequences that mayhybridize in a non-specific manner to sequences other than a selectedtarget nucleic acid (i.e., non-target or off-target sequences).

There may be variation in activity (e.g., as defined by percentreduction of target nucleic acid levels) of the antisense compoundswithin an active target region. In certain embodiments, reductions inFGFR4 mRNA levels are indicative of inhibition of FGFR4 expression.Reductions in levels of a FGFR4 protein are also indicative ofinhibition of target mRNA expression. Further, phenotypic changes areindicative of inhibition of FGFR4 expression. In certain embodiments,reduced glucose levels, reduced lipid levels, and reduced body weightcan be indicative of inhibition of FGFR4 expression. In certainembodiments, amelioration of symptoms associated with metabolic diseasecan be indicative of inhibition of FGFR4 expression. In certainembodiments, amelioration of symptoms associated with diabetes can beindicative of inhibition of FGFR4 expression. In certain embodiments,reduction of insulin resistance is indicative of inhibition of FGFR4expression. In certain embodiments, reduction of diabetes biomarkers canbe indicative of inhibition of FGFR4 expression. In certain embodiments,reduction of FGFR4 expression is accompanied by an increase in FGF15and/or FGF19 gene expression and/or an increase in FGF15 and/or FGF19protein levels. In certain embodiments, reduction of FGFR4 expression isaccompanied by an increase in ileum FGF15 and/or ileum FGF19 geneexpression and plasma FGF15 and/or plasma FGF19 protein levels.Therefore, certain embodiments provide methods of measuring reduction ofFGFR expression by measuring an increase in ileum FGF15 and/or ileumFGF19 gene expression and plasma FGF15 and/or plasma FGF19 proteinlevels. In certain embodiments, a biomarker of the anti-obesity effectof an FGFR4 inhibitor is an increase in FGF15 and/or FGF19 geneexpression levels. In certain embodiments, a biomarker of theanti-obesity effect of an FGFR4 inhibitor is an increase in FGF15 and/orFGF19 protein levels. In certain embodiments, a biomarker of FGFR4antisense oligonucleotide-caused anti-obesity effect is an increase inFGF15 and/or FGF19 gene expression levels. In certain embodiments, abiomarker of FGFR4 antisense oligonucleotide-caused anti-obesity effectis an increase in FGF15 and/or FGF19 protein levels. In certainembodiments, a biomarker of FGFR4 antisense oligonucleotide-causedanti-obesity effect is an increase in FGF15 and/or FGF19 gene expressionlevels.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal by measuring an increase in ileumFGF15 and/or ileum FGF19 gene expression and plasma FGF15 and/or plasmaFGF19 protein levels.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF15 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF15 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF15 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF19 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF19 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF19 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF15protein levels in an individual prior to administration of a FGFR4inhibitor (b) administering an FGFR4 inhibitor (c) measuring FGF15protein levels after administration of a FGFR4 inhibitor (d) detectingan increase of FGF15 protein levels. In certain embodiments, the FGFR4inhibitor is a modified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods of detecting the anti-obesity effectof a FGFR4 inhibitor in an animal comprising: (a) measuring FGF19protein levels in an individual prior to administration of a FGFR4inhibitor (b) administering an FGFR4 inhibitor (c) measuring FGF19protein levels after administration of a FGFR4 inhibitor (d) detectingan increase of FGF19 protein levels. In certain embodiments, the FGFR4inhibitor is a modified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF15 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF15 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF15 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF19 geneexpression in an individual prior to administration of a FGFR4 inhibitor(b) administering an FGFR4 inhibitor (c) measuring FGF19 gene expressionafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF19 gene expression. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor by measuring an increase in ileum FGF15and/or ileum FGF19 gene expression and plasma FGF15 and/or plasma FGF19protein levels.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF15 proteinlevels in an individual prior to administration of a FGFR4 inhibitor (b)administering an FGFR4 inhibitor (c) measuring FGF15 protein levelsafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF15 protein levels. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Certain embodiments provide methods for predicting responsiveness of ananimal to an FGFR4 inhibitor comprising: (a) measuring FGF19 proteinlevels in an individual prior to administration of a FGFR4 inhibitor (b)administering an FGFR4 inhibitor (c) measuring FGF19 protein levelsafter administration of a FGFR4 inhibitor (d) detecting an increase ofFGF19 protein levels. In certain embodiments, the FGFR4 inhibitor is amodified antisense oligonucleotide targeted to FGFR4.

Hybridization

In some embodiments, hybridization occurs between an antisense compounddisclosed herein and a FGFR4 nucleic acid. The most common mechanism ofhybridization involves hydrogen bonding (e.g., Watson-Crick, Hoogsteenor reversed Hoogsteen hydrogen bonding) between complementarynucleobases of the nucleic acid molecules.

Hybridization can occur under varying conditions. Stringent conditionsare sequence-dependent and are determined by the nature and compositionof the nucleic acid molecules to be hybridized.

Methods of determining whether a sequence is specifically hybridizableto a target nucleic acid are well known in the art. In certainembodiments, the antisense compounds provided herein are specificallyhybridizable with a FGFR4 nucleic acid.

Complementarity

An antisense compound and a target nucleic acid are complementary toeach other when a sufficient number of nucleobases of the antisensecompound can hydrogen bond with the corresponding nucleobases of thetarget nucleic acid, such that a desired effect will occur (e.g.,antisense inhibition of a target nucleic acid, such as a FGFR4 nucleicacid).

An antisense compound may hybridize over one or more segments of a FGFR4nucleic acid such that intervening or adjacent segments are not involvedin the hybridization event (e.g., a loop structure, mismatch or hairpinstructure).

In certain embodiments, the antisense compounds provided herein, or aspecified portion thereof, are, or are at least, 70%, 80%, 85%, 86%,87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%complementary to a FGFR4 nucleic acid, a target region, target segment,or specified portion thereof. Percent complementarity of an antisensecompound with a target nucleic acid can be determined using routinemethods.

For example, an antisense compound in which 18 of 20 nucleobases of theantisense compound are complementary to a target region, and wouldtherefore specifically hybridize, would represent 90 percentcomplementarity. In this example, the remaining non-complementarynucleobases may be clustered or interspersed with complementarynucleobases and need not be contiguous to each other or to complementarynucleobases. As such, an antisense compound which is 18 nucleobases inlength having 4 (four) non-complementary nucleobases which are flankedby two regions of complete complementarity with the target nucleic acidwould have 77.8% overall complementarity with the target nucleic acidand would thus fall within the scope of the present invention. Percentcomplementarity of an antisense compound with a region of a targetnucleic acid can be determined routinely using BLAST programs (basiclocal alignment search tools) and PowerBLAST programs known in the art(Altschul et al., J. Mol. Biol., 1990, 215, 403 410; Zhang and Madden,Genome Res., 1997, 7, 649 656). Percent homology, sequence identity orcomplementarity, can be determined by, for example, the Gap program(Wisconsin Sequence Analysis Package, Version 8 for Unix, GeneticsComputer Group, University Research Park, Madison Wis.), using defaultsettings, which uses the algorithm of Smith and Waterman (Adv. Appl.Math., 1981, 2, 482 489).

In certain embodiments, the antisense compounds provided herein, orspecified portions thereof, are fully complementary (i.e. 100%complementary) to a target nucleic acid, or specified portion thereof.For example, antisense compound may be fully complementary to a FGFR4nucleic acid, or a target region, or a target segment or target sequencethereof. As used herein, “fully complementary” means each nucleobase ofan antisense compound is capable of precise base pairing with thecorresponding nucleobases of a target nucleic acid. For example, a 20nucleobase antisense compound is fully complementary to a targetsequence that is 400 nucleobases long, so long as there is acorresponding 20 nucleobase portion of the target nucleic acid that isfully complementary to the antisense compound. Fully complementary canalso be used in reference to a specified portion of the first and/or thesecond nucleic acid. For example, a 20 nucleobase portion of a 30nucleobase antisense compound can be “fully complementary” to a targetsequence that is 400 nucleobases long. The 20 nucleobase portion of the30 nucleobase oligonucleotide is fully complementary to the targetsequence if the target sequence has a corresponding 20 nucleobaseportion wherein each nucleobase is complementary to the 20 nucleobaseportion of the antisense compound. At the same time, the entire 30nucleobase antisense compound may or may not be fully complementary tothe target sequence, depending on whether the remaining 10 nucleobasesof the antisense compound are also complementary to the target sequence.

The location of a non-complementary nucleobase may be at the 5′ end or3′ end of the antisense compound. Alternatively, the non-complementarynucleobase or nucleobases may be at an internal position of theantisense compound. When two or more non-complementary nucleobases arepresent, they may be contiguous (i.e. linked) or non-contiguous. In oneembodiment, a non-complementary nucleobase is located in the wingsegment of a gapmer antisense oligonucleotide.

In certain embodiments, antisense compounds that are, or are up to 12,13, 14, 15, 16, 17, 18, 19, or 20 nucleobases in length comprise no morethan 4, no more than 3, no more than 2, or no more than 1non-complementary nucleobase(s) relative to a target nucleic acid, suchas a FGFR4 nucleic acid, or specified portion thereof.

In certain embodiments, antisense compounds that are, or are up to 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or30 nucleobases in length comprise no more than 6, no more than 5, nomore than 4, no more than 3, no more than 2, or no more than 1non-complementary nucleobase(s) relative to a target nucleic acid, suchas a FGFR4 nucleic acid, or specified portion thereof.

The antisense compounds provided herein also include those which arecomplementary to a portion of a target nucleic acid. As used herein,“portion” refers to a defined number of contiguous (i.e. linked)nucleobases within a region or segment of a target nucleic acid. A“portion” can also refer to a defined number of contiguous nucleobasesof an antisense compound. In certain embodiments, the antisensecompounds, are complementary to at least an 8 nucleobase portion of atarget segment. In certain embodiments, the antisense compounds arecomplementary to at least a 12 nucleobase portion of a target segment.In certain embodiments, the antisense compounds are complementary to atleast a 13 nucleobase portion of a target segment. In certainembodiments, the antisense compounds are complementary to at least a 14nucleobase portion of a target segment. In certain embodiments, theantisense compounds are complementary to at least a 15 nucleobaseportion of a target segment. In certain embodiments, the antisensecompounds are complementary to at least a 16 nucleobase portion of atarget segment. In certain embodiments, the antisense compounds arecomplementary to at least a 17 nucleobase portion of a target segment.In certain embodiments, the antisense compounds are complementary to atleast a 18 nucleobase portion of a target segment. In certainembodiments, the antisense compounds are complementary to at least a 19nucleobase portion of a target segment. In certain embodiments, theantisense compounds are complementary to at least a 20 nucleobaseportion of a target segment. Also contemplated are antisense compoundsthat are complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, or more nucleobase portion of a target segment, or a rangedefined by any two of these values.

Identity

The antisense compounds provided herein may also have a defined percentidentity to a particular nucleotide sequence, SEQ ID NO, or compoundrepresented by a specific Isis number, or portion thereof. As usedherein, an antisense compound is identical to the sequence disclosedherein if it has the same nucleobase pairing ability. For example, a RNAwhich contains uracil in place of thymidine in a disclosed DNA sequencewould be considered identical to the DNA sequence since both uracil andthymidine pair with adenine. Shortened and lengthened versions of theantisense compounds described herein as well as compounds havingnon-identical bases relative to the antisense compounds provided hereinalso are contemplated. The non-identical bases may be adjacent to eachother or dispersed throughout the antisense compound. Percent identityof an antisense compound is calculated according to the number of basesthat have identical base pairing relative to the sequence to which it isbeing compared.

In certain embodiments, the antisense compounds, or portions thereof,are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99% or 100% identical to one or more of the antisense compounds orSEQ ID NOs, or a portion thereof, disclosed herein.

Modifications

A nucleoside is a base-sugar combination. The nucleobase (also known asbase) portion of the nucleoside is normally a heterocyclic base moiety.Nucleotides are nucleosides that further include a phosphate groupcovalently linked to the sugar portion of the nucleoside. For thosenucleosides that include a pentofuranosyl sugar, the phosphate group canbe linked to the 2′, 3′ or 5′ hydroxyl moiety of the sugar.Oligonucleotides are formed through the covalent linkage of adjacentnucleosides to one another, to form a linear polymeric oligonucleotide.Within the oligonucleotide structure, the phosphate groups are commonlyreferred to as forming the internucleoside linkages of theoligonucleotide.

Modifications to antisense compounds encompass substitutions or changesto internucleoside linkages, sugar moieties, or nucleobases. Modifiedantisense compounds are often preferred over native forms because ofdesirable properties such as, for example, enhanced cellular uptake,enhanced affinity for nucleic acid target, increased stability in thepresence of nucleases, or increased inhibitory activity.

Chemically modified nucleosides may also be employed to increase thebinding affinity of a shortened or truncated antisense oligonucleotidefor its target nucleic acid. Consequently, comparable results can oftenbe obtained with shorter antisense compounds that have such chemicallymodified nucleosides.

Modified Internucleoside Linkages

The naturally occurring internucleoside linkage of RNA and DNA is a 3′to 5′ phosphodiester linkage. Antisense compounds having one or moremodified, i.e. non-naturally occurring, internucleoside linkages areoften selected over antisense compounds having naturally occurringinternucleoside linkages because of desirable properties such as, forexample, enhanced cellular uptake, enhanced affinity for target nucleicacids, and increased stability in the presence of nucleases.

Oligonucleotides having modified internucleoside linkages includeinternucleoside linkages that retain a phosphorus atom as well asinternucleoside linkages that do not have a phosphorus atom.Representative phosphorus containing internucleoside linkages include,but are not limited to, phosphodiesters, phosphotriesters,methylphosphonates, phosphoramidate, and phosphorothioates. Methods ofpreparation of phosphorous-containing and non-phosphorous-containinglinkages are well known.

In certain embodiments, antisense compounds targeted to a FGFR4 nucleicacid comprise one or more modified internucleoside linkages. In certainembodiments, the modified internucleoside linkages are phosphorothioatelinkages. In certain embodiments, each internucleoside linkage of anantisense compound is a phosphorothioate internucleoside linkage.

Modified Sugar Moieties

Antisense compounds provided herein can optionally contain one or morenucleosides wherein the sugar group has been modified. Such sugarmodified nucleosides may impart enhanced nuclease stability, increasedbinding affinity, or some other beneficial biological property to theantisense compounds. In certain embodiments, nucleosides comprise achemically modified ribofuranose ring moiety. Examples of chemicallymodified ribofuranose rings include, without limitation, addition ofsubstitutent groups (including 5′ and 2′ substituent groups); bridgingof non-geminal ring atoms to form bicyclic nucleic acids (BNA);replacement of the ribosyl ring oxygen atom with S, N(R), or C(R1)(R)2(R=H, C₁-C₁₂ alkyl or a protecting group); and combinations thereof.Examples of chemically modified sugars include, 2′-F-5′-methylsubstituted nucleoside (see, PCT International Application WO2008/101157, published on Aug. 21, 2008 for other disclosed 5′,2′-bissubstituted nucleosides), replacement of the ribosyl ring oxygen atomwith S with further substitution at the 2′-position (see, published U.S.Patent Application US2005/0130923, published on Jun. 16, 2005), or,alternatively, 5′-substitution of a BNA (see, PCT InternationalApplication WO 2007/134181, published on Nov. 22, 2007, wherein LNA issubstituted with, for example, a 5′-methyl or a 5′-vinyl group).

Examples of nucleosides having modified sugar moieties include, withoutlimitation, nucleosides comprising 5′-vinyl, 5′-methyl (R or S), 4′-S,2′-F, 2′-OCH₃, and 2′-O(CH₂)2OCH₃ substituent groups. The substituent atthe 2′ position can also be selected from allyl, amino, azido, thio,O-allyl, O—C₁-C₁₀ alkyl, OCF₃, O(CH₂)2SCH₃, O(CH₂)2-O—N(Rm)(Rn), andO—CH₂—C(═O)—N(Rm)(Rn), where each Rm and Rn is, independently, H orsubstituted or unsubstituted C₁-C₁₀ alkyl.

As used herein, “bicyclic nucleosides” refer to modified nucleosidescomprising a bicyclic sugar moiety. Examples of bicyclic nucleosidesinclude, without limitation, nucleosides comprising a bridge between the4′ and the 2′ ribosyl ring atoms. In certain embodiments, antisensecompounds provided herein include one or more bicyclic nucleosideswherein the bridge comprises a 4′ to 2′ bicyclic nucleoside. Examples ofsuch 4′ to 2′ bicyclic nucleosides, include, but are not limited to, oneof the formulae: 4′-(CH₂)—O-2′ (LNA); 4′-(CH₂)—S-2; 4′-(CH₂)₂—O-2′(ENA); 4′-CH(CH₃)—O-2′ and 4′-CH(CH₂OCH₃)—O-2′, and analogs thereof(see, U.S. Pat. No. 7,399,845, issued on Jul. 15, 2008);4′-C(CH₃)(CH₃)—O-2′, and analogs thereof (see, published PCTInternational Application WO2009/006478, published Jan. 8, 2009);4′-CH₂—N(OCH₃)-2′, and analogs thereof (see, published PCT InternationalApplication WO2008/150729, published Dec. 11, 2008); 4′-CH₂—O—N(CH₃)-2′(see, published U.S. Patent Application US2004/0171570, published Sep.2, 2004); 4′-CH₂—N(R)—O-2′, wherein R is H, C₁-C₁₂ alkyl, or aprotecting group (see, U.S. Pat. No. 7,427,672, issued on Sep. 23,2008); 4′-CH₂—C(H)(CH₃)-2′ (see, Chattopadhyaya, et al., J. Org. Chem.,2009, 74, 118-134); and 4′-CH₂—C(═CH₂)-2′, and analogs thereof (see,published PCT International Application WO 2008/154401, published onDec. 8, 2008). Also see, for example: Singh et al., Chem. Commun., 1998,4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedtet al., Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638; Kumar etal., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org.Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc.,129(26) 8362-8379 (Jul. 4, 2007); Elayadi et al., Curr. Opinion Invens.Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orumet al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos.6,670,461, 7,053,207, 6,268,490, 6,770,748, 6,794,499, 7,034,133,6,525,191, 7,399,845; published PCT International applications WO2004/106356, WO 94/14226, WO 2005/021570, and WO 2007/134181; U.S.Patent Publication Nos. US2004/0171570, US2007/0287831, andUS2008/0039618; and U.S. patent Ser. Nos. 12/129,154, 60/989,574,61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and61/099,844; and PCT International Application Nos. PCT/US2008/064591,PCT/US2008/066154, and PCT/US2008/068922. Each of the foregoing bicyclicnucleosides can be prepared having one or more stereochemical sugarconfigurations including for example α-L-ribofuranose andβ-D-ribofuranose (see PCT international application PCT/DK98/00393,published on Mar. 25, 1999 as WO 99/14226).

In certain embodiments, bicyclic sugar moieties of BNA nucleosidesinclude, but are not limited to, compounds having at least one bridgebetween the 4′ and the 2′ position of the pentofuranosyl sugar moietywherein such bridges independently comprises 1 or from 2 to 4 linkedgroups independently selected from —[C(R_(a))(R_(b))]_(n)—,—C(R_(a))═C(R_(b))—, —C(R_(a))═N—, —C(═NR_(a))—, —C(═O)—, —C(═S)—, —O—,—Si(R_(a))₂—, —S(═O)_(x)—, and —N(R_(a))—;

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_(a) and R_(b) is, independently, H, a protecting group, hydroxyl,C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substitutedC₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl,substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycleradical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical,substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃,COOJ₁, acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O)₂-J₁), orsulfoxyl (S(═O)-J₁); and

each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl,substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl(C(═O)—H), substituted acyl, a heterocycle radical, a substitutedheterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl,or a protecting group.

In certain embodiments, the bridge of a bicyclic sugar moiety is,—[C(R_(a))(R_(b))]_(n)—, —[C(R_(a))(R_(b))]_(n)—O—,—C(R_(a)R_(b))—N(R)—O— or, —C(R_(a)R_(b))—O—N(R)—. In certainembodiments, the bridge is 4′-CH₂-2′, 4′-(CH₂)₂-2′, 4′-(CH₂)₃-2′,4′-CH₂—O-2′, 4′-(CH₂)₂—O-2′, 4′-CH₂—O—N(R)-2′, and 4′-CH₂—N(R)—O-2′-,wherein each R is, independently, H, a protecting group, or C₁-C₁₂alkyl.

In certain embodiments, bicyclic nucleosides are further defined byisomeric configuration. For example, a nucleoside comprising a 4′-2′methylene-oxy bridge, may be in the α-L configuration or in the β-Dconfiguration. Previously, α-L-methyleneoxy (4′-CH₂—O-2′) BNA's havebeen incorporated into antisense oligonucleotides that showed antisenseactivity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372).

In certain embodiments, bicyclic nucleosides include, but are notlimited to, (A) α-L-Methyleneoxy (4′-CH₂—O-2′) BNA, (B) β-D-Methyleneoxy(4′-CH₂—O-2′) BNA, (C) Ethyleneoxy (4′-(CH₂)₂—O-2′) BNA, (D) Aminooxy(4′-CH₂—O—N(R)-2′) BNA, (E) Oxyamino (4′-CH₂—N(R)—O-2′) BNA, (F)Methyl(methyleneoxy) (4′-CH(CH₃)—O-2′) BNA, (G) methylene-thio(4′-CH₂—S-2′) BNA, (H) methylene-amino (4′-CH2-N(R)-2′) BNA, (I) methylcarbocyclic (4′-CH₂—CH(CH₃)-2′) BNA, and (J) propylene carbocyclic(4′-(CH₂)₃-2′) BNA as depicted below.

wherein Bx is the base moiety and R is, independently, H, a protectinggroup or C₁-C₁₂ alkyl.

In certain embodiments, bicyclic nucleoside having Formula I:

wherein:

Bx is a heterocyclic base moiety;

-Q_(a)-Q_(b)-Q_(c)- is —CH₂—N(R_(c))—CH₂—, —C(═O)—N(R_(c))—CH₂—,—CH₂—O—N(R_(c))—, —CH₂—N(R_(c))—O—, or —N(R_(c))—O—CH₂;

R_(c) is C₁-C₁₂ alkyl or an amino protecting group; and

T_(a) and T_(b) are each, independently, H, a hydroxyl protecting group,a conjugate group, a reactive phosphorus group, a phosphorus moiety, ora covalent attachment to a support medium.

In certain embodiments, bicyclic nucleoside having Formula II:

wherein:

Bx is a heterocyclic base moiety;

T_(a) and T_(b) are each, independently, H, a hydroxyl protecting group,a conjugate group, a reactive phosphorus group, a phosphorus moiety, ora covalent attachment to a support medium;

Z_(a) is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₁-C₆alkyl, substituted C₂-C₆ alkenyl, substituted C₂-C₆ alkynyl, acyl,substituted acyl, substituted amide, thiol, or substituted thio.

In one embodiment, each of the substituted groups is, independently,mono or poly substituted with substituent groups independently selectedfrom halogen, oxo, hydroxyl, OJ_(c), NJ_(c)J_(d), SJ_(c), N₃,OC(═X)J_(c), and NJ_(e)C(═X)NJ_(c)J_(d), wherein each J_(c), J_(d), andJ_(e) is, independently, H, C₁-C₆ alkyl, or substituted C₁-C₆ alkyl andX is O or NJ_(e).

In certain embodiments, bicyclic nucleoside having Formula III:

wherein:

Bx is a heterocyclic base moiety;

T_(a) and T_(b) are each, independently, H, a hydroxyl protecting group,a conjugate group, a reactive phosphorus group, a phosphorus moiety, ora covalent attachment to a support medium;

Z_(b) is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₁-C₆alkyl, substituted C₂-C₆ alkenyl, substituted C₂-C₆ alkynyl, orsubstituted acyl (C(═O)—).

In certain embodiments, bicyclic nucleoside having Formula IV:

wherein:

Bx is a heterocyclic base moiety;

T_(a) and T_(b) are each, independently H, a hydroxyl protecting group,a conjugate group, a reactive phosphorus group, a phosphorus moiety, ora covalent attachment to a support medium;

R_(d) is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl,substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl;

each q_(a), q_(b), q_(c) and q_(d) is, independently, H, halogen, C₁-C₆alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl, C₁-C₆ alkoxyl,substituted C₁-C₆ alkoxyl, acyl, substituted acyl, C₁-C₆ aminoalkyl, orsubstituted C₁-C₆ aminoalkyl;

In certain embodiments, bicyclic nucleoside having Formula V:

wherein:

Bx is a heterocyclic base moiety;

T_(a) and T_(b) are each, independently, H, a hydroxyl protecting group,a conjugate group, a reactive phosphorus group, a phosphorus moiety, ora covalent attachment to a support medium;

q_(a), q_(b), q_(e) and q_(f) are each, independently, hydrogen,halogen, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl,substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl,C₁-C₁₂ alkoxy, substituted C₁-C₁₂ alkoxy, OJ_(j), SJ_(j), SOJ_(j),SO₂J_(j), NJ_(j)J_(k), N₃, CN, C(═O)OJ_(j), C(═O)NJ_(j)J_(k),C(═O)J_(j), O—C(═O)NJ_(j)J_(k), N(H)C(═NH)NJ_(j)J_(k),N(H)C(═O)NJ_(j)J_(k) or N(H)C(═S)NJ_(j)J_(k);

or q_(e) and q_(f) together are ═C(q_(g))(q_(h));

q_(g) and q_(h) are each, independently, H, halogen, C₁-C₁₂ alkyl, orsubstituted C₁-C₁₂ alkyl.

The synthesis and preparation of the methyleneoxy (4′-CH₂—O-2′) BNAmonomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine, anduracil, along with their oligomerization, and nucleic acid recognitionproperties have been described (see, e.g., Koshkin et al., Tetrahedron,1998, 54, 3607-3630). BNAs and preparation thereof are also described inWO 98/39352 and WO 99/14226.

Analogs of methyleneoxy (4′-CH₂—O-2′) BNA, methyleneoxy (4′-CH₂—O-2′)BNA, and 2′-thio-BNAs, have also been prepared (see, e.g., Kumar et al.,Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222). Preparation of lockednucleoside analogs comprising oligodeoxyribonucleotide duplexes assubstrates for nucleic acid polymerases has also been described (see,e.g., Wengel et al., WO 99/14226). Furthermore, synthesis of2′-amino-BNA, a novel comformationally restricted high-affinityoligonucleotide analog, has been described in the art (see, e.g., Singhet al., J. Org. Chem., 1998, 63, 10035-10039). In addition, 2′-amino-and 2′-methylamino-BNA's have been prepared and the thermal stability oftheir duplexes with complementary RNA and DNA strands has beenpreviously reported.

In certain embodiments, bicyclic nucleoside having Formula VI:

wherein:

Bx is a heterocyclic base moiety;

T_(a) and T_(b) are each, independently, H, a hydroxyl protecting group,a conjugate group, a reactive phosphorus group, a phosphorus moiety, ora covalent attachment to a support medium;

each q_(i), q_(j), q_(k) and q_(l) is, independently, H, halogen, C₁-C₁₂alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₁-C₁₂ alkoxyl,substituted C₁-C₁₂ alkoxyl, OJ_(j), SJ_(j), SOJ_(j), SO₂J_(j),NJ_(j)J_(k), N₃, CN, C(═O)OJ_(j), C(═O)NJ_(j)J_(k), C(═O)J_(j),O—C(═O)NJ_(j)J_(k), N(H)C(═NH)NJ_(j)J_(k), N(H)C(═O)NJ_(j)J_(k), orN(H)C(═S)NJ_(j)J_(k); and

q_(i) and q_(j) or q_(l) and q_(k) together are ═C(q_(g))(q_(h)),wherein q_(g) and q_(h) are each, independently, H, halogen, C₁-C₁₂alkyl, or substituted C₁-C₁₂ alkyl.

One carbocyclic bicyclic nucleoside having a 4′-(CH₂)₃-2′ bridge and thealkenyl analog, bridge 4′-CH═CH—CH₂-2′, have been described (see, e.g.,Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443 andAlbaek et al., J. Org. Chem., 2006, 71, 7731-7740). The synthesis andpreparation of carbocyclic bicyclic nucleosides along with theiroligomerization and biochemical studies have also been described (see,e.g., Srivastava et al., J. Am. Chem. Soc. 2007, 129(26), 8362-8379).

As used herein, “4′-2′ bicyclic nucleoside” or “4′ to 2′ bicyclicnucleoside” refers to a bicyclic nucleoside comprising a furanose ringcomprising a bridge connecting the 2′ carbon atom and the 4′ carbonatom.

As used herein, “monocylic nucleosides” refer to nucleosides comprisingmodified sugar moieties that are not bicyclic sugar moieties. In certainembodiments, the sugar moiety, or sugar moiety analogue, of a nucleosidemay be modified or substituted at any position.

As used herein, “2′-modified sugar” means a furanosyl sugar modified atthe 2′ position. In certain embodiments, such modifications includesubstituents selected from: a halide, including, but not limited tosubstituted and unsubstituted alkoxy, substituted and unsubstitutedthioalkyl, substituted and unsubstituted amino alkyl, substituted andunsubstituted alkyl, substituted and unsubstituted allyl, andsubstituted and unsubstituted alkynyl. In certain embodiments, 2′modifications are selected from substituents including, but not limitedto: O[(CH₂)_(m)O]_(m)CH₃, O(CH₂)_(n)NH₂, O(CH₂)_(n)CH₃, O(CH₂)_(n)ONH₂,OCH₂C(═O)N(H)CH₃, and O(CH₂)_(n)ON[(CH₂)_(n)CH₃]₂, where n and m arefrom 1 to about 10. Other 2′-substituent groups can also be selectedfrom: C₁-C₁₂ alkyl; substituted alkyl; alkenyl; alkynyl; alkaryl;aralkyl; O-alkaryl or O-aralkyl; SH; SCH₃; OCN; Cl; Br; CN; CF₃; OCF₃;SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl;aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleavinggroup; a reporter group; an intercalator; a group for improvingpharmacokinetic properties; and a group for improving thepharmacodynamic properties of an antisense compound, and othersubstituents having similar properties. In certain embodiments, modifednucleosides comprise a 2′-MOE side chain (see, e.g., Baker et al., J.Biol. Chem., 1997, 272, 11944-12000). Such 2′-MOE substitution have beendescribed as having improved binding affinity compared to unmodifiednucleosides and to other modified nucleosides, such as 2′-O-methyl,O-propyl, and O-aminopropyl. Oligonucleotides having the 2′-MOEsubstituent also have been shown to be antisense inhibitors of geneexpression with promising features for in vivo use (see, e.g., Martin,P., Helv. Chim. Acta, 1995, 78, 486-504; Altmann et al., Chimia, 1996,50, 168-176; Altmann et al., Biochem. Soc. Trans., 1996, 24, 630-637;and Altmann et al., Nucleosides Nucleotides, 1997, 16, 917-926).

As used herein, a “modified tetrahydropyran nucleoside” or “modified THPnucleoside” means a nucleoside having a six-membered tetrahydropyran“sugar” substituted in for the pentofuranosyl residue in normalnucleosides (a sugar surrogate). Modified THP nucleosides include, butare not limited to, what is referred to in the art as hexitol nucleicacid (HNA), anitol nucleic acid (ANA), manitol nucleic acid (MNA) (seeLeumann, C J. Bioorg. & Med. Chem. (2002) 10:841-854), fluoro HNA(F-HNA), or those compounds having Formula X:

Formula X:

wherein independently for each of said at least one tetrahydropyrannucleoside analog of Formula X:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking grouplinking the tetrahydropyran nucleoside analog to the antisense compoundor one of T₃ and T₄ is an internucleoside linking group linking thetetrahydropyran nucleoside analog to the antisense compound and theother of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugategroup, or a 5′ or 3′-terminal group;

q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl, or substituted C₂-C₆ alkynyl; and

one of R₁ and R₂ is hydrogen and the other is selected from halogen,substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(═X)J₁,OC(═X)NJ₁J₂, NJ₃C(═X)NJ₁J₂, and CN, wherein X is O, S, or NJ₁, and eachJ₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, the modified THP nucleosides of Formula X areprovided wherein q_(m), q_(n), q_(p), q_(r), q_(s), q_(t), and q_(u) areeach H. In certain embodiments, at least one of q_(m), q_(n), q_(p),q_(r), q_(s), q_(t), and q_(u) is other than H. In certain embodiments,at least one of q_(m), q_(n), q_(p), q_(r), q_(s), q_(t) and q_(u) ismethyl. In certain embodiments, THP nucleosides of Formula X areprovided wherein one of R₁ and R₂ is F. In certain embodiments, R₁ isfluoro and R₂ is H, R₁ is methoxy and R₂ is H, and R₁ is methoxyethoxyand R₂ is H.

As used herein, “2′-modified” or “2′-substituted” refers to a nucleosidecomprising a sugar comprising a substituent at the 2′ position otherthan H or OH. 2′-modified nucleosides, include, but are not limited to,bicyclic nucleosides wherein the bridge connecting two carbon atoms ofthe sugar ring connects the 2′ carbon and another carbon of the sugarring and nucleosides with non-bridging 2′ substituents, such as allyl,amino, azido, thio, O-allyl, O—C₁-C₁₀ alkyl, —OCF₃, O—(CH₂)₂—O—CH₃,2′-O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)), orO—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,independently, H or substituted or unsubstituted C₁-C₁₀ alkyl.2′-modifed nucleosides may further comprise other modifications, forexample, at other positions of the sugar and/or at the nucleobase.

As used herein, “2′-F” refers to a sugar comprising a fluoro group atthe 2′ position.

As used herein, “2′-OMe” or “2′-OCH₃” or “2′-O-methyl” each refers to asugar comprising an —OCH₃ group at the 2′ position of the sugar ring.

As used herein, “oligonucleotide” refers to a compound comprising aplurality of linked nucleosides. In certain embodiments, one or more ofthe plurality of nucleosides is modified. In certain embodiments, anoligonucleotide comprises one or more ribonucleosides (RNA) and/ordeoxyribonucleosides (DNA).

Many other bicyclo and tricyclo sugar surrogate ring systems are alsoknown in the art that can be used to modify nucleosides forincorporation into antisense compounds (see, e.g., review article:Leumann, J. C, Bioorganic & Medicinal Chemistry, 2002, 10, 841-854).

Such ring systems can undergo various additional substitutions toenhance activity.

Methods for the preparations of modified sugars are well known to thoseskilled in the art.

In nucleotides having modified sugar moieties, the nucleobase moieties(natural, modified, or a combination thereof) are maintained forhybridization with an appropriate nucleic acid target.

In certain embodiments, antisense compounds comprise one or morenucleotides having modified sugar moieties. In certain embodiments, themodified sugar moiety is 2′-MOE. In certain embodiments, the 2′-MOEmodified nucleotides are arranged in a gapmer motif. In certainembodiments, the modified sugar moiety is a cEt. In certain embodiments,the cEt modified nucleotides are arranged throughout the wings of agapmer motif

Modified Nucleobases

Nucleobase (or base) modifications or substitutions are structurallydistinguishable from, yet functionally interchangeable with, naturallyoccurring or synthetic unmodified nucleobases. Both natural and modifiednucleobases are capable of participating in hydrogen bonding. Suchnucleobase modifications may impart nuclease stability, binding affinityor some other beneficial biological property to antisense compounds.Modified nucleobases include synthetic and natural nucleobases such as,for example, 5-methylcytosine (5-me-C). Certain nucleobasesubstitutions, including 5-methylcytosine substitutions, areparticularly useful for increasing the binding affinity of an antisensecompound for a target nucleic acid. For example, 5-methylcytosinesubstitutions have been shown to increase nucleic acid duplex stabilityby 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds.,Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp.276-278).

Additional unmodified nucleobases include 5-hydroxymethyl cytosine,xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkylderivatives of adenine and guanine, 2-propyl and other alkyl derivativesof adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine,5-halouracil and cytosine, 5-propynyl (—C≡C—CH₃) uracil and cytosine andother alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosineand thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino,8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines andguanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other5-substituted uracils and cytosines, 7-methylguanine and7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and3-deazaadenine.

Heterocyclic base moieties may also include those in which the purine orpyrimidine base is replaced with other heterocycles, for example7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone.Nucleobases that are particularly useful for increasing the bindingaffinity of antisense compounds include 5-substituted pyrimidines,6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

In certain embodiments, antisense compounds targeted to a FGFR4 nucleicacid comprise one or more modified nucleobases. In certain embodiments,gap-widened antisense oligonucleotides targeted to a FGFR4 nucleic acidcomprise one or more modified nucleobases. In certain embodiments, themodified nucleobase is 5-methylcytosine. In certain embodiments, eachcytosine is a 5-methylcytosine.

Compositions and Methods for Formulating Pharmaceutical Compositions

Antisense oligonucleotides may be admixed with pharmaceuticallyacceptable active or inert substance for the preparation ofpharmaceutical compositions or formulations. Compositions and methodsfor the formulation of pharmaceutical compositions are dependent upon anumber of criteria, including, but not limited to, route ofadministration, extent of disease, or dose to be administered.

Antisense compound targeted to a FGFR4 nucleic acid can be utilized inpharmaceutical compositions by combining the antisense compound with asuitable pharmaceutically acceptable diluent or carrier. Apharmaceutically acceptable diluent includes phosphate-buffered saline(PBS). PBS is a diluent suitable for use in compositions to be deliveredparenterally. Accordingly, in one embodiment, employed in the methodsdescribed herein is a pharmaceutical composition comprising an antisensecompound targeted to a FGFR4 nucleic acid and a pharmaceuticallyacceptable diluent. In certain embodiments, the pharmaceuticallyacceptable diluent is PBS. In certain embodiments, the antisensecompound is an antisense oligonucleotide.

Pharmaceutical compositions comprising antisense compounds encompass anypharmaceutically acceptable salts, esters, or salts of such esters, orany other oligonucleotide which, upon administration to an animal,including a human, is capable of providing (directly or indirectly) thebiologically active metabolite or residue thereof. Accordingly, forexample, the disclosure is also drawn to pharmaceutically acceptablesalts of antisense compounds, prodrugs, pharmaceutically acceptablesalts of such prodrugs, and other bioequivalents. Suitablepharmaceutically acceptable salts include, but are not limited to,sodium and potassium salts.

Pharmaceutically acceptable salts of the compounds described herein maybe prepared by methods well-known in the art. For a review ofpharmaceutically acceptable salts, see Stahl and Wermuth, Handbook ofPharmaceutical Salts: Properties, Selection and Use (Wiley-VCH,Weinheim, Germany, 2002). Sodium salts of antisense oligonucleotides areuseful and are well accepted for therapeutic administration to humans.Accordingly, in one embodiment the compounds described herein are in theform of a sodium salt.

A prodrug can include the incorporation of additional nucleosides at oneor both ends of an antisense compound which are cleaved by endogenousnucleases within the body, to form the active antisense compound.

Conjugated Antisense Compounds

Antisense compounds may be covalently linked to one or more moieties orconjugates which enhance the activity, cellular distribution or cellularuptake of the resulting antisense oligonucleotides. Typical conjugategroups include cholesterol moieties and lipid moieties. Additionalconjugate groups include carbohydrates, phospholipids, biotin,phenazine, folate, phenanthridine, anthraquinone, acridine,fluoresceins, rhodamines, coumarins, and dyes.

Antisense compounds can also be modified to have one or more stabilizinggroups that are generally attached to one or both termini of antisensecompounds to enhance properties such as, for example, nucleasestability. Included in stabilizing groups are cap structures. Theseterminal modifications protect the antisense compound having terminalnucleic acid from exonuclease degradation, and can help in deliveryand/or localization within a cell. The cap can be present at the5′-terminus (5′-cap), or at the 3′-terminus (3′-cap), or can be presenton both termini. Cap structures are well known in the art and include,for example, inverted deoxy abasic caps. Further 3′ and 5′-stabilizinggroups that can be used to cap one or both ends of an antisense compoundto impart nuclease stability include those disclosed in WO 03/004602published on Jan. 16, 2003.

Cell Culture and Antisense Compounds Treatment

The effects of antisense compounds on the level, activity or expressionof FGFR4 nucleic acids can be tested in vitro in a variety of celltypes. Cell types used for such analyses are available from commercialvendors (e.g. American Type Culture Collection, Manassas, Va.; Zen-Bio,Inc., Research Triangle Park, NC; Clonetics Corporation, Walkersville,Md.) and cells are cultured according to the vendor's instructions usingcommercially available reagents (e.g. Invitrogen Life Technologies,Carlsbad, Calif.). Illustrative cell types include, but are not limitedto, HepG2 cells and primary hepatocytes.

In Vitro Testing of Antisense Oligonucleotides

Described herein are methods for treatment of cells with antisenseoligonucleotides, which can be modified appropriately for treatment withother antisense compounds.

In general, cells are treated with antisense oligonucleotides when thecells reach approximately 60-80% confluence in culture.

One reagent commonly used to introduce antisense oligonucleotides intocultured cells includes the cationic lipid transfection reagentLIPOFECTIN® (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotidesare mixed with LIPOFECTIN® in OPTI-MEM® 1 (Invitrogen, Carlsbad, Calif.)to achieve the desired final concentration of antisense oligonucleotideand a LIPOFECTIN® concentration that typically ranges 2 to 12 ug/mL per100 nM antisense oligonucleotide.

Another reagent used to introduce antisense oligonucleotides intocultured cells includes LIPOFECTAMINE 2000® (Invitrogen, Carlsbad,Calif.). Antisense oligonucleotide is mixed with LIPOFECTAMINE 2000® inOPTI-MEM® 1 reduced serum medium (Invitrogen, Carlsbad, Calif.) toachieve the desired concentration of antisense oligonucleotide and aLIPOFECTAMINE® concentration that typically ranges 2 to 12 ug/mL per 100nM antisense oligonucleotide.

Another reagent used to introduce antisense oligonucleotides intocultured cells includes Cytofectin® (Invitrogen, Carlsbad, Calif.).Antisense oligonucleotide is mixed with Cytofectin® in OPTI-MEM® 1reduced serum medium (Invitrogen, Carlsbad, Calif.) to achieve thedesired concentration of antisense oligonucleotide and a Cytofectin®concentration that typically ranges 2 to 12 ug/mL per 100 nM antisenseoligonucleotide.

Another technique used to introduce antisense oligonucleotides intocultured cells includes electroporation.

Cells are treated with antisense oligonucleotides by routine methods.Cells are typically harvested 16-24 hours after antisenseoligonucleotide treatment, at which time RNA or protein levels of targetnucleic acids are measured by methods known in the art and describedherein. In general, when treatments are performed in multiplereplicates, the data are presented as the average of the replicatetreatments.

The concentration of antisense oligonucleotide used varies from cellline to cell line. Methods to determine the optimal antisenseoligonucleotide concentration for a particular cell line are well knownin the art. Antisense oligonucleotides are typically used atconcentrations ranging from 1 nM to 300 nM when transfected withLIPOFECTAMINE2000®, Lipofectin or Cytofectin. Antisense oligonucleotidesare used at higher concentrations ranging from 625 to 20,000 nM whentransfected using electroporation.

RNA Isolation

RNA analysis can be performed on total cellular RNA or poly(A)+mRNA.Methods of RNA isolation are well known in the art. RNA is preparedusing methods well known in the art, for example, using the TRIZOL®Reagent (Invitrogen, Carlsbad, Calif.) according to the manufacturer'srecommended protocols.

Analysis of Inhibition of Target Levels or Expression

Inhibition of levels or expression of a FGFR4 nucleic acid can beassayed in a variety of ways known in the art. For example, targetnucleic acid levels can be quantitated by, e.g., Northern blot analysis,competitive polymerase chain reaction (PCR), or quantitative real-timePCR. RNA analysis can be performed on total cellular RNA or poly(A)+mRNA. Methods of RNA isolation are well known in the art. Northern blotanalysis is also routine in the art. Quantitative real-time PCR can beconveniently accomplished using the commercially available ABI PRISM®7600, 7700, or 7900 Sequence Detection System, available from PE-AppliedBiosystems, Foster City, Calif. and used according to manufacturer'sinstructions.

Quantitative Real-Time PCR Analysis of Target RNA Levels

Quantitation of target RNA levels may be accomplished by quantitativereal-time PCR using the ABI PRISM® 7600, 7700, or 7900 SequenceDetection System (PE-Applied Biosystems, Foster City, Calif.) accordingto manufacturer's instructions. Methods of quantitative real-time PCRare well known in the art.

Prior to real-time PCR, the isolated RNA is subjected to a reversetranscriptase (RT) reaction, which produces complementary DNA (cDNA)that is then used as the substrate for the real-time PCR amplification.The RT and real-time PCR reactions are performed sequentially in thesame sample well. RT and real-time PCR reagents are obtained fromInvitrogen (Carlsbad, Calif.). RT, real-time-PCR reactions are carriedout by methods well known to those skilled in the art.

Gene (or RNA) target quantities obtained by real time PCR are normalizedusing either the expression level of a gene whose expression isconstant, such as cyclophilin A, or by quantifying total RNA usingRIBOGREEN® (Invitrogen, Inc. Carlsbad, Calif.). Cyclophilin A expressionis quantified by real time PCR, by being run simultaneously with thetarget, multiplexing, or separately. Total RNA is quantified usingRIBOGREEN® RNA quantification reagent (Invitrogen, Inc. Eugene, Oreg.).Methods of RNA quantification by RIBOGREEN® are taught in Jones, L. J.,et al, (Analytical Biochemistry, 1998, 265, 368-374). A CYTOFLUOR® 4000instrument (PE Applied Biosystems) is used to measure RIBOGREEN®fluorescence.

Probes and primers are designed to hybridize to a FGFR4 nucleic acid.Methods for designing real-time PCR probes and primers are well known inthe art, and may include the use of software such as PRIMER EXPRESS®Software (Applied Biosystems, Foster City, Calif.).

Analysis of Protein Levels

Antisense inhibition of FGFR4 nucleic acids can be assessed by measuringFGFR4 protein levels. Protein levels of FGFR4 can be evaluated orquantitated in a variety of ways well known in the art, such asimmunoprecipitation, Western blot analysis (immunoblotting),enzyme-linked immunosorbent assay (ELISA), quantitative protein assays,protein activity assays (for example, caspase activity assays),immunohistochemistry, immunocytochemistry or fluorescence-activated cellsorting (FACS). Antibodies directed to a target can be identified andobtained from a variety of sources, such as the MSRS catalog ofantibodies (Aerie Corporation, Birmingham, Mich.), or can be preparedvia conventional monoclonal or polyclonal antibody generation methodswell known in the art. Antibodies useful for the detection of human andrat FGFR4 are commercially available.

In Vivo Testing of Antisense Compounds

Antisense compounds, for example, antisense oligonucleotides, are testedin animals to assess their ability to inhibit expression of FGFR4 andproduce phenotypic changes. Testing may be performed in normal animals,or in experimental disease models. For administration to animals,antisense oligonucleotides are formulated in a pharmaceuticallyacceptable diluent, such as phosphate-buffered saline. Administrationincludes parenteral routes of administration. Following a period oftreatment with antisense oligonucleotides, RNA is isolated from tissueand changes in FGFR4 nucleic acid expression are measured. Changes inFGFR4 protein levels are also measured.

Certain Indications

In certain embodiments, provided herein are methods of treating anindividual comprising administering one or more pharmaceuticalcompositions as described herein. In certain embodiments, the individualhas a metabolic disease.

As shown in the examples below, compounds targeted to FGFR4, asdescribed herein, have been shown to reduce the severity ofphysiological symptoms of a metabolic disease, including obesity oradiposity, metabolic syndrome, diabetes mellitus, insulin resistance,diabetic dyslipidemia, and hypertriglyceridemia. In certain of theexperiments, the compounds reduced body weight, e.g., the animalscontinued to experience symptoms, but the symptoms were less severecompared to untreated animals. In certain of the experiments, thecompounds reduced body fat, e.g., the animals continued to experiencesymptoms, but the symptoms were less severe compared to untreatedanimals. In certain of the experiments, the compounds reduced adiposetissue, e.g., the animals continued to experience symptoms, but thesymptoms were less severe compared to untreated animals. In other of theexperiments, however, the compounds appear to reduce the symptoms ofobesity; e.g., animals treated for a longer period of time experiencedless severe symptoms than those administered the compounds for a shorterperiod of time. In other of the experiments, however, the compoundsappear to reduce the symptoms of diabetes; e.g., animals treated for alonger period of time experienced less severe symptoms than thoseadministered the compounds for a shorter period of time. In other of theexperiments, however, the compounds appear to inhibit weight gain; e.g.,animals treated for a longer period of time experienced less severesymptoms than those administered the compounds for a shorter period oftime. In other of the experiments, however, the compounds appear toreduce glucose levels; e.g., animals treated for a longer period of timeexperienced less severe symptoms than those administered the compoundsfor a shorter period of time. In other of the experiments, however, thecompounds appear to increase fatty acid oxidation; e.g., animals treatedfor a longer period of time experienced less severe symptoms than thoseadministered the compounds for a shorter period of time. The ability ofthe compounds exemplified below to restore function thereforedemonstrates that symptoms of the disease may be reversed by treatmentwith a compound as described herein.

Obesity is characterized by numerous physical and physiologicalsymptoms. Any symptom known to one of skill in the art to be associatedwith obesity can be ameliorated or otherwise modulated as set forthabove in the methods described above. In certain embodiments, thesymptom is a physical symptom selected from the group consisting ofincreased adipose tissue mass or weight, increased weight gain,increased fat pad weight, imbalance with caloric intake and energyexpenditure, increase in body fat, increase in body mass, having a bodymass index (BMI) of 30 or higher, increase in body frame, increasedsweating, sleep apnea, difficulty in sleeping, inability to cope withsudden physical activity, lethargy, back and joint problems, increase inbreathlessness, increase in breast region adiposity, increase in abdomensize or fat, extreme hunger, or extreme fatigue.

In certain embodiments, the symptom is a physiological symptom selectedfrom the group consisting of high blood pressure, hypertension, highcholesterol levels, type 2 diabetes, stroke, cardiac insufficiency,heart disease, coronary artery obstruction, breast cancer in women,gastro-oesophageal reflux disease, hip and knee arthrosis, and reducedlife expectancy.

In certain embodiments, the physical symptom is excess body weight. Incertain embodiments, the symptom is excess fat mass. In certainembodiments, the symptom is a body mass index of 30 or higher. Incertain embodiments, the symptom is breathlessness. In certainembodiments, the symptom is increased sweating. In certain embodiments,the symptom is sleep apnea. In certain embodiments, the symptom isdifficulty in sleeping. In certain embodiments, the symptom is inabilityto cope with sudden physical activity. In certain embodiments, thesymptom is lethargy. In certain embodiments, the symptom is back andjoint problems.

In certain embodiments, the physiological symptom is high bloodpressure. In certain embodiments, the symptom is hypertension. Incertain embodiments, the symptom is high cholesterol levels. In certainembodiments, the symptom is type 2 diabetes. In certain embodiments, thesymptom is stroke. In certain embodiments, the symptom is cardiacinsufficiency. In certain embodiments, the symptom is heart disease. Incertain embodiments, the symptom is coronary artery obstruction. Incertain embodiments, the symptom is breast cancer in women. In certainembodiments, the symptom is gastro-oesophageal reflux disease. Incertain embodiments, the symptom is hip and knee arthrosis. In certainembodiments, the symptom is reduced life expectancy.

Diabetes mellitus is characterized by numerous physical andphysiological symptoms. Any symptom known to one of skill in the art tobe associated with Type 2 diabetes can be ameliorated or otherwisemodulated as set forth above in the methods described above. In certainembodiments, the symptom is a physical symptom selected from the groupconsisting of increased glucose levels, increased weight gain, frequenturination, unusual thirst, extreme hunger, extreme fatigue, blurredvision, frequent infections, tingling or numbness at the extremities,dry and itchy skin, weight loss, slow-healing sores, and swollen gums.

In certain embodiments, the symptom is a physiological symptom selectedfrom the group consisting of increased insulin resistance, increasedglucose levels, increased fat mass, decreased metabolic rate, decreasedglucose clearance, decreased glucose tolerance, decreased insulinsensitivity, decreased hepatic insulin sensitivity, increased adiposetissue size and weight, increased body fat, and increased body weight.

In certain embodiments, the physical symptom is increased weight gain.In certain embodiments, the symptom is frequent urination. In certainembodiments, the symptom is unusual thirst. In certain embodiments, thesymptom is extreme hunger. In certain embodiments, the symptom isextreme fatigue. In certain embodiments, the symptom is blurred vision.In certain embodiments, the symptom is frequent infections. In certainembodiments, the symptom is tingling or numbness at the extremities. Incertain embodiments, the symptom is dry and itchy skin. In certainembodiments, the symptom is weight loss. In certain embodiments, thesymptom is slow-healing sores. In certain embodiments, the symptom isswollen gums. In certain embodiments, the symptom is increased insulinresistance. In certain embodiments, the symptom is increased fat mass.In certain embodiments, the symptom is decreased metabolic rate. Incertain embodiments, the symptom is decreased glucose clearance. Incertain embodiments, the symptom is decreased glucose tolerance. Incertain embodiments, the symptom is decreased insulin sensitivity. Incertain embodiments, the symptom is decreased hepatic insulinsensitivity. In certain embodiments, the symptom is increased adiposetissue size and weight. In certain embodiments, the symptom is increasedbody fat. In certain embodiments, the symptom is increased body weight.

In certain embodiments, provided are methods of treating an individualcomprising administering one or more pharmaceutical compositions asdescribed herein. In certain embodiments, the individual has metabolicrelated disease.

In certain embodiments, administration of an antisense compound targetedto a FGFR4 nucleic acid results in reduction of FGFR4 expression by atleast about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,90, 95 or 99%, or a range defined by any two of these values.

In certain embodiments, pharmaceutical compositions comprising anantisense compound targeted to FGFR4 are used for the preparation of amedicament for treating a patient suffering or susceptible to ametabolic disease.

In certain embodiments, the methods described herein includeadministering a compound comprising a modified oligonucleotide having acontiguous nucleobases portion as described herein of a sequence recitedin SEQ ID NO: 16.

In certain embodiments, the methods described herein includeadministering a compound comprising a modified oligonucleotide having acontiguous nucleobases portion as described herein of a sequence recitedin SEQ ID NO: 45.

Administration

In certain embodiments, the compounds and compositions as describedherein may be administered in a number of ways depending upon whetherlocal or systemic treatment is desired and upon the area to be treated.Administration may be topical, pulmonary, e.g., by inhalation orinsufflation of powders or aerosols, including by nebulizer;intratracheal, intranasal, epidermal and transdermal, oral orparenteral. The compounds and compositions as described herein can beadministered directly to a tissue or organ.

In certain embodiments, the compounds and compositions as describedherein are administered parenterally. “Parenteral administration” meansadministration through injection or infusion. Parenteral administrationincludes subcutaneous administration, intravenous administration,intramuscular administration, intraarterial administration,intraperitoneal administration, or intracranial administration, e.g.intracerebral administration, intrathecal administration,intraventricular administration, ventricular administration,intracerebroventricular administration, cerebral intraventricularadministration or cerebral ventricular administration. Administrationcan be continuous, or chronic, or short or intermittent.

In certain embodiments, parenteral administration is by injection. Theinjection can be delivered with a syringe or a pump. In certainembodiments, the injection is a bolus injection. In certain embodiments,the injection is administered directly to a tissue or organ.

In certain embodiments, the compounds and compositions as describedherein are administered parenterally.

In certain embodiments, parenteral administration is subcutaneous.

In further embodiments, the formulation for administration is thecompounds described herein and saline.

In certain embodiments, an antisense oligonucleotide is delivered byinjection or infusion once every month, every two months, every 90 days,every 3 months, every 6 months, twice a year or once a year.

Certain Combination Therapies

In certain embodiments, one or more pharmaceutical compositionsdescribed herein are co-administered with one or more otherpharmaceutical agents. In certain embodiments, such one or more otherpharmaceutical agents are designed to treat the same disease, disorder,or condition as the one or more pharmaceutical compositions describedherein. In certain embodiments, such one or more other pharmaceuticalagents are designed to treat a different disease, disorder, or conditionas the one or more pharmaceutical compositions described herein. Incertain embodiments, such one or more other pharmaceutical agents aredesigned to treat an undesired side effect of one or more pharmaceuticalcompositions as described herein. In certain embodiments, one or morepharmaceutical compositions are co-administered with anotherpharmaceutical agent to treat an undesired effect of that otherpharmaceutical agent. In certain embodiments, one or more pharmaceuticalcompositions are co-administered with another pharmaceutical agent toproduce a combinational effect. In certain embodiments, one or morepharmaceutical compositions are co-administered with anotherpharmaceutical agent to produce a synergistic effect.

In certain embodiments, a first agent and one or more second agents areadministered at the same time. In certain embodiments, the first agentand one or more second agents are administered at different times. Incertain embodiments, the first agent and one or more second agents areprepared together in a single pharmaceutical formulation. In certainembodiments, the first agent and one or more second agents are preparedseparately.

In certain embodiments, the second compound is administered prior toadministration of a pharmaceutical composition described herein. Incertain embodiments, the second compound is administered followingadministration of a pharmaceutical composition described herein. Incertain embodiments, the second compound is administered at the sametime as a pharmaceutical composition described herein. In certainembodiments, the dose of a co-administered second compound is the sameas the dose that would be administered if the second compound wasadministered alone. In certain embodiments, the dose of aco-administered second compound is lower than the dose that would beadministered if the second compound was administered alone. In certainembodiments, the dose of a co-administered second compound is greaterthan the dose that would be administered if the second compound wasadministered alone.

In certain embodiments, the co-administration of a second compoundenhances the effect of a first compound, such that co-administration ofthe compounds results in an effect that is greater than the effect ofadministering the first compound alone. In certain embodiments, theco-administration results in effects that are additive of the effects ofthe compounds when administered alone. In certain embodiments, theco-administration results in effects that are supra-additive of theeffects of the compounds when administered alone. In certainembodiments, the first compound is an antisense compound. In certainembodiments, the second compound is an antisense compound.

In certain embodiments the FGFR4 antisense oligonucleotide is deliveredconcomitant with delivery of the second agent. Alternatively, deliverycan be in the same formulation or can be administered separately. Incertain embodiments, FGFR4 antisense oligonucleotide is administeredprior to the treatment with the second agents. In a certain embodiment,the FGFR4 antisense oligonucleotide is administered after treatment withan obesity inducing drug or agent is ceased.

In certain embodiments, second agents include, but are not limited to, aglucose-lowering agent. The glucose lowering agent can include, but isnot limited to, a therapeutic lifestyle change, PPAR agonist, adipeptidyl peptidase (IV) inhibitor, a GLP-1 analog, insulin or aninsulin analog, an insulin secretagogue, a SGLT2 inhibitor, a humanamylin analog, a biguanide, an alpha-glucosidase inhibitor, or acombination thereof. The glucose-lowering agent can include, but is notlimited to metformin, sulfonylurea, rosiglitazone, meglitinide,thiazolidinedione, alpha-glucosidase inhibitor or a combination thereof.The sulfonylurea can be acetohexamide, chlorpropamide, tolbutamide,tolazamide, glimepiride, a glipizide, a glyburide, or a gliclazide. Themeglitinide can be nateglinide or repaglinide. The thiazolidinedione canbe pioglitazone or rosiglitazone. The alpha-glucosidase can be acarboseor miglitol.

In some embodiments, the glucose-lowering therapeutic is a GLP-1 analog.In some embodiments, the GLP-1 analog is exendin-4 or liraglutide.

In other embodiments, the glucose-lowering therapeutic is asulfonylurea. In some embodiments, the sulfonylurea is acetohexamide,chlorpropamide, tolbutamide, tolazamide, glimepiride, a glipizide, aglyburide, or a gliclazide.

In some embodiments, the glucose-lowering drug is a biguanide. In someembodiments, the biguanide is metformin, and in some embodiments, bloodglucose levels are decreased without increased lactic acidosis ascompared to the lactic acidosis observed after treatment with metforminalone.

In some embodiments, the glucose-lowering drug is a meglitinide. In someembodiments, the meglitinide is nateglinide or repaglinide.

In some embodiments, the glucose-lowering drug is a thiazolidinedione.In some embodiments, the thiazolidinedione is pioglitazone,rosiglitazone, or troglitazone. In some embodiments, blood glucoselevels are decreased without greater weight gain than observed withrosiglitazone treatment alone.

In some embodiments, the glucose-lowering drug is an alpha-glucosidaseinhibitor. In some embodiments, the alpha-glucosidase inhibitor isacarbose or miglitol.

In a certain embodiment, a co-administered glucose-lowering agent isISIS 113715.

In a certain embodiment, glucose-lowering therapy is therapeuticlifestyle change.

In certain embodiments, second agents include, but are not limited to,lipid-lowering agents. The lipid-lowering agent can include, but is notlimited to atorvastatin, simvastatin, rosuvastatin, and ezetimibe. Incertain such embodiments, the lipid-lowering agent is administered priorto administration of a pharmaceutical composition described herein. Incertain such embodiments, the lipid-lowering agent is administeredfollowing administration of a pharmaceutical composition describedherein. In certain such embodiments the lipid-lowering agent isadministered at the same time as a pharmaceutical composition describedherein. In certain such embodiments the dose of a co-administeredlipid-lowering agent is the same as the dose that would be administeredif the lipid-lowering agent was administered alone. In certain suchembodiments the dose of a co-administered lipid-lowering agent is lowerthan the dose that would be administered if the lipid-lowering agent wasadministered alone. In certain such embodiments the dose of aco-administered lipid-lowering agent is greater than the dose that wouldbe administered if the lipid-lowering agent was administered alone.

In certain embodiments, a co-administered lipid-lowering agent is aHMG-CoA reductase inhibitor. In certain such embodiments the HMG-CoAreductase inhibitor is a statin. In certain such embodiments the statinis selected from atorvastatin, simvastatin, pravastatin, fluvastatin,and rosuvastatin.

In certain embodiments, a co-administered lipid-lowering agent is acholesterol absorption inhibitor. In certain such embodiments,cholesterol absorption inhibitor is ezetimibe.

In certain embodiments, a co-administered lipid-lowering agent is aco-formulated HMG-CoA reductase inhibitor and cholesterol absorptioninhibitor. In certain such embodiments the co-formulated lipid-loweringagent is ezetimibe/simvastatin.

In certain embodiments, a co-administered lipid-lowering agent is amicrosomal triglyceride transfer protein inhibitor (MTP inhibitor).

In certain embodiments, a co-administered lipid-lowering agent is anoligonucleotide targeted to ApoB.

In certain embodiments, second agents include, but are not limited to ananti-obesity drug or agent. Such anti-obesity agents include but are notlimited to Orlistat, Sibutramine, or Rimonabant, and may be administeredas described above as adipose or body weight lowering agents. In certainembodiments, the antisense compound may be co-administered with appetitesuppressants. Such appetite suppressants include but are not limited todiethylpropion tenuate, mazindol, orlistat, phendimetrazine,phentermine, and sibutramine and may be administered as describedherein. In certain embodiment, the anti-obesity agents are CNS basedsuch as, but not limited to, sibutramine or GLP-1 based such as, but notlimited to, liraglutide.

In certain embodiments, second agents include, but are not limited to anantipsychotic drug or agent. Such antipsychotic agents therapeutics maybe administered as described above to reduce metabolic abnormalitiesassociated with treatment with antipsychotic agents. In a particularembodiment administering of the FGFR4 antisense compound results inincreased metabolic rate or decreasing adiposity or decreasing bodyweight or all three without affecting the CNS effects of thepsychotherapeutic agent

Due to the ability of FGFR4 antisense oligonucleotides to increasemetabolic rate and insulin sensitivity and reduce adiposity and weightgain, these compounds can be administered to reduce metabolicabnormalities associated with treatment with antipsychotic agents. Incertain embodiments the FGFR4 antisense oligonucleotide is delivered ina method of reducing metabolic abnormalities associated with thetherapeutic use of psychotherapeutic agents. Such weight inducingantipsychotic agents include, but are not limited to clozapine,olanzapine, aripiprazole, risperidone and ziprasidone.

Further provided is a method of administering an antisense compoundtargeted to a FGFR4 nucleic acid via injection and further includingadministering a topical steroid at the injection site.

Further examples of pharmaceutical agents that may be co-administeredwith a pharmaceutical composition of the present invention include, butare not limited to, corticosteroids, including but not limited toprednisone; immunoglobulins, including, but not limited to intravenousimmunoglobulin (IVIg); analgesics (e.g., acetaminophen);anti-inflammatory agents, including, but not limited to non-steroidalanti-inflammatory drugs (e.g., ibuprofen, COX-1 inhibitors, and COX-2,inhibitors); salicylates; antibiotics; antivirals; antifungal agents;antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins,sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics;hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin,progestin, somatostan, and thyroid hormones); immunomodulators; musclerelaxants; antihistamines; osteoporosis agents (e.g., biphosphonates,calcitonin, and estrogens); prostaglandins, antineoplastic agents;psychotherapeutic agents; sedatives; poison oak or poison sumacproducts; antibodies; and vaccines.

In certain embodiments, the pharmaceutical compositions of the presentinvention may be administered in conjunction with a lipid-loweringtherapy. In certain such embodiments, a lipid-lowering therapy istherapeutic lifestyle change. In certain such embodiments, alipid-lowering therapy is LDL apheresis.

Formulations

The compounds provided herein may also be admixed, conjugated orotherwise associated with other molecules, molecule structures ormixtures of compounds, as for example, liposomes, receptor-targetedmolecules, or other formulations, for assisting in uptake, distributionand/or absorption. Representative United States patents that teach thepreparation of such uptake, distribution and/or absorption-assistingformulations include, but are not limited to, U.S. Pat. Nos. 5,108,921;5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932;5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921;5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016;5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259;5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is hereinincorporated by reference.

The antisense compounds provided herein encompass any pharmaceuticallyacceptable salts, esters, or salts of such esters, or any other compoundwhich, upon administration to an animal, including a human, is capableof providing (directly or indirectly) the biologically active metaboliteor residue thereof.

The term “pharmaceutically acceptable salts” refers to physiologicallyand pharmaceutically acceptable salts of the compounds provided herein:i.e., salts that retain the desired biological activity of the parentcompound and do not impart undesired toxicological effects thereto. Theterm “pharmaceutically acceptable salt” includes a salt prepared frompharmaceutically acceptable non-toxic acids or bases, includinginorganic or organic acids and bases. For oligonucleotides, preferredexamples of pharmaceutically acceptable salts and their uses are furtherdescribed in U.S. Pat. No. 6,287,860, which is incorporated herein inits entirety. Sodium salts have been shown to be suitable forms ofoligonucleotide drugs.

The term “pharmaceutically acceptable derivative” encompasses, but isnot limited to, pharmaceutically acceptable salts, solvates, hydrates,esters, prodrugs, polymorphs, isomers, isotopically labeled variants ofthe compounds described herein.

The present invention also includes pharmaceutical compositions andformulations which include the antisense compounds provided herein. Thepharmaceutical compositions described herein may be administered in anumber of ways depending upon whether local or systemic treatment isdesired and upon the area to be treated. Administration may beparenteral. Parenteral administration includes intravenous,intraarterial, subcutaneous, intraperitoneal or intramuscular injectionor infusion; or intracranial, e.g., intracerebral administration,intrathecal administration, intraventricular administration, ventricularadministration, intracerebroventricular administration, cerebralintraventricular administration or cerebral ventricular administration.

Parenteral administration, is preferred to target FGFR4 expression inthe liver and plasma. Oligonucleotides with at least one2′-O-methoxyethyl modification are believed to be particularly usefulfor oral administration. Pharmaceutical compositions and formulationsfor topical administration may include transdermal patches, ointments,lotions, creams, gels, drops, suppositories, sprays, liquids andpowders. Conventional pharmaceutical carriers, aqueous, powder or oilybases, thickeners and the like may be necessary or desirable. Coatedcondoms, gloves and the like may also be useful.

The pharmaceutical formulations described herein, which may convenientlybe presented in unit dosage form, may be prepared according toconventional techniques well known in the pharmaceutical industry. Suchtechniques include the step of bringing into association the activeingredients with the pharmaceutical carrier(s) or excipient(s). Ingeneral, the formulations are prepared by uniformly and intimatelybringing into association the active ingredients with liquid carriers orfinely divided solid carriers or both, and then, if necessary, shapingthe product.

The compositions described herein may be formulated into any of manypossible dosage forms such as, but not limited to, tablets, capsules,gel capsules, liquid syrups, soft gels, suppositories, and enemas. Thecompositions described herein may also be formulated as suspensions inaqueous, non-aqueous or mixed media. Aqueous suspensions may furthercontain substances which increase the viscosity of the suspensionincluding, for example, sodium carboxymethylcellulose, sorbitol and/ordextran. The suspension may also contain stabilizers.

Pharmaceutical compositions described herein include, but are notlimited to, solutions, emulsions, foams and liposome-containingformulations. The pharmaceutical compositions and formulations describedherein may comprise one or more penetration enhancers, carriers,excipients or other active or inactive ingredients.

Emulsions are typically heterogenous systems of one liquid dispersed inanother in the form of droplets usually exceeding 0.1 μm in diameter.Emulsions may contain additional components in addition to the dispersedphases, and the active drug which may be present as a solution in theaqueous phase, oily phase or itself as a separate phase. Microemulsionsare included as an embodiment described herein. Emulsions and their usesare well known in the art and are further described in U.S. Pat. No.6,287,860, which is incorporated herein in its entirety.

Formulations include liposomal formulations. As used in the presentinvention, the term “liposome” means a vesicle composed of amphiphiliclipids arranged in a spherical bilayer or bilayers. Liposomes areunilamellar or multilamellar vesicles which have a membrane formed froma lipophilic material and an aqueous interior that contains thecomposition to be delivered. Cationic liposomes are positively chargedliposomes which are believed to interact with negatively charged DNAmolecules to form a stable complex. Liposomes that are pH-sensitive ornegatively-charged are believed to entrap DNA rather than complex withit. Both cationic and noncationic liposomes have been used to deliverDNA to cells.

Liposomes also include “sterically stabilized” liposomes, a term which,as used herein, refers to liposomes comprising one or more specializedlipids that, when incorporated into liposomes, result in enhancedcirculation lifetimes relative to liposomes lacking such specializedlipids. Liposomes and their uses are further described in U.S. Pat. No.6,287,860, which is incorporated herein in its entirety.

In another embodiment, formulations include saline formulations. Incertain embodiments, a formulation consists of the compounds describedherein and saline. In certain embodiments, a formulation consistsessentially of the compounds described herein and saline. In certainembodiments, the saline is pharmaceutically acceptable grade saline. Incertain embodiments, the saline is buffered saline. In certainembodiments, the saline is phosphate buffered saline (PBS).

In certain embodiments, a formulation excludes liposomes. In certainembodiments, the formulation excludes sterically stabilized liposomes.In certain embodiments, a formulation excludes phospholipids. In certainembodiments, the formulation consists essentially of the compoundsdescribed herein and saline and excludes liposomes.

The pharmaceutical formulations and compositions may also includesurfactants. Surfactants and their uses are further described in U.S.Pat. No. 6,287,860, which is incorporated herein in its entirety.

In one embodiment, the present invention employs various penetrationenhancers to affect the efficient delivery of nucleic acids,particularly oligonucleotides. Penetration enhancers and their uses arefurther described in U.S. Pat. No. 6,287,860, which is incorporatedherein in its entirety.

One of skill in the art will recognize that formulations are routinelydesigned according to their intended use, i.e. route of administration.

Formulations for topical administration include those in which theoligonucleotides provided herein are in admixture with a topicaldelivery agent such as lipids, liposomes, fatty acids, fatty acidesters, steroids, chelating agents and surfactants. Preferred lipids andliposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine,dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline)negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g.dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidylethanolamine DOTMA).

Compositions and formulations for parenteral administration, includingintravenous, intraarterial, subcutaneous, intraperitoneal, intramuscularinjection or infusion, or intracranial may include sterile aqueoussolutions which may also contain buffers, diluents and other suitableadditives such as, but not limited to, penetration enhancers, carriercompounds and other pharmaceutically acceptable carriers or excipients.

Certain embodiments provided herein provide pharmaceutical compositionscontaining one or more oligomeric compounds and one or more otherchemotherapeutic agents which function by a non-antisense mechanism.Examples of such chemotherapeutic agents include but are not limited tocancer chemotherapeutic drugs such as daunorubicin, daunomycin,dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin,bleomycin, mafosfamide, ifosfamide, cytosine arabinoside,bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D,mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen,dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine,mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea,nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine,6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin,4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU),5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol,vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan,topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol(DES). When used with the compounds provided herein, suchchemotherapeutic agents may be used individually (e.g., 5-FU andoligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for aperiod of time followed by MTX and oligonucleotide), or in combinationwith one or more other such chemotherapeutic agents (e.g., 5-FU, MTX andoligonucleotide, or 5-FU, radiotherapy and oligonucleotide).Anti-inflammatory drugs, including but not limited to nonsteroidalanti-inflammatory drugs and corticosteroids, and antiviral drugs,including but not limited to ribivirin, vidarabine, acyclovir andganciclovir, may also be combined in compositions provided herein.Combinations of antisense compounds and other non-antisense drugs arealso within the scope of this invention. Two or more combined compoundsmay be used together or sequentially.

In another related embodiment, compositions provided herein may containone or more antisense compounds, particularly oligonucleotides, targetedto a first nucleic acid and one or more additional antisense compoundstargeted to a second nucleic acid target. Alternatively, compositionsprovided herein may contain two or more antisense compounds targeted todifferent regions of the same nucleic acid target. Numerous examples ofantisense compounds are known in the art. Two or more combined compoundsmay be used together or sequentially.

Dosing

Dosing is dependent on severity and responsiveness of the disease stateto be treated, with the course of treatment lasting from several days toseveral months, or until a cure is effected or a diminution of thedisease state is achieved. Optimal dosing schedules can be calculatedfrom measurements of drug accumulation in the body of the patient.Optimum dosages may vary depending on the relative potency of individualoligonucleotides, and can generally be estimated based on EC₅₀s found tobe effective in in vitro and in vivo animal models. In general, dosageis from 0.01 μg to 100 g per kg of body weight, and may be given once ormore daily, weekly, monthly or yearly, or at desired intervals.Following successful treatment, it may be desirable to have the patientundergo maintenance therapy to prevent the recurrence of the diseasestate, wherein the oligonucleotide is administered in maintenance doses,ranging from 0.01 μg to 100 g per kg of body weight, once or more daily.

While the present invention has been described with specificity inaccordance with certain of its preferred embodiments, the followingexamples serve only to illustrate the invention and are not intended tolimit the same. Each of the references, GENBANK accession numbers, andthe like recited in the present application is incorporated herein byreference in its entirety.

Certain Compounds

About one thousand four hundred and fifty four newly designed andpreviously disclosed antisense compounds of various lengths, motifs andbackbone composition were tested for their effect on human FGFR4 mRNA invitro in several cell types. The new compounds were compared with ninepreviously designed compounds, including ISIS 299005, ISIS 299010, ISIS299018, ISIS 299022, ISIS 299024, ISIS 299025, ISIS 299028, ISIS 299029,and ISIS 299030 which have previously been determined to be some of themost potent antisense compounds in vitro (see e.g., U.S. PatentPublication No. US2010/0292140). Of the one thousand four hundred andfifty four newly designed and the nine previously designed antisensecompounds, fifty three compounds were selected for further study basedon in vitro potency. The selected compounds were tested for dosedependent inhibition in HepG2 (Examples 8 and 9).

Certain oligonucleotides were then tested for tolerability in a CD1mouse model, as well as a Sprague-Dawley rat model. The oligonucleotidestested for tolerability include oligonucleotides, ISIS 299005 (SEQ IDNO: 7), ISIS 463588 (SEQ ID NO: 16), ISIS 463589 (SEQ ID NO: 17), ISIS463628 (SEQ ID NO: 28), ISIS 463690 (SEQ ID NO: 45), ISIS 463691 (SEQ IDNO: 46), ISIS 463835 (SEQ ID NO: 70), ISIS 463837 (SEQ ID NO: 72), ISIS464222 (SEQ ID NO: 135), ISIS 464225 (SEQ ID NO: 138), ISIS 464228 (SEQID NO: 141), ISIS 464286 (SEQ ID NO: 154), ISIS 464308 (SEQ ID NO: 163),ISIS 464449 (SEQ ID NO: 174), ISIS 464587 (SEQ ID NO: 186), ISIS 464588(SEQ ID NO: 187), ISIS 464589 (SEQ ID NO: 188), ISIS 464718 (SEQ ID NO:221), ISIS 479533 (SEQ ID NO: 241), ISIS 479551 (SEQ ID NO: 259), ISIS479691 (SEQ ID NO: 299), ISIS 479692 (SEQ ID NO: 300), ISIS 479698 (SEQID NO: 305), ISIS 479699 (SEQ ID NO: 306), ISIS 479703 (SEQ ID NO: 307),ISIS 479704 (SEQ ID NO: 308), ISIS 479706 (SEQ ID NO: 310), and ISIS479736 (SEQ ID NO: 317). By virtue of their complementary sequence, thecompounds are complementary to the regions 192-211, 191-210, 193-212,291-310, 369-388, 370-389, 788-807, 790-809, 2951-2970, 2954-2973, and2981-3000 of SEQ ID NO: 1; 11621-11640, 11624-11643, 11651-11670,1463-1482, 3325-3344, 7802-7821, 2110-2129, 2112-2131, 2114-2133,3575-3594, 2111-2130, 3570-3589, 11623-11639, 11624-11640, 11652-11668,11653-11669, 2113-2129, 2114-2130, 2116-2132, and 3571-3587 of SEQ IDNO: 2; and 103-122, 1569-1588, 5122-5138, 5123-5139, 5151-5167,5152-5168, 105-121, 106-122, 108-124, and 1570-1586 of SEQ ID NO: 3.

In the in vivo models, the liver function markers, such as alaninetransaminase, aspartate transaminase and bilirubin, and kidney functionmarkers, such as BUN and creatinine were measured. (Example 11).

Eight oligonucleotides having a nucleobase sequence of a sequencerecited in SEQ ID NO: 7 (ISIS 299005), 16 (ISIS 463588), 17 (ISIS463589), 45 (ISIS 463690), 46 (ISIS 463691), 70 (ISIS 463835), 72 (ISIS463837) and 138 (ISIS 464225) were tested. By virtue of theircomplementary sequence, the compounds are complementary to the regions192-211, 191-210, 193-212, 369-388, 370-389, 788-807, 790-809, and2954-2973 of SEQ ID NO: 1. In certain embodiments, the compoundstargeting the listed regions, as further described herein, comprise amodified oligonucleotide having some nucleobase portion of the sequencerecited in the SEQ ID NOs, as further described herein, In certainembodiments, the compounds targeting the listed regions or having anucleobase portion of a sequence recited in the listed SEQ ID NOs can beof various length, as further described herein, and can have one ofvarious motifs, as further described herein. In certain embodiments, acompound targeting a region or having a nucleobase portion of a sequencerecited in the listed SEQ ID NOs has the specific length and motif, asindicated by the ISIS NOs: 299005, 463588, 463589, 463690, 463691,463835, 463837, and 464225.

These eight compounds, ISIS 299005 (SEQ ID NO: 7), ISIS 463588 (SEQ IDNO: 16), ISIS 463589 (SEQ ID NO: 17), ISIS 463690 (SEQ ID NO: 45), ISIS463691 (SEQ ID NO: 46), ISIS 463835 (SEQ ID NO: 70), ISIS 463837 (SEQ IDNO: 72), and ISIS 464225 (SEQ ID NO: 138), were assayed for long-termeffects on tolerability in a CD/1GS rat model for 13 weeks (Example 12).Body weights and organ weights, the liver function markers, such asalanine transaminase, aspartate transaminase and bilirubin, and kidneyfunction markers, such as BUN and creatinine were measured. The eightcompounds were also tested for their viscosity. (Example 14)

ISIS 463588, ISIS 463589, and ISIS 463690 which demonstrated very goodtolerability in all three in vivo models, were tested for theirhalf-life in CD1 mouse liver (Example 13).

These eight compounds, ISIS 299005 (SEQ ID NO: 7), ISIS 463588 (SEQ IDNO: 16), ISIS 463589 (SEQ ID NO: 17), ISIS 463690 (SEQ ID NO: 45), ISIS463691 (SEQ ID NO: 46), ISIS 463835 (SEQ ID NO: 70), ISIS 463837 (SEQ IDNO: 72), and ISIS 464225 (SEQ ID NO: 138), were tested for efficacy,pharmacokinetic profile and tolerability in cynomolgus monkeys (Example15). The inhibition studies in these monkeys indicated that treatmentwith some of these compounds caused reduction of FGFR4 mRNA in the livertissues. Specifically, treatment with ISIS 463588 caused significantlygreater reduction of FGFR4 mRNA in liver and kidney tissues,respectively compared to treatment with the previously disclosedcompound, ISIS 299005. It was noted that ISIS 463588 caused the highestreduction of FGFR4 mRNA compared to the PBS control, irrespective of theprimer probe set used. Hence, in terms of potency, treatment with ISIS463588 was the most effective in the monkey study. Treatment with ISIS463690 also caused a greater reduction of FGFR4 mRNA in liver and kidneytissues, respectively compared to treatment with the previouslydisclosed compound, ISIS 299005.

FGF19 has been known to reduce adiposity and improve insulin sensitivityin transgenic mice (Fu, L. et al., Endocrinology. 145: 2594-2603, 2004).FGF19 is also characterized as a high affinity ligand for FGFR4 (Xie,M.-H. et al., Cytokine. 11: 729-735, 1999). However, treating mice withFGF19 protein induces hepatocyte proliferation consistent with theincreased hepatocyte proliferation and liver tumor formation observed inFGF19 transgenic mice (Wu, X. et al., JBC 285(8): 5165-5170, 2010).Leptin is a hormone which has been found to be present at very highlevels in obese individuals compared to normal-weight individuals(Considine, R. V. et al., N. Engl. J. Med. 334: 292-295, 1996).Evaluation of FGF19 mRNA and plasma levels demonstrated the significantincrease in FGF19 mRNA and protein levels in all the treatment groups.Specifically, monkeys treated with ISIS 463588 had the most significantincrease in FGF19 levels. Evaluation of leptin plasma levelsdemonstrated a significant decrease in monkeys treated with ISIS 463588or ISIS 463690. Tolerability studies in cynomolgus monkeys (Example 15)were conducted after treatment with the ISIS oligonucleotides. Thisincluded measurement plasma levels of liver metabolites, kidneymetabolites, pro-inflammatory factors, such as C-reactive protein,complement C3 and cytokines. The results indicated that treatment withthe ISIS oligonucleotides in Example 15 remained within acceptablelevels for antisense oligonucleotides and were therefore tolerable tothe monkeys. In particular, treatment with ISIS 463588 was verywell-tolerated in this model.

Pharmacokinetic studies of the three most well-tolerated ISISoligonucleotides, ISIS 463588, ISIS 463589, and ISIS 463690, was alsoperformed in the monkeys and indicated that the pharmacokinetics of allthree were optimal.

Hence, the in vivo studies, particularly in the cynomolgus monkeys,indicate that ISIS 463588, ISIS 463589, and ISIS 463690, were a morepotent oligonucleotide compared to ISIS 299005 and was also considerablymore tolerable.

Accordingly, provided herein are antisense compounds with any one ormore of the improved characteristics. In a certain embodiments, providedherein are compounds comprising a modified oligonucleotide as furtherdescribed herein targeted to or specifically hybridizable with theregion of nucleotides of SEQ ID NO: 1.

In certain embodiments, the compounds as described herein areefficacious by virtue of having at least one of an in vitro IC₅₀ of lessthan 1.5 μM, less than 1.4 μM, less than 1.3 μM, less than 1.2 μM, lessthan 1.1 μM, less than 1.0 μM, less than 0.9 μM, less than 0.8 μM, lessthan 0.7 μM, less than 0.6 μM when delivered to a HepG2 cell line usingelectroporation as described in Example 8. In certain embodiments, thecompounds as described herein are efficacious in vivo, as demonstratedby decreasing the levels of FGFR4 mRNA by 60%, 65%, 70%, 75% or 80%. Infurther embodiments, the compounds are efficacious in vivo, asdemonstrated by increasing the levels of FGF15 and FGF19 mRNA andprotein by 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or1000%. In other embodiments, the compounds are efficacious in vivo, asdemonstrated by decreasing plasma levels of leptin by 30%, 35%, or 40%.

In certain embodiments, the compounds as described herein are highlytolerable, as demonstrated by having at least one of an increase an ALTor AST value of no more than 4 fold, 3 fold, or 2 fold over salinetreated animals; or an increase in liver, spleen or kidney weight of nomore than 30%, 20%, 15%, 12%, 10%, 5% or 2%.

EXAMPLES Non-Limiting Disclosure and Incorporation by Reference

While certain compounds, compositions and methods described herein havebeen described with specificity in accordance with certain embodiments,the following examples serve only to illustrate the compounds describedherein and are not intended to limit the same. Each of the referencesrecited in the present application is incorporated herein by referencein its entirety.

Example 1 Antisense Inhibition of Human Fibroblast Growth FactorReceptor (FGFR4) in HepG2 Cells

Antisense oligonucleotides were designed targeting a FGFR4 nucleic acidand were tested for their effects on FGFR4 mRNA in vitro. Cultured HepG2cells at a density of 20,000 cells per well were transfected usingelectroporation with 4,500 nM antisense oligonucleotide. After atreatment period of approximately 24 hours, RNA was isolated from thecells and FGFR4 mRNA levels were measured by quantitative real-time PCR.Human primer probe set RTS3232 (forward sequence TCATCAACGGCAGCAGCTT,designated herein as SEQ ID NO: 327; reverse sequenceAGCTATTGATGTCTGCAGTCTTTAGG, designated herein as SEQ ID NO: 328; probesequence AGCCGACGGTTTCCCCTATGTGCA, designated herein as SEQ ID NO: 329)was used to measure mRNA levels. FGFR4 mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN®. Results arepresented as percent inhibition of FGFR4, relative to untreated controlcells. A total of 458 oligonucleotides were tested. Only thoseoligonucleotides demonstrating greater than 65% inhibition in vitro orwhich were used in subsequent assays are shown in Table 1.

Some of the antisense oligonucleotides were also tested with anadditional primer probe set RTS1325 (forward sequenceTTGCTGTGCCGTGTCCAA, designated herein as SEQ ID NO: 330; reversesequence TCCAAGAAGCCGAGCAGAAC, designated herein as SEQ ID NO: 331;probe sequence AGCTGCCGTGCCTGTGTCCTGAT, designated herein as SEQ ID NO:332). ‘n/a.’ indicates that particular antisense oligonucleotide was nottested with RTS1325.

The newly designed chimeric antisense oligonucleotides in Table 1 weredesigned as 5-10-5 MOE gapmers. The gapmers are 20 nucleosides inlength, wherein the central gap segment comprises of ten2′-deoxynucleosides and is flanked by wing segments on the 5′ and 3′directions comprising five nucleosides each. Each nucleotide in the 5′wing segment and each nucleotide in the 3′ wing segment has a 2′-MOEmodification. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages. All cytosine residues throughout eachgapmer are 5-methylcytosines. “Start site” indicates the 5′-mostnucleoside to which the gapmer is targeted in the human gene sequence.“Stop site” indicates the 3′-most nucleoside to which the gapmer istargeted in the human gene sequence. Each gapmer listed in Table 1 istargeted to the human FGFR4 mRNA, designated herein as SEQ ID NO: 1(GENBANK Accession No. NM_(—)002011.3).

TABLE 1 Inhibition of human FGFR4 mRNA levels by chimeric antisenseoligonucleotides targeted to SEQ ID NO: 1 % % SEQ Start Stop ISISinhibition inhibition ID Site Site Sequence No (RTS3232) (RTS1325) NO192 211 GGCACACTCAGCAGGACCCC 299005 85 n/a 7 304 323AGGCTGCCCAAGGGCTACTG 299010 65 n/a 8 597 616 GTCCAGTAGGGTGCTTGCTG 29901868 n/a 9 727 746 CCCATGAAAGGCCTGTCCAT 299022 68 n/a 10 757 776GCGCAGCCGAATGCCTCCAA 299024 68 65 11 785 804 TCTCCATCACGAGACTCCAG 29902565 59 12 969 988 TACACCTTGCACAGCAGCTC 299028 68 66 13 1027 1046GCTGCTGCCGTTGATGACGA 299029 91 61 14 1032 1051 CCGAAGCTGCTGCCGTTGAT299030 72 19 15 191 210 GCACACTCAGCAGGACCCCC 463588 87 n/a 16 193 212AGGCACACTCAGCAGGACCC 463589 83 n/a 17 194 213 CAGGCACACTCAGCAGGACC463590 72 n/a 18 196 215 CCCAGGCACACTCAGCAGGA 463592 73 n/a 19 197 216GCCCAGGCACACTCAGCAGG 463593 71 n/a 20 198 217 GGCCCAGGCACACTCAGCAG463594 69 n/a 21 200 219 GAGGCCCAGGCACACTCAGC 463596 78 n/a 22 202 221TGGAGGCCCAGGCACACTCA 463598 72 n/a 23 203 222 CTGGAGGCCCAGGCACACTC463599 78 n/a 24 205 224 GACTGGAGGCCCAGGCACAC 463601 69 n/a 25 287 306CTGTCAGCTCCTGCTCTTGC 463625 65 n/a 26 290 309 CTACTGTCAGCTCCTGCTCT463627 74 n/a 27 291 310 GCTACTGTCAGCTCCTGCTC 463628 82 n/a 28 292 311GGCTACTGTCAGCTCCTGCT 463629 93 n/a 29 293 312 GGGCTACTGTCAGCTCCTGC463630 75 n/a 30 299 318 GCCCAAGGGCTACTGTCAGC 463636 69 n/a 31 309 328CGCACAGGCTGCCCAAGGGC 463645 75 n/a 32 332 351 GCTCAGCCCGCCCACAGCAC463648 81 n/a 33 338 357 CACCACGCTCAGCCCGCCCA 463654 77 n/a 34 339 358CCACCACGCTCAGCCCGCCC 463655 73 n/a 35 340 359 GCCACCACGCTCAGCCCGCC463656 69 n/a 36 341 360 GGCCACCACGCTCAGCCCGC 463657 65 n/a 37 347 366ACCAGTGGCCACCACGCTCA 463670 73 n/a 38 349 368 GTACCAGTGGCCACCACGCT463672 81 n/a 39 350 369 TGTACCAGTGGCCACCACGC 463673 69 n/a 40 355 374CTCCTTGTACCAGTGGCCAC 463677 67 n/a 41 356 375 CCTCCTTGTACCAGTGGCCA463678 66 n/a 42 357 376 CCCTCCTTGTACCAGTGGCC 463679 76 n/a 43 368 387CCAGGCGACTGCCCTCCTTG 463689 76 n/a 44 369 388 GCCAGGCGACTGCCCTCCTT463690 85 n/a 45 370 389 TGCCAGGCGACTGCCCTCCT 463691 78 n/a 46 371 390GTGCCAGGCGACTGCCCTCC 463692 81 n/a 47 372 391 GGTGCCAGGCGACTGCCCTC463693 70 n/a 48 388 407 CCGTACACGGCCAGCAGGTG 463708 80 n/a 49 389 408CCCGTACACGGCCAGCAGGT 463709 85 n/a 50 392 411 AGCCCCGTACACGGCCAGCA463712 73 n/a 51 397 416 CCTCCAGCCCCGTACACGGC 463717 66 n/a 52 398 417CCCTCCAGCCCCGTACACGG 463718 66 n/a 53 404 423 GGCGGCCCCTCCAGCCCCGT463724 70 n/a 54 414 433 GCAATCTCTAGGCGGCCCCT 463733 65 n/a 55 415 434GGCAATCTCTAGGCGGCCCC 463734 69 n/a 56 416 435 TGGCAATCTCTAGGCGGCCC463735 67 n/a 57 431 450 CCTCAGGTAGGAAGCTGGCA 463750 56 n/a 58 432 451TCCTCAGGTAGGAAGCTGGC 463751 76 n/a 59 443 462 AGCGGCCAGCATCCTCAGGT463762 58 n/a 60 444 463 TAGCGGCCAGCATCCTCAGG 463763 77 n/a 61 599 618GTGTCCAGTAGGGTGCTTGC 463770 66 n/a 62 601 620 GTGTGTCCAGTAGGGTGCTT463771 32 n/a 63 624 643 AGTTTCTTCTCCATGCGCTG 463774 72 n/a 64 717 736GCCTGTCCATCCTTAAGCCA 463791 68 n/a 65 732 751 TTCTCCCCATGAAAGGCCTG463805 65 n/a 66 734 753 GGTTCTCCCCATGAAAGGCC 463807 60 n/a 67 784 803CTCCATCACGAGACTCCAGT 463832 65 76 68 787 806 GCTCTCCATCACGAGACTCC 46383478 59 69 788 807 CGCTCTCCATCACGAGACTC 463835 78 67 70 789 808ACGCTCTCCATCACGAGACT 463836 69 66 71 790 809 CACGCTCTCCATCACGAGAC 46383780 75 72 791 810 CCACGCTCTCCATCACGAGA 463838 76 67 73 968 987ACACCTTGCACAGCAGCTCC 463860 66 67 74 970 989 GTACACCTTGCACAGCAGCT 46386176 74 75 1021 1040 GCCGTTGATGACGATGTGCT 463871 65 46 76 1024 1043GCTGCCGTTGATGACGATGT 463874 77 52 77 1025 1044 TGCTGCCGTTGATGACGATG463875 78 42 78 1026 1045 CTGCTGCCGTTGATGACGAT 463876 78 10 79 1028 1047AGCTGCTGCCGTTGATGACG 463877 90 54 80 1029 1048 AAGCTGCTGCCGTTGATGAC463878 73 22 81 1031 1050 CGAAGCTGCTGCCGTTGATG 463880 74 3 82 1084 1103GCTATTGATGTCTGCAGTCT 463882 76 67 83 1085 1104 AGCTATTGATGTCTGCAGTC463883 68 56 84 1086 1105 GAGCTATTGATGTCTGCAGT 463884 75 61 85 1097 1116CCTCCACCTCTGAGCTATTG 463893 74 73 86 1098 1117 ACCTCCACCTCTGAGCTATT463894 71 71 87 1099 1118 GACCTCCACCTCTGAGCTAT 463906 66 55 88 1100 1119GGACCTCCACCTCTGAGCTA 463907 77 90 89 1101 1120 AGGACCTCCACCTCTGAGCT463908 89 47 90 1102 1121 CAGGACCTCCACCTCTGAGC 463909 89 74 91 1103 1122ACAGGACCTCCACCTCTGAG 463910 79 55 92 1105 1124 GTACAGGACCTCCACCTCTG463912 69 75 93 1106 1125 GGTACAGGACCTCCACCTCT 463913 71 73 94 1111 1130CCGCAGGTACAGGACCTCCA 463918 67 72 95 1112 1131 TCCGCAGGTACAGGACCTCC463919 65 37 96 1115 1134 CGTTCCGCAGGTACAGGACC 463922 70 72 97 1185 1204GCAGACTGGTAGGAGAGGCC 463937 74 82 98 1186 1205 GGCAGACTGGTAGGAGAGGC463938 66 7 99 1214 1233 GGTCCTCCTCTGGCAGCACC 463947 68 55 100 1301 1320GCAGGAGCACAGCCAAGGCC 463967 67 77 101 1329 1348 GCCTGCCCTCGATACAGCCC463994 68 n/a 102 1417 1436 GCCTGACTCCAGGGAGAACT 464002 73 n/a 103 14191438 GAGCCTGACTCCAGGGAGAA 464004 68 n/a 104 1468 1487GGAGGAGAGACGCACGCCTC 464013 77 n/a 105 1469 1488 TGGAGGAGAGACGCACGCCT464014 82 n/a 106 1470 1489 CTGGAGGAGAGACGCACGCC 464015 68 n/a 107 15021521 GACTCACGAGGCCGGCGAGC 464030 68 n/a 108 1505 1524CTAGACTCACGAGGCCGGCG 464033 68 n/a 109 1558 1577 CCCAAGCACCAGCCTGTCCC464037 67 n/a 110 1559 1578 TCCCAAGCACCAGCCTGTCC 464038 79 n/a 111 15621581 GCTTCCCAAGCACCAGCCTG 464041 75 n/a 112 1564 1583GGGCTTCCCAAGCACCAGCC 464043 74 n/a 113 1616 1635 CCATGCCAAAGGCCTCTGCA464046 65 n/a 114 1618 1637 GTCCATGCCAAAGGCCTCTG 464048 68 n/a 115 16191638 GGTCCATGCCAAAGGCCTCT 464049 73 n/a 116

Example 2 Dose-Dependent Antisense Inhibition of Human FGFR4 in HepG2Cells

Gapmers from Example 1 exhibiting significant in vitro inhibition ofhuman FGFR4 were tested at various doses in HepG2 cells. Cells wereplated at a density of 20,000 cells per well and transfected usingelectroporation with 0.6 nM, 1.3 nM, 2.5 nM, 5.0 nM, and 10.0 μMconcentrations of antisense oligonucleotide, as specified in Table 2.After a treatment period of approximately 16 hours, RNA was isolatedfrom the cells and FGFR4 mRNA levels were measured by quantitativereal-time PCR. Human FGFR4 primer probe set RTS3232 was used to measuremRNA levels. FGFR4 mRNA levels were adjusted according to total RNAcontent, as measured by RIBOGREEN®. Results are presented as percentinhibition of FGFR4, relative to untreated control cells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotideis also presented in Table 2 and was calculated by plotting theconcentrations of oligonucleotides used versus the percent inhibition ofFGFR4 mRNA expression achieved at each concentration, and noting theconcentration of oligonucleotide at which 50% inhibition of FGFR4 mRNAexpression was achieved compared to the control. As illustrated in Table2, FGFR4 mRNA levels were significantly reduced in a dose-dependentmanner in antisense oligonucleotide treated cells.

TABLE 2 Dose-dependent antisense inhibition of human FGFR4 in HepG2cells using electroporation 0.6 1.3 2.5 5.0 10.0 IC₅₀ ISIS No μM μM μMμM μM (μM) 299005 45 63 77 92 95 0.7 463588 43 66 86 90 97 0.6 463589 4167 85 92 95 0.6 463628 55 68 87 94 92 0.3 463629 25 40 63 76 91 1.8463648 36 51 71 85 96 1.1 463672 19 46 74 90 96 1.5 463690 30 66 86 9497 0.9 463691 31 50 78 89 96 1.1 463692 33 56 75 90 94 1.1 463708 11 4563 77 94 1.9 463709 35 50 73 86 96 1.1 463750 24 42 54 80 93 1.8 46376257 76 90 95 98 <0.6 463771 53 44 66 83 88 1.4 463807 13 36 56 87 96 2.0463834 32 44 68 90 97 1.3 463835 37 59 82 91 97 0.9 463837 28 61 77 9297 1.1 463838 29 50 72 88 95 1.3 463861 44 52 78 90 97 0.8 463893 29 3365 84 95 1.6 464013 27 34 50 75 86 2.1 464014 16 33 55 78 90 2.1 46403837 55 74 90 96 1.0

Example 3 Antisense Inhibition of Human Fibroblast Growth FactorReceptor (FGFR4) in HepG2 Cells

Additional antisense oligonucleotides were designed targeting a FGFR4nucleic acid and were tested for their effects on FGFR4 mRNA in vitro.Some of the antisense oligonucleotides described in Example 1 were alsoincluded in the assay for comparison. Cultured HepG2 cells at a densityof 20,000 cells per well were transfected using electroporation with4,500 nM antisense oligonucleotide. After a treatment period ofapproximately 24 hours, RNA was isolated from the cells and FGFR4 mRNAlevels were measured by quantitative real-time PCR. Human primer probeset RTS3232 was used to measure mRNA levels. FGFR4 mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN®.Results are presented as percent inhibition of FGFR4, relative tountreated control cells. A total of 772 oligonucleotides were tested.Only those oligonucleotides demonstrating greater than 65% inhibitionare shown in Tables 3 and 4.

The newly designed chimeric antisense oligonucleotides in Table 3 weredesigned as 5-10-5 MOE gapmers. The gapmers are 20 nucleosides inlength, wherein the central gap segment comprises of ten2′-deoxynucleosides and is flanked by wing segments on the 5′ and 3′directions comprising five nucleosides each. Each nucleotide in the 5′wing segment and each nucleotide in the 3′ wing segment has a 2′-MOEmodification. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages. All cytosine residues throughout eachgapmer are 5-methylcytosines. “Start site” indicates the 5′-mostnucleoside to which the gapmer is targeted in the human gene sequence.“Stop site” indicates the 3′-most nucleoside to which the gapmer istargeted in the human gene sequence.

Each gapmer listed in Table 3 is targeted to either the human FGFR4mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No.NM_(—)002011.3) or the human FGFR4 genomic sequence, designated hereinas SEQ ID NO: 2 (GENBANK Accession No: NT_(—)023133.11 truncated fromnucleosides 21323018 to 21335213), or both. Some of the antisenseoligonucleotides were designed to target variant gene sequences and arelisted in Table 4. Each gapmer in Table 4 is listed to either SEQ ID NO:3 (GENBANK Accession No. AB209631.1)

TABLE 3 Inhibition of human FGFR4 mRNA levels by chimeric antisenseoligonucleotides targeted to SEQ ID NO: 1 and SEQ ID NO: 2 Start StopStart Stop Site on Site on Site on Site on SEQ SEQ SEQ SEQ SEQ ID IDISIS % ID ID ID NO: 1 NO: 1 No Sequence inhibition NO: 2 NO: 2 NO 160179 299004 CAGCAGCCGCATCTCCTTCT 88 3165 3184 117 2497 2516 299055GCTGAAGACAGAATCGCTGG 65 11167 11186 118 292 311 463629GGCTACTGTCAGCTCCTGCT 87 3993 4012 29 2325 2344 464138CAGCACTCACGCATCAGCCC 72 10866 10885 119 2326 2345 464139CCAGCACTCACGCATCAGCC 75 10867 10886 120 2437 2456 464167GGGTCCGAAGGTCAGGCGGA 68 11107 11126 121 2438 2457 464168AGGGTCCGAAGGTCAGGCGG 70 11108 11127 122 2440 2459 464170ATAGGGTCCGAAGGTCAGGC 67 11110 11129 123 2443 2462 464173GGAATAGGGTCCGAAGGTCA 69 11113 11132 124 2582 2601 464181GTGCCTGCACAGCCTTGAGC 66 11252 11271 125 2812 2831 464203TCTCCAGCCAGGCTCAGCCA 72 11482 11501 126 2816 2835 464207CAGCTCTCCAGCCAGGCTCA 72 11486 11505 127 2817 2836 464208GCAGCTCTCCAGCCAGGCTC 78 11487 11506 128 2818 2837 464209AGCAGCTCTCCAGCCAGGCT 79 11488 11507 129 2819 2838 464210TAGCAGCTCTCCAGCCAGGC 70 11489 11508 130 2822 2841 464213GCATAGCAGCTCTCCAGCCA 82 11492 11511 131 2823 2842 464214AGCATAGCAGCTCTCCAGCC 85 11493 11512 132 2824 2843 464215TAGCATAGCAGCTCTCCAGC 84 11494 11513 133 2825 2844 464216TTAGCATAGCAGCTCTCCAG 72 11495 11514 134 2951 2970 464222CCAGCTTCTCTGGGCTCAGG 88 11621 11640 135 2952 2971 464223TCCAGCTTCTCTGGGCTCAG 86 11622 11641 136 2953 2972 464224TTCCAGCTTCTCTGGGCTCA 81 11623 11642 137 2954 2973 464225CTTCCAGCTTCTCTGGGCTC 82 11624 11643 138 2955 2974 464226GCTTCCAGCTTCTCTGGGCT 79 11625 11644 139 2956 2975 464227GGCTTCCAGCTTCTCTGGGC 87 11626 11645 140 2981 3000 464228ACGCCATTTGCTCCTGTTTT 89 11651 11670 141 n/a n/a 464238TGCGAATCAATGGGTCCCGA 73 908 927 142 n/a n/a 464239 GGTGCGAATCAATGGGTCCC67 910 929 143 n/a n/a 464254 CCGCCGGCGCGAAGACAGCC 66 984 1003 144 n/an/a 464258 CATCTCTGCCGCCGGCGCGA 71 992 1011 145 n/a n/a 464266CTGACCGCTGACCGACCACC 76 1138 1157 146 n/a n/a 464268GCTGCTGACCGCTGACCGAC 73 1142 1161 147 n/a n/a 464269CTGCCCTGATATCAGAGTCC 65 1180 1199 148 n/a n/a 464270GGCTGCCCTGATATCAGAGT 65 1182 1201 149 n/a n/a 464278CTCAGATACTGCTGTCTCTG 71 1345 1364 150 n/a n/a 464280TGCCCATCCCTCTGTGCCCC 72 1386 1405 151 n/a n/a 464284TGCTCTCTTGCCCATCCCTC 82 1394 1413 152 n/a n/a 464285CTCTTTGGTCACACCGTCTG 82 1461 1480 153 n/a n/a 464286ATCTCTTTGGTCACACCGTC 90 1463 1482 154 n/a n/a 464287CTATCTCTTTGGTCACACCG 82 1465 1484 155 n/a n/a 464288GCCTATCTCTTTGGTCACAC 88 1467 1486 156 n/a n/a 464290CGCTGCCTATCTCTTTGGTC 70 1471 1490 157 n/a n/a 464291AGCTTGCAAGCCCTTAATGG 70 1542 1561 158 n/a n/a 464292CCAGCTTGCAAGCCCTTAAT 69 1544 1563 159 n/a n/a 464298ACCTTCATCTTCCAGCAGAG 80 1941 1960 160 n/a n/a 464299CAACCTTCATCTTCCAGCAG 76 1943 1962 161 n/a n/a 464300TTCAACCTTCATCTTCCAGC 81 1945 1964 162 n/a n/a 464308CAGCTTTGCTCAGCCCAGCA 90 3325 3344 163 n/a n/a 464309TCCAGCTTTGCTCAGCCCAG 87 3327 3346 164 n/a n/a 464310TTTCCAGCTTTGCTCAGCCC 78 3329 3348 165 n/a n/a 464311CCTTTCCAGCTTTGCTCAGC 78 3331 3350 166 n/a n/a 464333CCAGGTCCACAGTCCAGGGC 75 4799 4818 167 n/a n/a 464342ACTTGCCAGAGAGTAGCAGA 66 4836 4855 168 n/a n/a 464425GCCATAGCACCTCCTCCAGG 75 7684 7703 169 n/a n/a 464428CCCAATGCCATAGCACCTCC 73 7690 7709 170 n/a n/a 464429GTCCCAATGCCATAGCACCT 70 7692 7711 171 n/a n/a 464430TAGTCCCAATGCCATAGCAC 65 7694 7713 172 n/a n/a 464433TTCTATTAGTCCCAATGCCA 69 7700 7719 173 n/a n/a 464449GTCACTTGCCAGGGTCAGGA 81 7802 7821 174 n/a n/a 464453GCTCAGAAGTCACTTGCCAG 68 7810 7829 175 n/a n/a 464568GTCCATCTGGCTTCCCCTGC 68 2031 2050 176 n/a n/a 464569CAGTCCATCTGGCTTCCCCT 68 2033 2052 177 n/a n/a 464575CCACTCCACTTCCAGTCCAT 65 2045 2064 178 n/a n/a 464576TGCCACTCCACTTCCAGTCC 68 2047 2066 179 n/a n/a 464579GGTCACTGCCACTCCACTTC 78 2053 2072 180 n/a n/a 464581CCTTGGTCACTGCCACTCCA 68 2057 2076 181 n/a n/a 464582GGAAGCCTATCACACCTCCT 67 2080 2099 182 n/a n/a 464584GTGTCTCTGGATCTACCCTG 71 2104 2123 183 n/a n/a 464585TGGTGTCTCTGGATCTACCC 74 2106 2125 184 n/a n/a 464586ACTGGTGTCTCTGGATCTAC 72 2108 2127 185 n/a n/a 464587GCACTGGTGTCTCTGGATCT 83 2110 2129 186 n/a n/a 464588TGGCACTGGTGTCTCTGGAT 88 2112 2131 187 n/a n/a 464589GGTGGCACTGGTGTCTCTGG 88 2114 2133 188 n/a n/a 464590TGGGTGGCACTGGTGTCTCT 74 2116 2135 189 n/a n/a 464591TATGGGTGGCACTGGTGTCT 74 2118 2137 190 n/a n/a 464593GGCCTATGGGTGGCACTGGT 68 2122 2141 191 n/a n/a 464617GTCAGGCTGTGATGTACACA 69 2261 2280 192 n/a n/a 464622TGCTGTTACTGTCAGGCTGT 73 2271 2290 193 n/a n/a 464623GCCAGTCACCTCTGGTTCGG 68 2292 2311 194 n/a n/a 464657AGCAGTTTTGGGATTCTTTT 72 2838 2857 195 n/a n/a 464658AAAGCAGTTTTGGGATTCTT 67 2840 2859 196 n/a n/a 464677TCCAAGTCCCTGGCCAGGCT 65 2993 3012 197 n/a n/a 464682ATCCTTTCCAGCTTTGCTCA 78 3333 3352 198 n/a n/a 464683GGATCCTTTCCAGCTTTGCT 90 3335 3354 199 n/a n/a 464684AAGGATCCTTTCCAGCTTTG 72 3337 3356 200 n/a n/a 464685GCAAGGATCCTTTCCAGCTT 88 3339 3358 201 n/a n/a 464686GGGCAAGGATCCTTTCCAGC 82 3341 3360 202 n/a n/a 464687CTGGGCAAGGATCCTTTCCA 71 3343 3362 203 n/a n/a 464688GCCTGGGCAAGGATCCTTTC 69 3345 3364 204 n/a n/a 464689GTGGTTGAGCCCTGCCCTGC 67 3380 3399 205 n/a n/a 464692GTCTCAGTGGTTGAGCCCTG 71 3386 3405 206 n/a n/a 464696CTGACTGAGTCTCAGTGGTT 82 3394 3413 207 n/a n/a 464698GGCACTGACTGAGTCTCAGT 84 3398 3417 208 n/a n/a 464699CAGGCACTGACTGAGTCTCA 79 3400 3419 209 n/a n/a 464701AAGCCAGGCACTGACTGAGT 72 3404 3423 210 n/a n/a 464703CTGGAAGCCAGGCACTGACT 70 3408 3427 211 n/a n/a 464705GCTTGCTGGAAGCCAGGCAC 67 3413 3432 212 n/a n/a 464706ATGCTTGCTGGAAGCCAGGC 80 3415 3434 213 n/a n/a 464707GTCCTCTCTCGCAGACACAG 84 3445 3464 214 n/a n/a 464708CAGTCCTCTCTCGCAGACAC 86 3447 3466 215 n/a n/a 464709GCCAGTCCTCTCTCGCAGAC 86 3449 3468 216 n/a n/a 464710AGGCCAGTCCTCTCTCGCAG 90 3451 3470 217 n/a n/a 464711GAGCTCACCACCAGCTCTGC 70 3499 3518 218 n/a n/a 464716GCTGCCTGGACCTCCTAGGT 90 3571 3590 219 n/a n/a 464717ATGCTGCCTGGACCTCCTAG 85 3573 3592 220 n/a n/a 464718ACATGCTGCCTGGACCTCCT 89 3575 3594 221 n/a n/a 464719ACACATGCTGCCTGGACCTC 73 3577 3596 222 n/a n/a 464720CCACACATGCTGCCTGGACC 88 3579 3598 223 n/a n/a 464726GCAAATGCCACACTCTTGGG 67 3770 3789 224 n/a n/a 464727GGGCAAATGCCACACTCTTG 78 3772 3791 225 n/a n/a 464728CAGGGCAAATGCCACACTCT 71 3774 3793 226 n/a n/a 464729CCCAGGGCAAATGCCACACT 87 3776 3795 227 n/a n/a 464730CACCCAGGGCAAATGCCACA 78 3778 3797 228 n/a n/a 464732GCCACACCCAGGGCAAATGC 87 3782 3801 229 n/a n/a 464734GGATGCCACACCCAGGGCAA 66 3786 3805 230 n/a n/a 464735GCGGATGCCACACCCAGGGC 87 3788 3807 231 n/a n/a 464736CTGCGGATGCCACACCCAGG 67 3790 3809 232 n/a n/a 464740GCCACATGCTGCGGATGCCA 88 3798 3817 233 n/a n/a 464800GGACTTCCCACCAACTGCCT 71 3122 3141 234 n/a n/a 464801GCTGGACTTCCCACCAACTG 77 3125 3144 235

TABLE 4 Inhibition of human FGFR4 mRNA levels bychimeric antisense oligonucleotides targeted to SEQ ID NO: 3 TargetStart ISIS  % SEQ ID Site Sequence No inhibition NO 1502CAAGGAGCTCACCACCAGCT 464713 83 236 1504 GGCAAGGAGCTCACCACCAG 464714 76237 1506 CAGGCAAGGAGCTCACCACC 464715 69 238

Example 4 Dose-Dependent Antisense Inhibition of Human FGFR4 in HepG2Cells

Gapmers from Example 3 which caused significant inhibition of FGFR4 mRNAwere further tested at various doses in HepG2 cells. Cells were platedat a density of 20,000 cells per well and transfected usingelectroporation with 0.6 μM, 1.3 μM, 2.5 μM, 5.0 μM, and 10.0 μMconcentrations of antisense oligonucleotide, as specified in Table 5.After a treatment period of approximately 16 hours, RNA was isolatedfrom the cells and FGFR4 mRNA levels were measured by quantitativereal-time PCR. Human FGFR4 primer probe set RTS3232 was used to measuremRNA levels. FGFR4 mRNA levels were adjusted according to total RNAcontent, as measured by RIBOGREEN®. Results are presented as percentinhibition of FGFR4, relative to untreated control cells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotideis also presented in Table 5. As illustrated in Table 5, FGFR4 mRNAlevels were significantly reduced in a dose-dependent manner inantisense oligonucleotide treated cells.

TABLE 5 Dose-dependent antisense inhibition of human FGFR4 in HepG2cells using electroporation 0.6 1.3 2.5 5.0 10.0 IC₅₀ ISIS No μM μM μMμM μM (μM) 299004 20 44 73 87 96 1.5 463629 23 54 80 87 96 1.0 464138 032 57 84 91 2.3 464208 28 37 58 76 87 1.8 464209 22 30 64 79 80 2.0464213 21 40 54 79 90 1.9 464214 14 31 55 84 93 2.1 464215 35 38 67 8594 1.4 464222 29 53 73 89 93 1.2 464223 16 0 63 76 88 3.2 464225 36 4374 85 88 1.2 464227 29 56 64 86 90 1.3 464228 52 76 82 91 92 0.3 46428421 44 67 83 91 1.6 464285 27 36 57 81 93 1.9 464286 35 47 70 89 95 1.2464287 26 50 68 85 90 1.4 464288 19 49 55 83 90 1.7 464300 25 34 47 7593 2.1 464308 35 57 77 94 97 1.0 464309 4 25 65 89 95 2.1 464425 2 31 5271 81 2.7 464449 32 59 78 88 95 1.0 464587 25 52 75 88 91 1.3 464588 2674 84 93 93 1.0 464589 29 62 83 90 93 1.0 464683 10 35 50 71 90 2.4464685 14 42 42 62 88 2.6 464686 12 44 66 81 95 1.8 464696 22 43 68 8594 1.6 464698 12 10 20 44 71 5.9 464706 16 52 46 84 92 1.8 464707 26 4069 84 93 1.5 464708 18 46 57 84 94 1.7 464709 6 14 32 58 84 3.7 46471012 30 44 65 86 2.7 464713 9 28 47 78 92 2.4 464716 21 45 64 86 93 1.6464717 13 37 57 86 94 2.0 464718 22 56 80 93 97 1.2 464720 15 33 49 7792 2.2 464729 15 20 35 69 84 3.0 464732 19 55 73 85 93 1.4 464735 27 4562 89 94 1.5 464740 10 44 65 82 89 1.9 464801 17 53 56 81 92 1.7

Example 5 Dose-Dependent Antisense Inhibition of Human FGFR4 in HepG2Cells

Gapmers from the studies described above which caused significantinhibition of FGFR4 mRNA were further tested at various doses in HepG2cells. Cells were plated at a density of 20,000 cells per well andtransfected using electroporation with 0.3 μM, 0.6 μM, 1.3 μM, 2.5 μM,5.0 μM, and 10.0 μM concentrations of antisense oligonucleotide, asspecified in Table 6. After a treatment period of approximately 16hours, RNA was isolated from the cells and FGFR4 mRNA levels weremeasured by quantitative real-time PCR. Human FGFR4 primer probe setRTS3232 was used to measure mRNA levels. FGFR4 mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN®. Results arepresented as percent inhibition of FGFR4, relative to untreated controlcells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotideis also presented in Table 6. As illustrated in Table 6, FGFR4 mRNAlevels were significantly reduced in a dose-dependent manner inantisense oligonucleotide treated cells.

TABLE 6 Dose-dependent antisense inhibition of human FGFR4 in HepG2cells using electroporation 0.3 0.6 1.3 2.5 5.0 10.0 IC₅₀ ISIS No μM μMμM μM μM μM (μM) 299004 0 20 14 49 70 89 2.5 299005 7 25 52 76 92 96 1.3463588 26 22 43 84 94 98 1.3 463589 13 24 52 74 92 95 1.3 463628 27 4557 76 94 95 0.8 463629 24 36 67 85 93 96 0.9 463648 14 21 38 54 75 901.9 463672 8 28 41 57 86 95 1.6 463690 22 17 59 74 91 97 1.3 463691 1024 45 60 86 87 1.6 463692 0 10 33 56 76 92 2.2 463709 12 22 36 66 85 951.6 463762 0 22 16 29 0 84 >10.0 463771 0 29 38 49 66 89 2.2 463834 1424 43 52 79 94 1.7 463835 18 35 40 58 82 94 1.4 463837 8 22 53 73 89 971.4 463838 12 23 44 56 77 91 1.7 463861 25 41 41 61 76 90 1.3 463907 025 51 68 84 95 1.6 463909 19 39 54 82 93 97 1.0 464038 8 22 36 44 72 892.2

Example 6 Dose-Dependent Antisense Inhibition of Human FGFR4 in HepG2Cells

Gapmers from the study described in Example 4 exhibiting significant invitro inhibition of FGFR4 mRNA were selected and tested at various dosesin HepG2 cells. Cells were plated at a density of 20,000 cells per welland transfected using electroporation with 0.6 μM, 1.3 μM, 2.5 μM, 5.0μM and 10.0 μM concentrations of antisense oligonucleotide, as specifiedin Table 7. After a treatment period of approximately 16 hours, RNA wasisolated from the cells and FGFR4 mRNA levels were measured byquantitative real-time PCR. Human FGFR4 primer probe set RTS3232 wasused to measure mRNA levels. FGFR4 mRNA levels were adjusted accordingto total RNA content, as measured by RIBOGREEN®. Results are presentedas percent inhibition of FGFR4, relative to untreated control cells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotideis also presented in Table 7. As illustrated in Table 7, FGFR4 mRNAlevels were significantly reduced in a dose-dependent manner inantisense oligonucleotide treated cells.

TABLE 7 Dose-dependent antisense inhibition of human FGFR4 in HepG2cells using electroporation 0.6 1.3 2.5 5.0 10.0 IC₅₀ ISIS No μM μM μMμM μM (μM) 463629 44 73 86 96 98 <0.6 464222 40 65 81 88 96 0.7 46422547 76 84 92 86 <0.6 464228 56 80 86 92 95 <0.6 464284 24 47 62 78 90 1.6464286 23 60 73 86 93 1.2 464287 19 62 69 89 91 1.3 464308 38 54 78 9096 1.0 464449 27 69 80 91 94 0.9 464587 24 68 74 88 91 1.1 464588 42 7581 88 92 <0.6 464589 36 69 78 90 92 0.8 464716 52 60 75 90 95 0.6 46471838 61 76 91 95 0.9 464732 30 39 65 85 94 1.5

Example 7 Antisense Inhibition of Human Fibroblast Growth FactorReceptor (FGFR4) in HepG2 Cells

Additional antisense oligonucleotides were designed targeting a FGFR4nucleic acid and were tested for their effects on FGFR4 mRNA in vitro.ISIS 463629 and ISIS 463762 were also included in the assay forcomparison. Cultured HepG2 cells at a density of 20,000 cells per wellwere transfected using electroporation with 4,500 nM antisenseoligonucleotide. After a treatment period of approximately 24 hours, RNAwas isolated from the cells and FGFR4 mRNA levels were measured byquantitative real-time PCR. Human primer probe set RTS3232 was used tomeasure mRNA levels. FGFR4 mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN®. Results are presented as percentinhibition of FGFR4, relative to untreated control cells. A total of 230oligonucleotides were tested. Only those oligonucleotides demonstratinggreater than 65% inhibition are shown in Table 8.

The newly designed chimeric antisense oligonucleotides in Table 8 weredesigned as 5-10-5 MOE gapmers or 3-10-4 MOE gapmers. The 5-10-5 gapmersare 20 nucleosides in length, wherein the central gap segment comprisesof ten 2′-deoxynucleosides and is flanked by wing segments on the 5′ and3′ directions comprising five nucleosides each. The 3-10-4 gapmers are17 nucleosides in length, wherein the central gap segment comprises often 2′-deoxynucleosides and is flanked by a wing segment in the 5′direction comprising three nucleosides and a wing segment in the 3′direction comprising four nucleosides. Each nucleotide in the 5′ wingsegment and each nucleotide in the 3′ wing segment has a 2′-MOEmodification. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages. All cytosine residues throughout eachgapmer are 5-methylcytosines. “Start site” indicates the 5′-mostnucleoside to which the gapmer is targeted in the human gene sequence.“Stop site” indicates the 3′-most nucleoside to which the gapmer istargeted in the human gene sequence.

Each gapmer listed in Table 8 is targeted to either the human FGFR4mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No.NM_(—)002011.3) or the human FGFR4 genomic sequence, designated hereinas SEQ ID NO: 2 (GENBANK Accession No: NT_(—)023133.11 truncated fromnucleosides 21323018 to 21335213), or SEQ ID NO: 3 (GENBANK AccessionNo. AB209631.1), or all three.

TABLE 8Inhibition of human FGFR4 mRNA levels by chimeric antisense oligo-nucleotides targeted to SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3Start Start Start Site on Site on Site on SEQ SEQ SEQ SEQ ID NO: ID NO:ID NO: ISIS % ID 1 2 3 Motif Sequence No inhibition NO 292 3993 19965-10-5 GGCTACTGTCAGCTCCTGCT 463629 93 29 118 3123 1122 5-10-5TGGACTTCCCACCAACTGCC 479530 77 239 n/a 2109 101 5-10-5CACTGGTGTCTCTGGATCTA 479532 78 240 n/a 2111 103 5-10-5GGCACTGGTGTCTCTGGATC 479533 89 241 n/a 2113 105 5-10-5GTGGCACTGGTGTCTCTGGA 479534 92 242 n/a 2115 107 5-10-5GGGTGGCACTGGTGTCTCTG 479535 88 243 n/a 3334 1333 5-10-5GATCCTTTCCAGCTTTGCTC 479536 91 244 n/a 3336 1335 5-10-5AGGATCCTTTCCAGCTTTGC 479537 84 245 n/a 3338 1337 5-10-5CAAGGATCCTTTCCAGCTTT 479538 65 246 n/a 3340 1339 5-10-5GGCAAGGATCCTTTCCAGCT 479539 88 247 n/a 3342 1341 5-10-5TGGGCAAGGATCCTTTCCAG 479540 68 248 n/a 3393 1392 5-10-5TGACTGAGTCTCAGTGGTTG 479541 71 249 n/a 3395 1394 5-10-5ACTGACTGAGTCTCAGTGGT 479542 80 250 n/a 3397 1396 5-10-5GCACTGACTGAGTCTCAGTG 479543 76 251 n/a 3399 1398 5-10-5AGGCACTGACTGAGTCTCAG 479544 77 252 n/a 3414 1413 5-10-5TGCTTGCTGGAAGCCAGGCA 479545 83 253 n/a 3446 1445 5-10-5AGTCCTCTCTCGCAGACACA 479546 88 254 n/a 3448 1447 5-10-5CCAGTCCTCTCTCGCAGACA 479547 80 255 n/a 3450 1449 5-10-5GGCCAGTCCTCTCTCGCAGA 479548 92 256 n/a 3502 1501 5-10-5AAGGAGCTCACCACCAGCTC 479549 76 257 n/a n/a 1503 5-10-5GCAAGGAGCTCACCACCAGC 479550 79 258 n/a 3570 1569 5-10-5CTGCCTGGACCTCCTAGGTC 479551 95 259 n/a 3572 1571 5-10-5TGCTGCCTGGACCTCCTAGG 479552 85 260 n/a 3574 1573 5-10-5CATGCTGCCTGGACCTCCTA 479553 80 261 n/a 3576 1575 5-10-5CACATGCTGCCTGGACCTCC 479554 80 262 n/a 3578 1577 5-10-5CACACATGCTGCCTGGACCT 479555 71 263 n/a 3580 1579 5-10-5ACCACACATGCTGCCTGGAC 479556 87 264 n/a 3775 1778 5-10-5CCAGGGCAAATGCCACACTC 479557 71 265 n/a 3777 1780 5-10-5ACCCAGGGCAAATGCCACAC 479558 83 266 n/a 3783 1786 5-10-5TGCCACACCCAGGGCAAATG 479560 67 267 n/a 3787 1790 5-10-5CGGATGCCACACCCAGGGCA 479561 70 268 n/a 3789 1792 5-10-5TGCGGATGCCACACCCAGGG 479562 78 269 n/a 3799 1802 5-10-5AGCCACATGCTGCGGATGCC 479564 71 270 n/a 1393 n/a 5-10-5GCTCTCTTGCCCATCCCTCT 479565 81 271 n/a 1462 n/a 5-10-5TCTCTTTGGTCACACCGTCT 479566 90 272 n/a 1464 n/a 5-10-5TATCTCTTTGGTCACACCGT 479567 67 273 n/a 1466 n/a 5-10-5CCTATCTCTTTGGTCACACC 479568 83 274 n/a 1468 n/a 5-10-5TGCCTATCTCTTTGGTCACA 479569 76 275 n/a 1944 n/a 5-10-5TCAACCTTCATCTTCCAGCA 479570 80 276 n/a 3324 1323 5-10-5AGCTTTGCTCAGCCCAGCAG 479572 75 277 n/a 3326 1325 5-10-5CCAGCTTTGCTCAGCCCAGC 479573 85 278 n/a 3328 1327 5-10-5TTCCAGCTTTGCTCAGCCCA 479574 79 279 n/a 7801 n/a 5-10-5TCACTTGCCAGGGTCAGGAG 479576 70 280 n/a 7803 n/a 5-10-5AGTCACTTGCCAGGGTCAGG 479577 65 281 n/a 1462 n/a 3-10-4 CTTTGGTCACACCGTCT479582 74 282 n/a 1463 n/a 3-10-4 TCTTTGGTCACACCGTC 479583 84 283 n/a1464 n/a 3-10-4 CTCTTTGGTCACACCGT 479584 82 284 n/a 1465 n/a 3-10-4TCTCTTTGGTCACACCG 479585 71 285 n/a 3326 1325 3-10-4 GCTTTGCTCAGCCCAGC479594 80 286 n/a 3328 1327 3-10-4 CAGCTTTGCTCAGCCCA 479596 81 287 n/a3329 1328 3-10-4 CCAGCTTTGCTCAGCCC 479597 78 288 161 3166 1165 3-10-4GCAGCCGCATCTCCTTC 479608 70 289 194 3199 1198 3-10-4 GCACACTCAGCAGGACC479613 72 290 195 3200 1199 3-10-4 GGCACACTCAGCAGGAC 479614 78 291 3494050 2053 3-10-4 CCAGTGGCCACCACGCT 479622 67 292 369 4070 2073 3-10-4AGGCGACTGCCCTCCTT 479625 68 293 370 4071 2074 3-10-4 CAGGCGACTGCCCTCCT479626 71 294 602 4506 2418 3-10-4 GTGTCCAGTAGGGTGCT 479641 70 295 281911489 4988 3-10-4 CAGCTCTCCAGCCAGGC 479682 71 296 2951 11621 5120 3-10-4GCTTCTCTGGGCTCAGG 479689 72 297 2952 11622 5121 3-10-4 AGCTTCTCTGGGCTCAG479690 78 298 2953 11623 5122 3-10-4 CAGCTTCTCTGGGCTCA 479691 87 2992954 11624 5123 3-10-4 CCAGCTTCTCTGGGCTC 479692 87 300 2955 11625 51243-10-4 TCCAGCTTCTCTGGGCT 479693 71 301 2956 11626 5125 3-10-4TTCCAGCTTCTCTGGGC 479694 67 302 2958 11628 5127 3-10-4 GCTTCCAGCTTCTCTGG479696 65 303 2981 11651 5150 3-10-4 CCATTTGCTCCTGTTTT 479697 73 3042982 11652 5151 3-10-4 GCCATTTGCTCCTGTTT 479698 88 305 2983 11653 51523-10-4 CGCCATTTGCTCCTGTT 479699 92 306 n/a 2113 105 3-10-4GCACTGGTGTCTCTGGA 479703 88 307 n/a 2114 106 3-10-4 GGCACTGGTGTCTCTGG479704 95 308 n/a 2115 107 3-10-4 TGGCACTGGTGTCTCTG 479705 78 309 n/a2116 108 3-10-4 GTGGCACTGGTGTCTCT 479706 90 310 n/a 3395 1394 3-10-4GACTGAGTCTCAGTGGT 479716 71 311 n/a 3415 1414 3-10-4 CTTGCTGGAAGCCAGGC479721 82 312 n/a 3416 1415 3-10-4 GCTTGCTGGAAGCCAGG 479722 82 313 n/a3446 1445 3-10-4 CCTCTCTCGCAGACACA 479725 70 314 n/a 3452 1451 3-10-4GCCAGTCCTCTCTCGCA 479731 78 315 n/a 3453 1452 3-10-4 GGCCAGTCCTCTCTCGC479732 69 316 n/a 3571 1570 3-10-4 GCCTGGACCTCCTAGGT 479736 97 317 n/a3572 1571 3-10-4 TGCCTGGACCTCCTAGG 479737 69 318 n/a 3573 1572 3-10-4CTGCCTGGACCTCCTAG 479738 76 319 n/a 3574 1573 3-10-4 GCTGCCTGGACCTCCTA479739 88 320 n/a 3575 1574 3-10-4 TGCTGCCTGGACCTCCT 479740 66 321 n/a3576 1575 3-10-4 ATGCTGCCTGGACCTCC 479741 72 322

Example 8 Dose-Dependent Antisense Inhibition of Human FGFR4 in HepG2Cells

Gapmers from Examples 5, 6 and 7 exhibiting significant in vitroinhibition of FGFR4 mRNA were further selected and tested at variousdoses in HepG2 cells. Cells were plated at a density of 20,000 cells perwell and transfected using electroporation with 0.6 μM, 1.3 μM, 2.5 μM,5.0 μM, and 10.0 μM concentrations of antisense oligonucleotide, asspecified in Table 9. After a treatment period of approximately 16hours, RNA was isolated from the cells and FGFR4 mRNA levels weremeasured by quantitative real-time PCR. Human FGFR4 primer probe setRTS3232 was used to measure mRNA levels. FGFR4 mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN®. Results arepresented as percent inhibition of FGFR4, relative to untreated controlcells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotideis also presented in Table 9. As illustrated in Table 9, FGFR4 mRNAlevels were significantly reduced in a dose-dependent manner inantisense oligonucleotide treated cells.

TABLE 9 Dose-dependent antisense inhibition of human FGFR4 in HepG2cells using electroporation 0.6 1.3 2.5 5.0 10.0 IC₅₀ ISIS No μM μM μMμM μM (μM) 299005 31 50 66 89 95 1.3 463588 25 48 70 91 97 1.4 463589 3346 69 87 96 1.3 463628 49 67 77 90 97 <0.6 463629 36 58 70 88 92 1.6463648 34 41 49 64 84 1.9 463672 16 34 68 84 94 1.8 463690 42 58 75 8897 0.8 463691 27 38 73 83 96 1.5 463692 3 39 57 76 94 2.2 463709 22 4364 82 95 1.6 463762 13 29 46 74 90 2.5 463771 40 31 51 78 91 1.7 46383423 44 55 78 93 1.8 463835 30 39 65 83 95 1.5 463837 29 43 72 87 95 1.4463838 23 40 59 77 93 1.8 463861 9 33 61 82 97 2.1 464038 19 25 42 61 882.8 464222 30 56 75 87 95 1.1 464225 40 60 79 85 90 0.8 464228 50 72 8691 94 <0.6 464284 30 52 59 84 90 1.4 464286 50 65 83 92 95 <0.6 46428724 50 67 89 92 1.4 464308 36 56 76 90 97 1.0 464449 44 73 85 93 95 <0.6464587 33 54 79 92 98 1.0 464588 53 76 89 95 95 <0.6 464589 30 66 80 9395 0.9 464716 33 41 69 86 95 1.4 464718 33 56 77 93 98 1.0 464732 27 4361 86 95 1.6 479533 68 84 89 93 95 <0.6 479534 67 74 92 95 97 <0.6479535 54 72 81 91 95 <0.6 479536 38 68 86 96 98 0.7 479539 39 52 77 9298 1.0 479546 32 70 78 91 98 0.9 479548 49 71 81 93 96 <0.6 479551 72 8291 95 97 <0.6 479556 36 63 83 90 97 0.9

Example 9 Dose-Dependent Antisense Inhibition of Human FGFR4 in HepG2Cells

Gapmers from Examples 7 and 8 exhibiting significant in vitro inhibitionof FGFR4 mRNA were further selected and tested at various doses in HepG2cells. Cells were plated at a density of 20,000 cells per well andtransfected using electroporation with 0156 μM, 0.31 μM, 0.63 μM, 1.25μM, 2.50 μM and 5.00 μM concentrations of antisense oligonucleotide, asspecified in Table 10. After a treatment period of approximately 16hours, RNA was isolated from the cells and FGFR4 mRNA levels weremeasured by quantitative real-time PCR. Human FGFR4 primer probe setRTS3232 was used to measure mRNA levels. FGFR4 mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN®. Results arepresented as percent inhibition of FGFR4, relative to untreated controlcells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotideis also presented in Table 10. As illustrated in Table 10, FGFR4 mRNAlevels were significantly reduced in a dose-dependent manner inantisense oligonucleotide treated cells.

TABLE 10 Dose-dependent antisense inhibition of human FGFR4 in HepG2cells using electroporation 0.156 0.31 0.63 1.25 2.50 5.00 IC₅₀ ISIS NoμM μM μM μM μM μM (μM) 463629 19 30 48 66 84 91 0.7 479533 18 33 63 6784 86 0.6 479534 18 25 34 63 82 86 0.9 479535 24 28 43 62 68 81 0.9479536 25 28 29 62 78 90 0.8 479539 8 16 36 48 75 88 1.1 479546 0 27 3363 77 87 1.1 479548 8 39 30 62 74 85 0.9 479551 27 44 59 80 86 89 0.4479556 16 29 32 53 71 87 1.0 479566 19 27 29 63 81 88 0.9 479584 3 22 3058 80 88 1.0 479596 4 20 32 54 71 88 1.1 479691 18 11 50 62 80 91 0.8479692 12 26 49 61 79 90 0.8 479698 23 40 57 73 87 92 0.5 479699 17 3760 76 90 93 0.5 479703 18 20 41 67 82 89 0.8 479704 31 43 66 80 90 920.4 479706 26 18 36 58 76 90 0.9 479736 36 48 71 86 93 94 0.3

Example 10 Tolerability of Antisense Oligonucleotides Targeting HumanFGFR4 in CD1 Mice

CD1® mice (Charles River, MA) are a multipurpose mice model, frequentlyutilized for safety and efficacy testing. The mice were treated withISIS antisense oligonucleotides selected from studies described aboveand evaluated for changes in the levels of various markers.

Treatment

Groups of five male CD1 mice were injected subcutaneously twice a weekfor 6 weeks with 50 mg/kg of ISIS 299005, ISIS 463588, ISIS 463589, ISIS463628, ISIS 463690, ISIS 463691, ISIS 463835, ISIS 463837, ISIS 464222,ISIS 464225, ISIS 464228, ISIS 464286, ISIS 464308, ISIS 464449, ISIS464587, ISIS 464588, ISIS 464589, ISIS 464718, ISIS 479533, ISIS 479551,ISIS 479691, ISIS 479692, ISIS 479698, ISIS 479699, ISIS 479703, ISIS479704, ISIS 479706, or ISIS 479736. One group of male CD1 mice wasinjected subcutaneously twice a week for 6 weeks with PBS. Mice wereeuthanized 48 hours after the last dose, and plasma were harvested forfurther analysis. Treatment with ISIS 479691 caused death of the miceand that ISIS oligonucleotide was therefore removed from further study.

Plasma Chemistry Markers

To evaluate the effect of ISIS oligonucleotides on metabolic function,plasma concentrations of transaminases, bilirubin, albumin, creatinine,and BUN were measured using an automated clinical chemistry analyzer(Hitachi Olympus AU400e, Melville, N.Y.). The transaminase levels areexpressed as IU/L; the bilirubin, creatinine, and BUN levels areexpressed as mg/dL; and the albumin is expressed in g/dL. The resultsare presented in Table 11. ISIS oligonucleotides that caused adversechanges in the levels of any of the plasma chemistry markers wereexcluded in further studies.

TABLE 11 ALT, AST, Bilirubin, BUN, Creatinine and Albumin levels in CD1mouse plasma at week 6 ALT AST (IU/ (IU/ Bilirubin BUN CreatinineAlbumin L) L) (mg/dL) (mg/dL) (mg/dL) (g/dL) PBS 34 59 0.2 33 0.16 3.3ISIS 299005 50 72 0.1 27 0.12 2.8 ISIS 463588 55 72 0.1 30 0.12 3.0 ISIS463589 64 79 0.2 28 0.10 2.7 ISIS 463628 48 83 0.1 27 0.13 3.0 ISIS463690 71 93 0.2 29 0.13 3.0 ISIS 463691 145 134 0.2 26 0.10 3.0 ISIS463835 159 113 0.2 26 0.11 3.0 ISIS 463837 59 78 0.1 27 0.09 2.8 ISIS464222 559 564 0.2 23 0.09 2.7 ISIS 464225 83 88 0.1 25 0.09 2.8 ISIS464228 58 93 0.1 29 0.10 2.8 ISIS 464286 139 154 0.1 21 0.05 2.8 ISIS464308 2533 1673 0.2 28 0.11 3.3 ISIS 464449 748 451 0.2 24 0.08 3.0ISIS 464587 183 159 0.1 25 0.11 3.0 ISIS 464588 256 726 0.2 21 0.03 2.0ISIS 464589 142 126 0.2 27 0.09 2.9 ISIS 464718 789 608 0.2 19 0.03 2.7ISIS 479533 61 76 0.1 22 0.09 2.9 ISIS 479551 81 104 0.2 26 0.13 3.0ISIS 479692 847 1026 0.3 26 0.10 3.1 ISIS 479698 92 133 0.2 29 0.12 2.7ISIS 479699 57 95 0.1 20 0.09 2.6 ISIS 479703 158 108 0.1 23 0.11 3.0ISIS 479704 38 56 0.2 23 0.10 3.2 ISIS 479706 700 642 0.5 26 0.12 3.1ISIS 479736 204 134 0.1 25 0.11 2.9

Example 11 Tolerability of Antisense Oligonucleotides Targeting HumanFGFR4 in Sprague-Dawley Rats

Sprague-Dawley rats are a multipurpose model used for safety andefficacy evaluations. The rats were treated with ISIS antisenseoligonucleotides from the study described in Example 10 and evaluatedfor changes in the levels of various plasma chemistry markers.

Treatment

Seven week old male Sprague-Dawley rats were maintained on a 12-hourlight/dark cycle and fed ad libitum with Purina normal rat chow, diet5001. Groups of four Sprague-Dawley rats each were injectedsubcutaneously twice a week for 4 weeks with 50 mg/kg of ISIS 299005,ISIS 463588, ISIS 463589, ISIS 463628, ISIS 463690, ISIS 463691, ISIS463835, ISIS 463837, ISIS 464222, ISIS 464225, ISIS 464228, ISIS 464286,ISIS 464308, ISIS 464449, ISIS 464587, ISIS 464718, ISIS 479533, ISIS479551, ISIS 479691, ISIS 479692, ISIS 479698, ISIS 479699, ISIS 479703,ISIS 479704, ISIS 479706, or ISIS 479736. A group of rats were injectedsubcutaneously twice a week for 4 weeks with PBS. Forty eight hoursafter the last dose, rats were euthanized and plasmas were harvested forfurther analysis.

Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function,plasma concentrations of transaminases were measured using an automatedclinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.).Plasma concentrations of ALT (alanine transaminase) and AST (aspartatetransaminase) were measured and the results are presented in Table 12,expressed in IU/L. Plasma levels of bilirubin were also measured usingthe same clinical chemistry analyzer and the results are also presentedin Table 12, expressed as mg/dL. ISIS oligonucleotides that causedadverse changes were excluded in further studies.

TABLE 12 Effect of antisense oligonucleotide treatment on ALT, AST, andBilirubin in the liver of Sprague-Dawley rats ALT AST Bilirubin (IU/L)(IU/L) (g/dL) PBS 52 206 0.15 ISIS 299005 72 387 0.16 ISIS 463588 56 3050.13 ISIS 463589 82 553 0.15 ISIS 463628 351 351 0.13 ISIS 463690 81 3670.14 ISIS 463691 83 368 0.13 ISIS 463835 90 345 0.13 ISIS 463837 67 3010.11 ISIS 464222 231 322 0.19 ISIS 464225 66 241 0.11 ISIS 464228 77 3590.57 ISIS 464286 96 207 0.11 ISIS 464308 59 295 0.12 ISIS 464449 158 5090.15 ISIS 464587 414 373 0.29 ISIS 464588 215 278 0.40 ISIS 464589 282482 0.32 ISIS 464718 280 577 0.43 ISIS 479533 391 457 0.29 ISIS 4795511360 1300 0.41 ISIS 479691 383 439 0.35 ISIS 479692 674 675 0.24 ISIS479698 354 775 0.86 ISIS 479699 145 455 0.90 ISIS 479703 779 781 0.54ISIS 479704 790 1243 0.41 ISIS 479706 570 680 0.36 ISIS 479736 499 6440.24

Kidney Function

To evaluate the effect of ISIS oligonucleotides on kidney function,plasma concentrations of blood urea nitrogen (BUN) and creatinine weremeasured using an automated clinical chemistry analyzer (Hitachi OlympusAU400e, Melville, N.Y.). Results are presented in Table 13, expressed inmg/dL.

TABLE 13 Effect of antisense oligonucleotide treatment on renal functionmarkers (mg/dL) of Sprague-Dawley rats BUN Creatinine Saline 18 0.29ISIS 299005 20 0.33 ISIS 463588 23 0.35 ISIS 463589 19 0.32 ISIS 46362819 0.33 ISIS 463690 19 0.35 ISIS 463691 18 0.34 ISIS 463835 19 0.34 ISIS463837 18 0.32 ISIS 464222 21 0.37 ISIS 464225 20 0.29 ISIS 464228 220.32 ISIS 464286 22 0.36 ISIS 464308 18 0.32 ISIS 464449 16 0.32 ISIS464587 23 0.38 ISIS 464588 23 0.27 ISIS 464589 24 0.35 ISIS 464718 220.32 ISIS 479533 28 0.31 ISIS 479551 21 0.36 ISIS 479691 29 0.36 ISIS479692 25 0.40 ISIS 479698 30 0.34 ISIS 479699 30 0.35 ISIS 479703 280.31 ISIS 479704 31 0.42 ISIS 479706 26 0.38 ISIS 479736 22 0.37

Example 12 Tolerability of Antisense Oligonucleotides Targeting HumanFGFR4 in CD/IGS Rats

CD/IGS rats are a multipurpose model used for safety and efficacyevaluations. The rats were treated with ISIS antisense oligonucleotidesselected from the study described in Examples 10 and 11 and evaluatedfor changes in the levels of various markers.

Treatment

Ten-twelve week old male CD/IGS rats were maintained on a 12-hourlight/dark cycle and fed ad libitum with Purina normal rat chow, diet5001. Groups of four CD/IGS rats each were injected subcutaneously twicea week for 12 weeks with 30 mg/kg of ISIS 299005, ISIS 463588, ISIS463589, ISIS 463690, ISIS 463691, ISIS 463835, ISIS 463837, or ISIS464225. A group of 6 rats was injected subcutaneously twice a week for12 weeks with PBS and served as a control group. Urine and blood sampleswere collected at various time points. Forty eight hours after the lastdose, body weights were taken, rats were euthanized and organs andplasma were harvested for further analysis.

Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function,plasma concentrations of various liver function markers were measured onweek 8 and week 12 using an automated clinical chemistry analyzer(Hitachi Olympus AU400e, Melville, N.Y.). Plasma concentrations of ALT(alanine transaminase) and AST (aspartate transaminase) were measuredand the results are presented in Tables 14 and 15, expressed in IU/L.Plasma levels of bilirubin and BUN were also measured using the sameclinical chemistry analyzer and the results are also presented in Tables14 and 15, expressed as mg/dL. ISIS oligonucleotides that caused adversechanges in the levels of any of the markers of liver function wereexcluded in further studies.

TABLE 14 ALT, AST, Bilirubin and BUN of CD/IGS rats on week 8 ALT ASTBilirubin BUN (IU/L) (IU/L) (mg/dL) (mg/dL) PBS 31 71 0.16 13.6 ISIS299005 60 121 0.15 17.4 ISIS 463588 57 103 0.19 18.6 ISIS 463589 46 1360.14 16.8 ISIS 463690 79 91 0.24 18.1 ISIS 463691 80 93 0.18 18.8 ISIS463835 103 118 0.18 16.6 ISIS 463837 52 101 0.14 20.7 ISIS 464225 48 2530.14 18.9

TABLE 15 ALT, AST, TBIL, and BUN levels in the liver of CD/IGS rats onweek 12 ALT AST TBIL BUN (IU/L) (IU/L) (mg/dL) (mg/dL) PBS 38 60 0.1018.2 ISIS 299005 79 150 0.10 20.0 ISIS 463588 66 146 0.13 23.3 ISIS463589 47 106 0.10 18.3 ISIS 463690 66 65 0.10 20.3 ISIS 463691 72 680.13 20.3 ISIS 463835 63 76 0.10 18.8 ISIS 463837 52 98 0.10 21.8 ISIS464225 48 260 0.10 19.0

Example 13 Pharmacokinetic Measurement of Antisense Oligonucleotide inCD1 Mouse Liver

CD1 mice were treated with ISIS 463588, ISIS 463589, and ISIS 463690,and the oligonucleotide half-life as well as the elapsed time foroligonucleotide degradation and elimination from the liver wasevaluated.

Treatment

Group of ten CD1 mice each were injected subcutaneously twice per weekfor 2 weeks (4 doses) with 50 mg/kg of ISIS 463588, ISIS 463589, or ISIS463690. Groups of five mice each from each group were sacrificed 3 daysand 56 days following the final dose. Livers were harvested foranalysis.

Measurement of Oligonucleotide Concentration

The concentration of the full-length oligonucleotide as well as thetotal oligonucleotide concentration (including the degraded form) wasmeasured. The method used is a modification of previously publishedmethods (Leeds et al., 1996; Geary et al., 1999) which consist of aphenol-chloroform (liquid-liquid) extraction followed by a solid phaseextraction. An internal standard (ISIS 355868, a 27-mer2′-O-methoxyethyl modified phosphorothioate oligonucleotide,GCGTTTGCTCTTCTTCTTGCGTTTTTT, designated herein as SEQ ID NO: 323) wasadded prior to extraction. Tissue sample concentrations were calculatedusing calibration curves, with a lower limit of quantitation (LLOQ) ofapproximately 1.14 μg/g. Half-lives were then calculated using WinNonlinsoftware (PHARSIGHT).

The results are presented in Table 16, expressed as μg/g liver tissue.The half-life of the ISIS oligonucleotides was calculated from thesevalues and is also presented in Table 17. The half-life for eacholigonucleotide was considered optimal.

TABLE 16 Oligonucleotide concentration of ISIS oligonucleotides in theliver of CD1 mice ISIS ISIS ISIS 463588 463589 463690 Day 3 157 168 196Day 56 31 17 28

TABLE 17 Half-life of ISIS oligonucleotides in the liver of CD1 miceISIS No Days 463588 22.4 463589 15.9 463690 18.7

Example 14 Measurement of Viscosity of ISIS Antisense OligonucleotidesTargeting Human FGFR4

The viscosity of the antisense oligonucleotides selected from in vivostudies described above was measured with the aim of screening outantisense oligonucleotides which have a viscosity more than 40 cP at aconcentration of 165-185 mg/mL. Oligonucleotides having a viscositygreater than 40 cP would be too viscous to be administered to anysubject.

ISIS oligonucleotides (32-35 mg) were weighed into a glass vial, 120 μL,of water was added and the antisense oligonucleotide was dissolved intosolution by heating the vial at 50° C. Part of (75 μL) the pre-heatedsample was pipetted to a micro-viscometer (Cambridge). The temperatureof the micro-viscometer was set to 25° C. and the viscosity of thesample was measured. Another part (20 μL) of the pre-heated sample waspipetted into 10 mL of water for UV reading at 260 nM at 85° C. (Cary UVinstrument). The results are presented in Table 18 and indicate thatmost of the antisense oligonucleotide solutions are optimal in theirviscosity under the criterion stated above.

TABLE 18 Viscosity and concentration of ISIS antisense oligonucleotidestargeting human FGFR4 ISIS Viscosity Concentration No. (cP) (mg/mL)299005 44 174 463588 21 189 463589 17 174 463690 12 178 463691 9 194463835 25 174 463837 8 181 464225 21 204

Example 15 Effect of ISIS Antisense Oligonucleotides Targeting HumanFGFR4 in Cynomolgus Monkeys

Chinese cynomolgus monkeys were treated with ISIS antisenseoligonucleotides selected from studies described in Examples 11-14.Antisense oligonucleotide efficacy and tolerability, as well as theirpharmacokinetic profile in the liver and kidney, were evaluated. Thehuman antisense oligonucleotides tested are also cross-reactive with therhesus genomic sequence GENBANK Accession No NW_(—)001121000.1 truncatedfrom nucleosides 3094000 to 3109000 (SEQ ID NO: 5). The greater thecomplementarity between the human oligonucleotide and the rhesus monkeysequence, the more likely the human oligonucleotide can cross-react withthe rhesus monkey sequence. The start sites of each oligonucleotide toSEQ ID NO: 5 is presented in Table 19. “Target start site” indicates the5′-most nucleotide to which the gapmer is targeted in the rhesus monkeygene sequence.

TABLE 19 Antisense oligonucleotides complementary to SEQ ID NO: 5 TargetSEQ ID Start Site Sequence ISIS No Motif NO 4366 GGCACACTCAGCAGGACCCC299005 5-10-5 7 4365 GCACACTCAGCAGGACCCCC 463588 5-10-5 16 4367AGGCACACTCAGCAGGACCC 463589 5-10-5 17 5223 GCCAGGCGACTGCCCTCCTT 4636905-10-5 45 5224 TGCCAGGCGACTGCCCTCCT 463691 5-10-5 46 6420CGCTCTCCATCACGAGACTC 463835 5-10-5 70 6422 CACGCTCTCCATCACGAGAC 4638375-10-5 72 12755 CTTCCAGCTTCTCTGGGCTC 464225 5-10-5 138

Treatment

This study was conducted at Charles River Laboratories, Nevada. Prior tothe study, the monkeys were acclimated to their designated housing forat least 13 days before the start of dosing. The animals were confirmedto have at least one negative serum antibody test to simian retrovirus(SRV), as well as to other related viruses. Tuberculosis testing wasalso done. The animals were housed individually in stainless steelcages, as specified in the USDA Animal Welfare Act (9 CFR, Parts 1, 2,and 3). The monkeys were 2.5 to 8 years old and weighed between 2.5 and4.0 kg. Eight groups of five randomly assigned male cynomolgus monkeyseach were injected subcutaneously with ISIS oligonucleotide using astainless steel dosing needle and syringe of appropriate size into anyof six dosing sites, which were used on a rotational basis. These siteswere one site each on the lateral portion of each thigh, and fourseparate sites on the back. The monkeys were dosed once every other dayat a dose of 40 mg/kg for the first week (days 1, 3, and 5) as loadingdoses, and subsequently twice a week at a maintenance dose of 20 mg/kg(40 mg/kg/week) for weeks 2-13, with ISIS 299005, ISIS 463588, ISIS463589, ISIS 463690, ISIS 463691, ISIS 463835, ISIS 463837, or ISIS464225. A control group of 8 cynomolgus monkeys was injected with PBSsubcutaneously once every other day for the first week (days 1, 3, and5), and subsequently twice a week for weeks 2-13.

During the study period, the monkeys were observed twice daily for asign of illness or distress. Veterinary care was available throughoutthe course of the study and animals were examined by the veterinarystaff, as warranted for clinical signs or other changes. At the end ofthe study period, the animals were euthanized under deep anesthesiainduced by ketamine and Beuthanasia-D®, followed by exsanguination. Allorgans were collected within 10 minutes of exsanguinations.

RNA analysis

Total RNA was extracted from liver and kidney tissue for real-time PCRanalysis and FGFR4 mRNA levels were measured using human primer probeset RTS3232 and the rhesus primer probe set rhFGFR4_LTS00467 (forwardsequence TCATCAACGGCAGCAGCTT, designated herein as SEQ ID NO: 333;reverse sequence TGAGCTATTGATGTCTGCAGTCTTC, designated herein as SEQ IDNO: 334; probe sequence CCGACGGCTTCCCCTATGTGCA, designated herein as SEQID NO: 335). Results are presented as percent inhibition of FGFR4,relative to PBS control, normalized to Cyclophilin expression levelsand/or directly with RIBOGREEN®. As shown in Tables 20 and 21, treatmentwith ISIS antisense oligonucleotides resulted in significant reductionof FGFR4 mRNA in comparison to the PBS control.

TABLE 20 % Inhibition of FGFR4 mRNA in the cynomolgus monkey liverrelative to the PBS control RTS3232/ rhFGFR4_LTS00467/ rhFGFR4_LTS00467/ISIS No RTS3232/Ribogreen Cyclophilm RIBOGREEN Cyclophilin 299005 42 3341 32 463588 71 72 68 68 463589 40 38 44 43 463690 64 67 58 61 463691 4765 41 61 463835 61 51 50 37 463837 39 34 38 29 464225 65 64 61 60

TABLE 21 % Inhibition of FGFR4 mRNA in the cynomolgus monkey kidneyrelative to the PBS control rhFGFR4_LTS00467/ ISIS No RTS3232/RibogreenRIBOGREEN 299005 60 52 463588 86 85 463589 77 71 463690 76 68 463691 7563 463835 61 52 463837 54 49 464225 87 83

FGF19 and Leptin Levels

FGF19 has been known to reduce adiposity and improve insulin sensitivityin transgenic mice (Fu, L. et al., Endocrinology. 145: 2594-2603, 2004).FGF19 is also characterized as a high affinity ligand for FGFR4 (Xie,M.-H. et al., Cytokine. 11: 729-735, 1999). Leptin is a hormone whichhas been found to be present at very high levels in obese individualscompared to normal-weight individuals (Considine, R. V. et al., N. Engl.J. Med. 334: 292-295, 1996).

FGF19 mRNA levels were measured in ileum tissue samples by RT-PCRanalysis, using the primer probe set rhFGF19_LTS00681 (forward sequenceCCCCATGTGGGAATTGATCT, designated herein as SEQ ID NO: 336; reversesequence CATGCCTGCTTCAGTCAGTTCT, designated herein as SEQ ID NO: 337;probe sequence TTTGCCCTTCCCAAACCCCTCCA, designated herein as SEQ ID NO:338). The results are presented in Table 22, expressed as percentexpression over the PBS control. The data indicates that treatment withany of the ISIS oligonucleotides enhanced the expression of FGF19.

The plasma samples of monkeys treated with ISIS 299005, ISIS 463588,ISIS 463589, and ISIS 463690 were assessed for FGF19 levels. The plasmasamples of monkeys treated with ISIS 463588 and ISIS 463690 wereassessed for leptin levels. Plasma levels of FGF19 were measuredpre-dose and on days 23, 65 and 89 using an ELISA assay kit (R&DSystems). Plasma levels of leptin measured pre-dose and on days 58 and93 using an ELISA assay kit (Alpco). Results are presented in Tables 23and 24. The data indicates that treatment with any of the ISISoligonucleotides increased FGF19 plasma levels and decreases leptinlevels. In particular, treatment with ISIS 463588 caused the highestincrease in FGF19 plasma levels compared to the PBS control as well asto the other experimental plasma samples. Treatment with ISIS 463588caused the most significant decrease in leptin levels compared to thePBS control.

TABLE 22 Ileum FGF19 mRNA levels in the cynomolgus monkey (% expressionover the PBS control) % ISIS No expression 299005 688 463588 715 463589545 463690 1032 463691 477 463835 445 463837 384 464225 370

TABLE 23 Plasma FGF19 levels in the cynomolgus monkey (pg/ml) Pre- doseDay 23 Day 65 Day 89 PBS 106 79 104 84 ISIS 299005 125 110 191 202 ISIS463588 192 146 309 401 ISIS 463589 111 117 177 151 ISIS 463690 184 154287 266

TABLE 24 Plasma leptin levels in the cynomolgus monkey (ng/ml) Pre- doseDay 58 Day 93 PBS 0.21 0.60 0.53 ISIS 463588 0.15 0.23 0.26 ISIS 4636900.27 0.32 0.36

Tolerability Studies Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function,blood samples were collected from all the study groups. The bloodsamples were collected via femoral venipuncture on day 58, 48 hrspost-dosing and processed for serum. Concentrations of variousmetabolites were measured using an automated clinical chemistry analyzer(Hitachi Olympus AU400e, Melville, N.Y.). Plasma concentrations of ALTand AST were measured and the results are presented in Table 25,expressed in IU/L. Bilirubin is also a liver function marker, wassimilarly measured and is presented in Table 25, expressed in mg/dL. Theresults indicate that treatment with ISIS 463588, as well as severalother ISIS oligonucleotides, was well tolerated in terms of the liverfunction of the monkeys.

TABLE 25 ALT, AST, and Bilirubin in cynomolgus monkey plasma (on day 58)ALT AST Bilirubin (IU/L) (IU/L) (mg/dL) PBS 47.4 40.3 0.2 ISIS 29900545.2 37.4 0.2 ISIS 463588 77.6 73.2 0.1 ISIS 463589 33.8 29.8 0.2 ISIS463690 103.6 47.6 0.2 ISIS 463691 76.2 72.4 1.8 ISIS 463835 116.2 42.00.1 ISIS 463837 121.0 43.2 0.1 ISIS 464225 81.4 40.8 0.1

Kidney Function

To evaluate the effect of ISIS oligonucleotides on kidney function,blood samples were collected from all the study groups. The bloodsamples were collected via femoral venipuncture on day 58, 48 hrspost-dosing and processed for serum. Concentrations of BUN andcreatinine were measured using an automated clinical chemistry analyzer(Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Table26, expressed in mg/dL.

The results indicate that most of the ISIS oligonucleotides did not haveany adverse effects on the kidney function. Specifically, treatment withISIS 463588 was well tolerated in terms of the kidney function of themonkeys.

TABLE 26 Plasma BUN and creatinine levels (mg/dL) in cynomolgus monkeyson day 58 BUN Creatinine PBS 28.6 0.8 ISIS 299005 24.3 0.7 ISIS 46358823.2 0.7 ISIS 463589 28.7 0.8 ISIS 463690 22.7 0.7 ISIS 463691 16.8 0.5ISIS 463835 32.2 0.8 ISIS 463837 26.7 0.7 ISIS 464225 25.8 0.6

Analysis of Markers of Inflammation

To evaluate the effect of ISIS oligonucleotides on factors involved ininflammation, blood was collected from all available animals forC-reactive protein (CRP) and complement C3 analysis, as well as formeasurement of cytokine and chemokine levels. The blood samples werecollected via femoral venipuncture on day 93, 48 hrs post-dosing andprocessed for separately for serum and plasma. Serum CRP and plasmacomplement C3 was measured using an automated clinical chemistryanalyzer (Hitachi Olympus AU400e, Melville, N.Y.). The data is presentedin Tables 27 and 28, expressed in mg/dL.

For cytokine level analyses, blood (1 mL each) was collected and thencentrifuged 3,000 rpm for 10 min at 2-8° C. Plasma samples of micetreated with ISIS 463588, ISIS 463589, and ISIS 463690 were sent toAushon Biosystems Inc. (Billerica, Mass.) for measurement of chemokineand cytokine levels. Levels of IL-6, MIP-1α, IL-8, MIP-1β, MCP-1, IL-1β,and RANTES were measured using the respective cross-reacting humanantibodies and IFN-γ and IL-1β were measured using the respectiveprimate antibodies. Measurements were taken pre-dose and on day 93. Theresults are presented in Tables 29-36.

The data indicate that most of the ISIS oligonucleotides were notpro-inflammatory. Specifically, treatment with ISIS 463588 was welltolerated in terms of being non-pro-inflammatory in the monkeys sincethere were no changes in CRP, a marker of inflammation.

TABLE 27 CRP (mg/dL) in cynomolgus monkeys Pre-dose Day 30 Day 58 Day 93PBS 2.2 3.1 2.5 4.1 ISIS 299005 1.0 1.5 1.2 1.2 ISIS 463588 2.9 5.2 3.73.8 ISIS 463589 1.8 1.9 2.2 2.4 ISIS 463690 2.2 3.1 2.1 3.6 ISIS 4636916.3 5.2 10.3 2.6 ISIS 463835 9.7 16.2 4.7 5.7 ISIS 463837 2.5 11.4 2.82.9 ISIS 464225 2.5 8.1 6.9 5.2

TABLE 28 Complement C3 (mg/dL) in cynomolgus monkeys Pre-dose Day 30 Day58 Day 93 PBS 114.3 109.1 112.5 113.3 ISIS 299005 108.3 92.1 99.6 91.4ISIS 463588 106.7 91.9 94.9 95.7 ISIS 463589 116.3 102.0 105.1 100.9ISIS 463690 113.3 89.4 85.6 78.7 ISIS 463691 123.5 89.2 70.6 97.6 ISIS463835 105.5 66.2 66.5 69.0 ISIS 463837 107.1 91.1 88.7 86.5 ISIS 464225104.7 91.9 92.7 80.1

TABLE 29 IL-6 (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 1.0 1.0ISIS 463588 0.4 0.9 ISIS 463589 0.5 2.8 ISIS 463690 1.2 10.2

TABLE 30 IL-8 (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 544 482ISIS 463588 1255 1159 ISIS 463589 424 636 ISIS 463690 719 1344

TABLE 31 MIP-1α (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 7.68.9 ISIS 463588 8.9 10.8 ISIS 463589 7.9 11.2 ISIS 463690 13.8 18.9

TABLE 32 MIP-1β (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 249229 ISIS 463588 219 211 ISIS 463589 175 196 ISIS 463690 362 478

TABLE 33 MCP-1 (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 200 275ISIS 463588 420 496 ISIS 463589 343 363 ISIS 463690 441 709

TABLE 34 IFN-γ (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 22.125.9 ISIS 463588 1.6 1.5 ISIS 463589 10.8 12.3 ISIS 463690 20.8 17.4

TABLE 35 IL-1β (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 0.090.28 ISIS 463588 0.07 0.08 ISIS 463589 0.13 0.06 ISIS 463690 0.20 0.36

TABLE 36 RANTES (pg/mL) in cynomolgus monkeys Pre-dose Day 93 PBS 4333948967 ISIS 463588 45962 51326 ISIS 463589 38382 30985 ISIS 463690 3733029209

Hematology

To evaluate any effect of ISIS oligonucleotides in cynomolgus monkeys onhematologic parameters, approximately 1.3 mL of blood was collected onday 93 from each of the available study animals in tubes containingK₂-EDTA. Samples were analyzed for red blood cell (RBC) count, whiteblood cells (WBC) count, individual white blood cell counts, such asthat of monocytes, neutrophils, lymphocytes, as well as for plateletcount, hemoglobin content and hematocrit, using an ADVIA120 hematologyanalyzer (Bayer, USA). The data is presented in Tables 37 and 38.

The data indicate that most of the ISIS oligonucleotides did not haveany adverse effects on the any hematologic parameters. Specifically,treatment with ISIS 463588 was well tolerated in terms of thehematologic parameters of the monkeys.

TABLE 37 Blood cells in cynomolgus monkeys RBC Platelets WBC Neutro-Lympho- Mono- (×10⁶/ (×10³/ (×10³/ phils cytes cytes μL) μL) μL) (/μL)(/μL) (/μL) PBS 6.1 426 13.8 3244 9637 483 ISIS 299005 6.2 348 13.8 33959378 549 ISIS 463588 6.4 331 11.7 3081 7741 387 ISIS 463589 5.7 360 12.33590 8037 413 ISIS 463690 6.1 430 13.1 2592 9451 571 ISIS 463691 5.3 49417.5 7511 8534 1144 ISIS 463835 5.5 558 12.7 3129 8374 664 ISIS 4638375.8 480 13.3 3145 9025 566 ISIS 464225 5.9 429 13.6 2994 9349 762

TABLE 38 Hematologic parameters in cynomolgus monkeys Hemoglobin HCT(g/dL) (%) PBS 14.2 45.5 ISIS 299005 13.7 44.0 ISIS 463588 13.9 45.4ISIS 463589 13.3 41.9 ISIS 463690 13.8 44.7 ISIS 463691 12.7 40.8 ISIS463835 12.3 40.0 ISIS 463837 12.8 41.7 ISIS 464225 13.1 42.8

Pharmacokinetic Studies Measurement of Oligonucleotide Concentration

The concentration of the full-length oligonucleotide as well as thetotal oligonucleotide concentration (including the degraded form) wasmeasured. The method used is a modification of previously publishedmethods (Leeds et al., 1996; Geary et al., 1999) which consist of aphenol-chloroform (liquid-liquid) extraction followed by a solid phaseextraction. An internal standard (ISIS 355868, a 27-mer2′-O-methoxyethyl modified phosphorothioate oligonucleotide,GCGTTTGCTCTTCTTCTTGCGTTTTTT, designated herein as SEQ ID NO: 323) wasadded prior to extraction. Tissue sample concentrations were calculatedusing calibration curves, with a lower limit of quantitation (LLOQ) ofapproximately 1.14 μg/g. The results are presented in Table 39,expressed as μg/g tissue. The ratio of the concentrations in the kidneyversus the liver was calculated and presented in Table 39. Treatmentwith ISIS oligonucleotides did not result in any abnormality in theratio.

TABLE 39 Full-length oligonucleotide concentration (μg/g) in the liverand kidney of cynomolgus monkey ISIS No Kidney Liver Kidney/Liver 4635881717 1033 1.7 463589 1663 1227 1.4 463690 1395 1226 1.1

Overall, the results of the study indicate that ISIS 463588 is a potentand tolerable antisense oligonucleotide for treatment of metabolicdiseases, such as diabetes, obesity, insulin resistance, and insulindeficiency.

Example 16 In Vivo Effect of Antisense Inhibition of Murine FGFR4 inDiet-Induced Obesity (DIO) Mice with Caloric Restriction

DIO mice are C57BL/6 mice fed a high fat diet starting from 6 weeks ofage and are a standard model used for assays related to studying theeffect of therapeutic agents on lowering adiposity and improving insulinsensitivity. The antisense oligonucleotide, ISIS 393250, a 5-10-5 MOEgapmer, having a sequence of 5′-GCCACATTTCCTTCCAGCTG-3 (SEQ ID NO: 324),and with a target start site of 337 on murine FGFR4 mRNA (GENBANKAccession No. BC033313.1 (SEQ ID NO: 6) was used in this assay. Theeffect of ISIS 393250 on a DIO model under caloric restriction wasevaluated.

Treatment

Male 6 week-old C57BL/6 mice (Jackson Laboratories) were fed with 58kcal % high-fat diet (Research diet D12330) ad lib for 4 months toinduce obesity. The mice were divided into 4 groups based on body weightand body fat content. The first group of mice was treated with 25 mg/kgISIS 393250 administered subcutaneously twice weekly for 6 weeks. Thesecond group of mice was treated with 25 mg/kg control oligonucleotide,ISIS 141923 (CCTTCCCTGAAGGTTCCTCC (SEQ ID NO: 325), 5-10-5 MOE gapmerwith no known murine target), administered subcutaneously twice weeklyfor 6 weeks. Two control groups of mice were treated with PBSadministered subcutaneously twice weekly for 6 weeks. After two weeks oftreatment, the oligonucleotide-treated mice and one of the PBS controlgroup mice were subjected to caloric restriction by providing 95% of theamount of food consumed daily by the FGFR4 ASO-treated mice during thefirst two weeks of treatment. The second PBS control group continued tobe fed ad libitum with the same amount of food as in the first two weeksof treatment.

Weekly body weights were measured and body compositions were monitoredat different time point with an Echo MRI Body Composition Analyzer. Themice were euthanized after 6 weeks of treatment.

RNA Analysis

RNA was extracted from the liver for RT-PCR analysis of murine FGFR4expression. The primer probe set mFGFR4_LTS00702 (forward sequenceCCCTGAGGCCAGATACACAGATAT, designated herein as SEQ ID NO: 339; reversesequence ACGGATGACTTGCCGATGATA, designated herein as SEQ ID NO: 340;probe sequence CTCACTGGTTCTGCTTGTGCTCCTGCT, designated herein as SEQ IDNO: 341) was used for analysis. The results indicated that treatmentwith ISIS 393250 reduced murine FGFR4 levels by 76%.

Body Weight and Body Composition Analysis

Weekly body weights were measured and are presented in Table 40. Bodyfat content data is presented in Table 41, expressed as percent of thecorresponding body weight. Lean body mass is presented in Table 42,expressed in grams. White adipose tissue weight was measured aftereuthanizing the mice and is presented in Table 43, expressed in grams.The data indicates calorie restriction significantly lowered body weightand total body fat content. Treatment with ISIS 393250 further loweredboth body weight and fat content, but had no effect on body lean mass.Treatment with ISIS 141923 had no effect. Hence, antisense inhibition ofFGFR4 expression has a beneficial effect on body weight and body fatcontent in subjects suffering from obesity.

TABLE 40 Weekly body weights (g) Calorie- restrict- Pre- Week Week WeekWeek Week Week ed dose 1 2 3 4 5 6 PBS No 51.7 51.1 52.1 52.6 53.1 50.653.4 PBS Yes 50.3 50.4 51.1 50.0 47.6 46.0 45.4 ISIS 141923 Yes 49.550.1 50.9 49.8 48.1 46.3 45.2 ISIS 393250 Yes 50.5 50.9 50.9 48.9 46.744.4 42.1

TABLE 41 Body fat content (% body weight) Calorie- restricted Pre-doseWeek 2 Week 4 Week 6 PBS No 39.5 39.8 40 40 PBS Yes 38.7 40.2 39.1 38.3ISIS 141923 Yes 38.9 39.1 38.1 37.7 ISIS 393250 Yes 39.4 38.6 35.3 31.3

TABLE 42 Lean body mass (g) Calorie- restricted Pre-dose Week 2 Week 4Week 6 PBS No 27.8 28.2 28.2 28.3 PBS Yes 27.3 27.5 25.7 24.5 ISIS141923 Yes 26.7 27.3 26 24.9 ISIS 393250 Yes 27.1 27.8 25.9 24.8

TABLE 43 White adipose tissue weight (g) Calorie- restricted EpididymalPeri-renal PBS No 2.5 1.1 PBS Yes 2.2 0.9 ISIS 141923 Yes 2.2 0.9 ISIS393250 Yes 1.8 0.7

Metabolic Rate and Locomotor Activity Analysis

The metabolic rate was assessed by measuring the oxygen consumption andheat production of the mice. Both parameters were measured with anindirect calorimetry system (Oxymax system, Columbus Instruments).Locomotor activity was also assessed with the same instrument. Metabolicrate and locomotor activity was assessed both in darkness, when the miceare typically more active, and in light. The results are presented inTables 44-46. The results indicate that calorie restriction reducedwhole body oxygen consumption. Treatment with ISIS 393250 prevented thisdecrease in oxygen consumption without affecting locomotor activity.Hence, antisense inhibition of FGFR4 expression in obese subjects with acalorie-restricted diet would be beneficial as it would prevent anydecline in metabolic rate in the subject.

TABLE 44 O₂ consumption (mL/kg lean tissue/hr) Calorie- restricted darklight PBS No 4275 3327 PBS Yes 4085 3259 ISIS 141923 Yes 4094 3258 ISIS393250 Yes 4268 3359

TABLE 45 Heat production (kcal/kg lean tissue/hr) Calorie- restricteddark light PBS No 19.8 15 PBS Yes 19.1 15.1 ISIS 141923 Yes 19.1 15.1ISIS 393250 Yes 19.7 15.7

TABLE 46 Locomotor activity (events/min) Calorie- restricted dark lightPBS No 16.4 1.9 PBS Yes 21.9 3.1 ISIS 141923 Yes 16.1 2.5 ISIS 393250Yes 16.2 3

Example 17 In Vivo Effect of Antisense Inhibition of Murine FGFR4 inDiet-Induced Obesity (DIO) Mice with Caloric Restriction

The effect of ISIS 446259 (TCCATTTCCTCAGAGGCCTC (SEQ ID NO: 326), 5-10-5MOE gapmer, with a target start site of 407 on GENBANK Accession No.BC033313.1 (SEQ ID NO: 6)) on DIO mice under caloric restriction wasevaluated.

Treatment

Male 6 week-old C57BL/6 mice (Jackson Laboratories) were fed with 58kcal % high-fat diet Research diet D12330) ad lib for 3.5 months toinduce obesity. The mice were divided into 4 groups based on body weightand body fat content. The first group of mice was treated with 25 mg/kgISIS 446259 administered subcutaneously twice weekly for 8 weeks. Thesecond group of mice was treated with 25 mg/kg control oligonucleotide,ISIS 141923 administered subcutaneously twice weekly for 8 weeks. Twocontrol groups of mice were treated with PBS administered subcutaneouslytwice weekly for 8 weeks. After two weeks of treatment, theoligonucleotide-treated mice and one of the PBS control group mice weresubjected to caloric restriction by providing 90% of the amount of foodconsumed daily by the FGFR4 ASO-treated mice during the first two weeksof treatment. The second PBS control group continued to be fed adlibitum with the same amount of food as in the first two weeks oftreatment.

Weekly body weights were measured and body compositions were monitoredat different time point with an Echo MRI Body Composition Analyzer. Themice were euthanized after 8 weeks of treatment.

RNA Analysis

RNA was extracted from the liver for RT-PCR analysis of murine FGFR4expression. The primer probe set mFGFR4 LTS00702 was used to analyzemRNA levels. The results indicated that treatment with ISIS 446259reduced murine FGFR4 levels by 83%.

Body Weight and Body Composition Analysis

Weekly body weights were measured and are presented in Table 47. Bodyfat content data is presented in Table 48, expressed as percent of thecorresponding body weight. Lean body mass was presented in Table 49,expressed in grams. The data indicates calorie restriction significantlylowered body weight and total body fat content. Treatment with ISIS446259 further lowered both body weight and fat content, but had noeffect on body lean mass. Treatment with ISIS 141923 had no furthereffect. Hence, antisense inhibition of FGFR4 expression has a beneficialeffect on body weight and body fat content in subjects suffering fromobesity in addition to effects seen by caloric restriction alone.

TABLE 47 Weekly body weights (g) Calorie- Week Week Week Week Weekrestricted 0 2 4 6 8 PBS No 48.7 49.9 51 53.4 52.5 PBS Yes 49.7 50.746.9 46.9 46.2 ISIS 141923 Yes 49.6 50.5 46.9 46.1 44.5 ISIS 446259 Yes49.4 49.4 45.2 43.8 39.7

TABLE 48 Body fat content (% body weight) Calorie- restricted Week 0Week 2 Week 5 Week 8 PBS No 41 43 43 42 PBS Yes 41 43 41 39 ISIS 141923Yes 40 40 37 35 ISIS 446259 Yes 41 41 35 30

TABLE 49 Lean body mass (g) Calorie- restricted Week 0 Week 2 Week 5Week 8 PBS No 26 24 26 27 PBS Yes 26 25 25 25 ISIS 141923 Yes 27 26 2526 ISIS 446259 Yes 26 25 25 25

Plasma Lipid Analysis

To evaluate the effect of ISIS oligonucleotides on cholesterol andtriglyceride metabolism, plasma levels of each were measured at the endof the treatment period. The mice were euthanized and blood wascollected via cardiac puncture. The lipid levels were measured using anautomated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville,N.Y.). Results are presented in Table 50, expressed as mg/dL. Theresults indicate that treatment with ISIS 446259 reduced bothcholesterol and triglyceride levels in the mice. Therefore, antisenseinhibition of FGFR4 had a beneficial effect on the lipid profile and maybe used to reduce adiposity in obese subjects.

TABLE 50 Cholesterol and lipid levels (mg/dL) Calorie- restrictedCholesterol Triglycerides PBS No 270 137 PBS Yes 240 128 ISIS 141923 Yes222 113 ISIS 446259 Yes 181 84

Example 18 In Vivo Effect of Antisense Inhibition of Murine FGFR4 onFGF15 Levels in DIO Mice

The effect of ISIS 393250 and ISIS 446259 on FGF15 levels in DIO micewas evaluated.

Treatment

Male 6 week-old C57BL/6 mice (Jackson Laboratories) were fed with 58kcal % high-fat diet Research diet D12330) ad lib for 3.5 months toinduce obesity. A group of C57BL/6 mice were fed normal Purina mousechow and served as the naïve control. The DIO mice were divided intogroups based on body weight and body fat content. The first group of DIOmice was treated with 25 mg/kg ISIS 393250 administered subcutaneouslytwice weekly for 4 weeks. The second group of DIO mice was treated with25 mg/kg ISIS 446259 administered subcutaneously twice weekly for 4weeks. The third group of DIO mice was treated with 25 mg/kg controloligonucleotide, ISIS 141923 administered subcutaneously twice weeklyfor 4 weeks. A control group of DIO mice was treated with PBSadministered subcutaneously twice weekly for 4 weeks. The mice wereeuthanized after 4 weeks of treatment.

FGF15 Levels

FGF15 is the rodent equivalent of FGF19 (Wright, T. J. et al., Dev.Biol. 269: 264-275, 2004), and is therefore important for the reductionof adiposity and improvement of insulin sensitivity in mice.

RNA was extracted from liver and ileum. Liver RNA was analyzed by RT-PCRanalysis for FGFR4 mRNA levels using primer probe set mFGFR4_LTS00702.Ileum RNA was analyzed by RT-PCR analysis for FGF15 levels using primerprobe set mFgf15_LTS00635 (forward sequence GACCAAAACGAACGAAATTTGTT,designated herein as SEQ ID NO: 342; reverse sequenceACGTCCTTGATGGCAATCG, designated herein as SEQ ID NO: 343; probe sequenceAATTCCGCGCGGTCGCTCTG, designated herein as SEQ ID NO: 344). The resultsare presented in Table 51 and demonstrate that treatment with eitherantisense oligonucleotide significantly decreases FGFR4 mRNA levels andalso significantly enhances FGF15 expression levels.

Plasma samples of the mice group were also analyzed at weeks 2 and 4 forFGF15 protein levels with ELISA using an anti-FGF15 antibody (Santa CruzBiotechnology Inc). The results are presented in Table 52 anddemonstrate that antisense inhibition of FGFR4 results in enhancedplasma levels of FGF15.

TABLE 51 FGFR4 and FGF15 mRNA levels relative to control Liver IleumFGFR4 (% FGF15 (% ISIS No inhibition) expression) 141923 14 92 393250 961117 446259 94 707 C57BL/6 control 0 25

TABLE 52 FGF15 plasma levels at week 2 and 4 (ng/ml) Week 2 Week 4 PBS0.13 0.13 ISIS 141923 0.12 0.14 ISIS 393250 0.69 0.96 ISIS 446259 0.180.25 C57BL/6 control 0.1 0.12

Example 19 In Vivo Effect of Antisense Inhibition of Murine FGFR4 onFGF15 Levels in C57BL/6 Mice

The effect of ISIS 393250 on FGF15 levels in C57BL/6 mice was evaluated.

Treatment

Male 6 week-old C57BL/6 mice (Jackson Laboratories) were fed normalPurina mouse chow. The mice were randomly divided into 3 groups. Thefirst group of mice was treated with 50 mg/kg ISIS 393250 administeredsubcutaneously twice weekly for 5.5 weeks. The second group of mice wastreated with 50 mg/kg control oligonucleotide, ISIS 141923 administeredsubcutaneously twice weekly for 5.5 weeks. A control group of mice wastreated with PBS administered subcutaneously twice weekly for 5.5 weeks.

FGFR4 Levels

RNA was extracted from liver and RNA was analyzed by RT-PCR analysis forFGFR4 mRNA levels using primer probe set mFGFR4_LTS00702. The resultsare presented in Table 53 and demonstrate that treatment with ISIS393250 significantly decreases FGFR4 mRNA levels

TABLE 53 FGFR4 mRNA inhibition levels (%) ISIS No % 141923 0 393250 79

FGF15 Levels

Plasma samples of the mice group were analyzed for FGF15 protein levelsusing with ELISA using an anti-FGF15 antibody (Santa Cruz BiotechnologyInc). The results are presented in Table 54 and demonstrate thatantisense inhibition of FGFR4 results in enhanced plasma levels ofFGF15.

TABLE 54 FGF15 plasma levels at day 16 ng/mL PBS 0.07 ISIS 141923 0.08ISIS 393250 0.28

Example 20 In Vivo Effect of Antisense Inhibition of Murine FGFR4 onFGF15 Levels in Ob/Ob Mice

Leptin is a hormone produced by fat that regulates appetite. Deficiencyof this hormone in both humans and in non-human animals, leads toobesity. ob/ob mice have a mutation in the leptin gene which results inobesity and hyperglycemia. As such, these mice are a useful model forthe investigation of obesity and diabetes and related conditionsprovided herein. These mice models are also useful for testingcompounds, compositions and methods designed to treat, prevent orameliorate such conditions.

In accordance with the present invention, the effects of antisenseinhibition of FGFR4 were investigated in the ob/ob mouse model ofobesity. Male 12 week old ob/ob (C57Bl/6J-Lep^(ob)/Lep^(ob)) mice werepurchased from Jackson Laboratories (Bar Harbor, Me.) and used for thecurrent study.

Treatment

The mice were divided into groups based on body weight and body fatcontent. The first group of mice was treated with 25 mg/kg ISIS 393250administered subcutaneously twice weekly for 14 weeks. The second groupof mice was treated with 25 mg/kg control oligonucleotide, ISIS 141923administered subcutaneously twice weekly for 14 weeks. A control groupof mice was treated with PBS administered subcutaneously twice weeklyfor 14 weeks.

FGFR4 Levels

RNA was extracted from liver and RNA was analyzed by RT-PCR analysis forFGFR4 mRNA levels using primer probe set mFGFR4_LTS00702. The resultsare presented in Table 55 and demonstrate that treatment with ISIS393250 significantly decreases FGFR4 mRNA levels

TABLE 55 FGFR4 mRNA inhibition levels (%) ISIS No % 141923 0 393250 89

FGF15 Levels

Plasma samples of the mice group were analyzed for FGF15 protein levelsusing with ELISA using an anti-FGF15 antibody (Santa Cruz BiotechnologyInc). The results are presented in Table 56 and demonstrate thatantisense inhibition of FGFR4 results in enhanced plasma levels ofFGF15.

TABLE 56 FGF15 plasma levels at week 4 and 8 (ng/mL) Week 4 Week 8 PBS0.5 1.2 ISIS 141923 0.8 0.5 ISIS 393250 4.2 4.2

Example 21 Effect of Antisense Inhibition of Murine FGFR4 in MonkeyPrimary Hepatocytes

The effect of antisense inhibition of FGFR4 with ISIS 299004 on fattyacid oxidation in monkey hepatocytes was evaluated. AICAR was used as apositive control.

Treatment

Primary hepatocytes purchased from APL/Lovelace In Vitro Enterprises andcultured in William E medium. The cells were seeded at a density of 1million cells per 25 ml flask. After 4-5 hrs of culture, the cells weretreated with 30 nM of ISIS 299004 or 1000 μM AICAR for 18 hrs. A controlset of cells was treated with PBS. FGFR4 levels were measured using theprimer probe set cynoFGFR4_MGB_LTS00689 (forward sequenceGCACCAGGGATGAGCTTGAC, designated herein as SEQ ID NO: 348; reversesequence CCAAGTCTCCCACTTTCCAGTT, designated herein as SEQ ID NO: 349;probe sequence AAGAGCCTGACTCCAGT, designated herein as SEQ ID NO: 350).Treatment with ISIS 299004 reduced FGFR4 levels by 83%.

For evaluation of fatty acid oxidation, the cells were placed in lowglucose media containing ^(1-14c)Oleic acid and BSA, and the cultureflasks were capped with a rubber stopper containing a hanging reservoirbucket. The cells were then incubated at 37° C. under 5% CO₂ for 1.5hrs. Following incubation, 200 μl of 1M hyamine hydroxide (a ¹⁴CO₂trapping agent) was added to the reservoir bucket and 1 ml of 10%perchloric acid solution was added to the cells. The flasks weretransferred to a 37° C. shaking incubator for 40 min. Upon completion ofthe incubation, the hanging bucket reservoir containing the hyaminehydroxide was separated from the flask and placed in scintillation fluidovernight, and read in the scintillation counter the next day.Bradford-based protein measurements were conducted on an equal number ofprimary monkey hepatocytes, by using the DC™ Biorad protein assay kit(Bearden, J. Biochem. Biophys. Acta. 533: 525. 1978). The valuesobtained from the protein readout was used for normalization of the CO₂production counted by the scintillation counter. The results arepresented in Table 57 and indicate that antisense inhibition of FGFR4increased fatty acid oxidation in primary hepatocytes. Five independentfatty acid oxidation experiments were conducted, which demonstrated asimilar trend on the results.

TABLE 57 CO₂ production (% of the control) CO₂ ISIS 141923 +2 ISIS299004 +48 AICAR +44

1. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the linked nucleosides comprise at least 8 contiguous nucleobases of a sequence recited in SEQ ID NOs: 17, 45, 46, 70, 72, or
 138. 2-7. (canceled)
 8. The compound of claim 1 wherein the modified oligonucleotide is a single-stranded oligonucleotide.
 9. (canceled)
 10. The compound of claim 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to SEQ ID NO 1 or
 2. 11. The compound of claim 1, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO 1 or
 2. 12. The compound of claim 1 wherein at least one internucleoside linkage is a modified internucleoside linkage.
 13. The compound of claim 12, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.
 14. The compound of claim 1, wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.
 15. The compound of claim 14, wherein the at least one modified sugar is a bicyclic sugar.
 16. The compound of claim 15, wherein each of the at least one bicyclic sugar comprises a 4′-CH2-N(R)—O-2′ bridge wherein R is, independently, H, C1-C12 alkyl, or a protecting group.
 17. The compound of claim 15, wherein each of the at least one bicyclic sugar comprises a 4′-CH(CH3)-O-2′ bridge.
 18. The compound of claim 14, wherein at least one modified sugar comprises a 2′-O-methoxyethyl group.
 19. (canceled)
 20. (canceled)
 21. The compound of claim 1, wherein at least one nucleoside comprises a modified nucleobase.
 22. The compound of claim 21, wherein the modified nucleobase is a 5-methylcytosine.
 23. The compound of claim 1, wherein the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
 24. The compound of claim 23, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides; a 5′ wing segment consisting of five linked nucleosides; and a 3′ wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage.
 25. (canceled)
 26. (canceled)
 27. The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides.
 28. A composition comprising the compound of claim 1 or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent. 29-46. (canceled)
 47. A method for reducing or preventing a metabolic disease comprising administering to a human a therapeutically effective amount of a compound of claim 1, thereby reducing or preventing a metabolic disease.
 48. The method of claim 47, wherein the metabolic disease is obesity.
 49. The method of claim 47, comprising co-administering the compound or composition and a second agent. 50-91. (canceled) 